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A B S T R A C T
Background
Fluoroquinolones are recommended as first-line therapy for typhoid and paratyphoid fever (enteric fever), but how they compare with
other antibiotics and different fluoroquinolones is unclear.
Objectives
To evaluate fluoroquinolone antibiotics for treating enteric fever in children and adults compared with other antibiotics, different
fluoroquinolones, and different durations of fluoroquinolone treatment.
Search strategy
In November 2007, we searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (The Cochrane Library 2007,
Issue 4), MEDLINE, EMBASE, LILACS, mRCT, conference proceedings, and reference lists.
Selection criteria
Randomized controlled trials of fluoroquinolones in people with blood or bone marrow culture-confirmed enteric fever.
Data collection and analysis
Two authors independently assessed the trials’ methodological quality and extracted data. We calculated odds ratios (OR) for dichoto-
mous data with 95% confidence intervals (CI). We analysed trials with greater than 60% children separately from trials of mostly
adults.
Main results
Of 38 included trials, 22 had unclear allocation concealment and 34 did not use blinding. Four trials included exclusively children, seven
had both adults and children, and three studied outpatients. ADULTS: Among primary outcomes (clinical failure, microbiological
failure, and relapse), compared with chloramphenicol, fluoroquinolones were not statistically significantly different for clinical failure
(594 participants) or microbiological failure (378 participants), but they reduced clinical relapse (OR 0.14, 95% CI 0.04 to 0.50; 467
participants, 6 trials). We detected no statistically significant difference versus co-trimoxazole (82 participants, 2 trials) or azithromycin
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(152 participants, 2 trials). Fluoroquinolones reduced clinical failure compared with ceftriaxone (OR 0.08, 95% CI 0.01 to 0.45; 120
participants, 3 trials), but not microbiological failure or relapse. Versus cefixime, fluoroquinolones reduced clinical failure (OR 0.05,
95% CI 0.01 to 0.24; 238 participants; 2 trials) and relapse (OR 0.18, 95% CI 0.03 to 0.91; 218 participants, 2 trials). CHILDREN:
In children with high proportions of nalidixic acid-resistant strains, older fluoroquinolones increased clinical failures compared with
azithromycin (OR 2.67, 95% CI 1.16 to 6.11; 125 participants, 1 trial), with no differences using newer fluoroquinolones (285
participants, 1 trial). Fluoroquinolones and cefiximewere not statistically significantly different (82participants, 1 trial). Trials comparing
different durations of fluoroquinolone treatment were not statistically significantly different (889 participants, 9 trials). Norfloxacin
had more clinical failures than other fluoroquinolones (417 participants, 5 trials).
Authors’ conclusions
Trials were small and methodological quality varied. In adults, fluoroquinolones may be better for reducing clinical relapse rates
compared to chloramphenicol. Data are limited for other comparisons, particularly in children.
P L A I N L A N G U A G E S U M M A R Y
Not enough sound evidence for using fluoroquinolones in typhoid and paratyphoid fever comparedwith the standard antibiotics
The potentially fatal typhoid and paratyphoid fevers are caused by bacterial infection that begins in the small intestine (enteric fever).
Transmission occurs through contaminated food and water, and there are areas where these diseases are endemic, such as Asia, Africa,
and South and Central America. People often relapse or become carriers. Chloramphenicol has been the standard treatment, but the
bacteria are becoming resistant. A new group of drugs, the fluoroquinolones, are being tried, but the review of trials found there were
insufficient numbers of participants in the trials, which were also of varying quality, to be able to give recommendations with any degree
of certainty, especially for children.
B A C K G R O U N D
Definition
Enteric fever refers to either typhoid or paratyphoid fever. Ty-
phoid fever is caused by Salmonella enterica serovar Typhi (S. Ty-
phi), an enteric bacterium that colonizes only human hosts. Since
humans are the only natural hosts of S. Typhi, direct or indirect
contact with someone with typhoid fever or who is carrying S. Ty-
phi (without symptoms) is essential for transmission of infection
(Cleary 2000). Transmission most commonly occurs when sus-
ceptible individuals ingest food or water contaminated with fae-
ces harbouring S. Typhi. Paratyphoid fever is considered a similar,
but generally milder illness, and is caused by S. enterica serovar
Paratyphi (S. Paratyphi) A, B, or C (Lee 2000). A recent report,
however, suggests that the illness caused by S. Paratyphi A may be
equal in severity to typhoid fever (Maskey 2006).
Epidemiology
Enteric fever− the majority of cases of which are caused by S. Ty-
phi− continues to be amajor health problemdue to poor hygienic
and sanitary conditions prevalent in low-income and middle-in-
come countries. However, the pattern of enteric fever is changing
in some endemic areas with an increase in the relative frequency of
S. Paratyphi A isolated from patients with enteric fever (Chandel
2000; Ahmad 2002; Butt 2005; Ochiai 2005; Jesudason 2005;
Woods 2006; Maskey 2008). Each year there are an estimated
16 million cases of enteric fever caused by S. Typhi and about
600,000 deaths (Ivanoff 1995). According to recent estimates the
burden of typhoid for the year 2000 was 21 million cases (Crump
2004). Endemic regions comprise almost all of Asia (with South
and South-East Asia considered areas of high incidence, ie over 100
cases per 100,000 population per year), Middle East, Africa, and
South and Central America (Ivanoff 1995; Crump 2004). In pop-
ulation-based studies from endemic areas, the highest incidence
has been reported in children between five and 10 years of age (Lin
2Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever) (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
2000; Siddiqui 2006; Sur 2006) as well as in children under five
years of age (Sinha 1999; Saha 2001; Saha 2003; Brooks 2005).
In high-income countries, enteric fever has been virtually elimi-
nated and most cases are those occurring in travellers returning
from endemic areas. In the USA, 2445 cases of infections caused
by S. Typhi were reported to the Centers for Disease Control and
Prevention between 1985 and 1994, 72% of which were associ-
ated with international travel mainly to Mexico and the Indian
subcontinent (Mermin 1998).
In endemic areas, most people are treated as outpatients, thus
hospital-based data represent a subset of patientswith amore severe
illness who may consequently have a less favourable response to
conventional therapy.
Pathogenesis
On ingestion, the salmonellae invade the intestinal epithelium,
probably through the Peyer’s patches (Cleary 2000). They then
multiply in the lymphoid tissue, enter themesenteric lymphnodes,
and eventually reach the bloodstream. Once in the bloodstream,
which is referred to as the ’primary blood stream invasion’, the
bacteria seed and multiply in several reticuloendothelial sites. The
bacteria then spill over from these primarily infected sites back into
the bloodstream, referred to as the ’secondary bloodstream inva-
sion’, and the patient begins to exhibit symptoms (Richens 2000).
Infection then disseminates to several sites, most commonly the
liver, spleen, bone marrow, gall bladder, and Peyer’s patches (Lee
2000; Richens 2000). The ability of S. Typhi and S. Paratyphi to
survive within macrophages is considered essential to the patho-
genesis of enteric fever (Miller 2000).
Clinical features and diagnosis
The clinical features of enteric fever are non-specific and vary in
different populations (Parry 2002). Common symptoms include
fever, headache, and gastrointestinal complaints, such as diarrhoea
or constipation, abdominal pain, nausea and vomiting, or loss of
appetite (Lee 2000; Richens 2000). Some commonfindings on ex-
amination include liver enlargement, spleen enlargement, a coated
tongue, and abdominal tenderness (Lee 2000; Richens 2000). The
definitive diagnosis of enteric fever requires the isolation of S. Ty-
phi or S. Paratyphi from blood, bone marrow, urine, bile, rose
spots, and gastric or intestinal secretions. Blood cultures have a
sensitivity of 60% to 80%, while bone marrow cultures have a
greater sensitivity of 80% to 95% (Parry 2002).
Prognosis
About 10% of people infected with S. Typhi experience a relapse
in the absence of treatment (Richens 2000). About 1% to 4% of
people become long-term carriers (Lee 2000). Case-fatality rates
range widely, from 1.6% in a hospital in Pakistan (Bhutta 1996)
to as high as 44% in a subgroup of people with severe S. Typhi
infection in PapuaNewGuinea (Richens 1995). The greater num-
ber of deaths observed in some low-income and middle-income
countries could be due to delays in diagnosis, hospitalization, and
commencement of effective treatment.
Treatment
Since its introduction in 1948, chloramphenicol has been widely
used for treating enteric fever because of its wide availability and
low cost. But chloramphenicol has some major disadvantages: it
does not reduce the relapse rate (the rate of recurrence of infection
with symptoms); it has no effect on the convalescent carrier or
chronic carrier (a person who continues to excrete the organism in
stool for one year after the illness); and it is not useful for treating
multiple-drug-resistant (MDR) S. Typhi (Lee 2000).
MDR strains of S. Typhi, carrying plasmid-encoded resistance
to all conventional first-line antibiotics (chloramphenicol, co-tri-
moxazole, and ampicillin or amoxicillin), have become highly
prevalent in several areas of the world since 1989. In the Indian
subcontinent and China, the frequency of these MDR strains
ranged from 50% to 80% of all S. Typhi isolates and reached
100% during outbreaks (Lee 2000). Effective treatment for peo-
ple infected with MDR strains is critical because they have been
observed to have a significantly higher incidence of complications
than people infected with fully sensitive strains (Bhutta 1996).
Many areas reported lower rates of MDR strains, and the re-emer-
gence in some areas of strains fully susceptible to first-line antibi-
otics suggests that chloramphenicol could still be a valuable treat-
ment option for enteric fever (Takkar 1995; Sood 1999; Wasfy
2002; Rodrigues 2003; Butt 2005; Walia 2005; Mohanty 2006).
Conversely, recent studies have reported the emergence of MDR
strains of S. Paratyphi A (Chandel 2000; Mahmood 2000; Butt
2005; Mohanty 2006).
The fluoroquinolones and other second-line antibiotics, such as
third-generation cephalosporins (eg ceftriaxone and cefixime) and
azithromycin (a macrolide antibiotic), are currently regarded as
the antibiotics of choice for treating MDR strains.
The fluoroquinolones
The fluoroquinolones, such as ciprofloxacin, ofloxacin, fleroxacin,
enoxacin, and pefloxacin, are a large family of anti-infective drugs
synthesized around the quinolone core and that possess a broad
antibacterial spectrum (Congeni 2002). The fluoroquinolones ef-
fectively penetrate macrophages and achieve high concentrations
in bile (Miller 2000). Norfloxacin is the exception, because the
World Health Organization (WHO) does not recommend it for
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treating enteric fever due to its low bioavailability (WHO 2003),
which is 50% compared with 95% for ofloxacin (Hooper 2000).
The fluoroquinolones are generally contraindicated for use in chil-
dren under the age of 18 years, except for the treatment of certain
infections, when no alternate agent is available (Gendrel 2003;
Committee 2006). This contraindication is primarily due to con-
cerns regarding their potential to cause arthropathy (joint disease),
which has been clearly established in juvenile animal experiments
(Simonin 1999). A review, however, reported that numerous stud-
ies evaluating ciprofloxacin use in children and adults have con-
sistently failed to demonstrate cartilage damage (Congeni 2002).
Arthralgia (joint pain) has been reported with fluoroquinolone
use, but it occurs at a rate of less than 1.5% and appears to resolve
entirely on discontinuation of the drug without leaving any evi-
dence of long-term damage (Fish 2001).
The most common adverse effects associated with fluoro-
quinolones are gastrointestinal, such as nausea and diarrhoea, and
central nervous system effects, such as headache, dizziness, and
drowsiness (Fish 2001). Severe central nervous system events,
such as psychosis and seizures are rare (Cross 2001). Other ad-
verse effects include dermatologic reactions, hepatic enzyme ele-
vation, hypersensitivity, nephrotoxicity, haematological reactions,
tendonitis, and tendon rupture. Tendon rupture can occur with
short-term use and small doses (Cross 2001). A potentially serious
adverse effect is the prolongation of the QTc interval (Congeni
2002), which can lead to cardiac arrhythmias.
A summary of randomized controlled trials has shown that fluoro-
quinolones, when compared with ceftriaxone, cefixime, and first-
line antibiotics, have lower clinical failure rates and lower fever
clearance times in the treatment of enteric fever (Parry 2002).
However, the review combined the data for both adults and chil-
dren, and more importantly, the results for drug-sensitive and
drug-resistant strains of S. Typhi and S. Paratyphi. The review also
does not present findings of unpublished trials andmay under rep-
resent non-English language trials, both of which are considered
important components of a systematic review (Davies 1998).
The optimal duration of treatment for fluoroquinolones in enteric
fever has yet to be clearly established. Although the recommended
duration is 10 to 14 days, recent randomized controlled trials
in Vietnam suggest that two-day and three-day courses may be
sufficient to treat uncomplicated S. Typhi infections in children
and adults (Tran 1995; Vinh 1996; Nguyen 1997). Such short-
course therapy is favourable, as it will prove less costly, possibly
less toxic, and will increase adherence to treatment.
However, a fact of great concern is the emergence of strains of
S. Typhi and S. Paratyphi with reduced susceptibility to fluo-
roquinolones (Murdoch 1998; Threlfall 2001; Threlfall 2003;
Rodrigues 2003; Karunanayake 2004; Slinger 2004; Butt 2005;
Manchanda 2006; Mohanty 2006; Walia 2006; Chau 2007; Joshi
2007). This is demonstrated with the minimum inhibitory con-
centration (MIC) values for ciprofloxacin, which are higher (0.125
to 1 mg/L) compared with the usual values for fully suscepti-
ble strains (< 0.125 mg/L) (Parry 2004). Increasing numbers of
treatment failures in infections caused by such strains are be-
ing reported, with short as well as long durations of fluoro-
quinolones (Brown 1994; Wain 1997; Asna 2003; Butt 2003;
Rupali 2004; Slinger 2004; Manchanda 2006; Dimitrov 2007).
These strains often display resistance to nalidixic acid (a first-gen-
eration quinolone) on routine disk diffusion susceptibility testing.
Thus the presence of nalidixic acid resistance (NaR) among S. Ty-
phi and S. Paratyphi can be used to identify strains with reduced
susceptibility to fluoroquinolones (Wain 1997; Parry 2004), and
is also the rationale for using NaR to denote reduced susceptibil-
ity to fluoroquinolones in this review. However, some strains with
reduced susceptibility to fluoroquinolones do not exhibit NaR (
Threlfall 2003; Cooke 2006), which suggests the need, in future,
for direct determination and interpretation of fluoroquinolone
MICs. More concerning are the emerging reports of isolates with
absolute fluoroquinolone resistance (Harish 2004; Adachi 2005;
Renuka 2005; Ahmed 2006; Mohanty 2006; Walia 2006; Joshi
2007). Newer generation fluoroquinolones, such as gatifloxacin,
however, have been found to be active against NaR strains (Pandit
2007; Dolecek 2008).
O B J E C T I V E S
To evaluate fluoroquinolone antibiotics for treating enteric fever
in children and adults compared with other antibiotics, differ-
ent fluoroquinolones, and different durations of fluoroquinolone
treatment.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials.
Types of participants
People diagnosed with typhoid or paratyphoid fever based on mi-
crobiological confirmation from blood or bone marrow.
Types of interventions
Intervention
Fluoroquinolone antibiotic.
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Control
• Non-fluoroquinolone antibiotic (one or more).
• Different fluoroquinolone antibiotic.
• Different treatment duration of same fluoroquinolone
antibiotic.
Types of outcome measures
Primary
• Clinical failure, defined as the presence of symptoms or the
development of complications that necessitate change in
antibiotic therapy or prolongation of existing therapy at the
period specified by trial authors.
• Microbiological failure, defined as a positive culture from
blood, bone marrow, or any sterile anatomic site at the period
specified by trial authors.
• Relapse, defined as the recurrence of symptoms with a
positive culture from blood or bone marrow or any sterile
anatomic site, to the point of follow up defined by trial authors.
Secondary
• Fever clearance time, defined as the time in hours taken to
defervesce from the start of the intervention or control drug with
the definition of fever clearance as specified by trial authors.
• Length of hospital stay, defined as the time in days from
entry into trial until discharge.
• Cost of therapy, defined as the total cost in US$ of the
drug, drug delivery, and hospital stay.
• Convalescent faecal carriage, defined as a positive faecal
culture detected at any time after the end of treatment up to one
year of follow up.
Complications and adverse events (as defined by trial
authors)
• Complications, defined as the appearance of complications
during therapy such as abdominal (intestinal perforation,
intestinal haemorrhage, hepatitis), cardiovascular (myocarditis,
shock), neuropsychiatric (delirium, meningitis), respiratory
(pneumonia, bronchitis), or haematological (anaemia,
disseminated intravascular coagulation).
• Serious adverse events, defined as adverse events leading to
death, requiring inpatient hospitalization or prolonged existing
hospitalization, or life threatening, or resulting in persistent or
significant disability or incapacity, such as joint disease,
tendonitis and tendon rupture, prolongation of QTc interval,
seizures, nephrotoxicity, haematological reactions, or severe
dermatologic reactions.
• Other adverse events, such as nausea, diarrhoea, headache,
dizziness, mild photosensitivity, hepatic enzyme elevations, and
hypersensitivity reactions.
Search methods for identification of studies
Durrane Thaver worked with Vittoria Lutje (Information Re-
trieval Specialist, Cochrane Infectious Diseases Group) to attempt
to identify all relevant trials regardless of language or publication
status.
Databases
We searched the following databases using the search terms and
strategy described in Table 4: Cochrane Infectious Diseases Group
SpecializedRegister (November 2007); Cochrane Central Register
of Controlled Trials (CENTRAL), published in The Cochrane Li-
brary (2007, Issue 4);MEDLINE (1966 toNovember 2007); EM-
BASE (1974 to November 2007); and LILACS (1982 to Novem-
ber 2007). We also searched the metaRegister of Controlled Tri-
als (mRCT) in November 2007 using the search term “(typhoid
fever) NOT vaccine”.
Table 4. Detailed search strategies
Search set CIDG SRa CENTRAL MEDLINEb EMBASEb LILACSb
1 typhoid fever fluoroquinolone QUINOLINES QUINOLONE
DERIVEDANTIIN-
FECTIVE AGENT
typhoid
2 enteric fever amifloxacin QUINOLONES fluoroquinolones typhoid fever
5Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever) (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 4. Detailed search strategies (Continued)
3 paratyphoid fever balofloxacin ANTI-IN-
FECTIVE AGENTS,
QUINOLONE
amifloxacin enteric fever
4 Salmonella typhi cetefloxacin ANTI-INFECTIVE
AGENTS, FLUO-
ROQUINOLONE
BALOFLOXACIN Salmonella typhi
5 Salmonella paratyphi ciprofloxacin FLUORO-
QUINOLONES
balofloxacin Salmonella paratyphi
6 - clinafloxacin fluoroquinolones CETEFLOXACIN -
7 - enoxacin amifloxacin cetefloxacin -
8 - fleroxacin balofloxacin CIPROFLOXACIN -
9 - gatifloxacin cetefloxacin ciprofloxacin -
10 - gemifloxacin CIPROFLOXACIN CLINAFLOXACIN -
11 - grepafloxacin ciprofloxacin clinafloxacin -
12 - irloxacin clinafloxacin ENOXACIN -
13 - levofloxacin ENOXACIN enoxacin -
14 - lomefloxacin enoxacin FLEROXACIN -
15 - moxifloxacin FLEROXACIN fleroxacin -
16 - nordifloxacin fleroxacin GATIFLOXACIN -
17 - norfleroxacin gatifloxacin gatifloxacin -
18 - norfloxacin gemifloxacin GEMIFLOXACIN -
19 - ofloxacin grepafloxacin gemifloxacin -
20 - oxociprofloxacin irloxacin GREPAFLOXACIN -
21 - pefloxacin levofloxacin grepafloxacin -
22 - premafloxacin lomefloxacin IRLOXACIN -
23 - prulifloxacin moxifloxacin irloxacin -
24 - rufloxacin nordifloxacin LEVOFLOXACIN -
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Table 4. Detailed search strategies (Continued)
25 - sitafloxacin norfleroxacin levofloxacin -
26 - sparfloxacin NORFLOXACIN LOMEFLOXACIN -
27 - temafloxacin norfloxacin lomefloxacin -
28 - tosufloxacin ofloxacin MOXIFLOXACIN -
29 - trovafloxacin oxociprofloxacin moxifloxacin -
30 - 1/29 - OR PEFLOXACIN NORDIFLOXACIN -
31 - typhoid fever pefloxacin nordifloxacin -
32 - enteric fever premafloxacin NORFLEROXACIN -
33 - paratyphoid fever prulifloxacin norfleroxacin -
34 - Salmonella typhi rufloxacin NORFLOXACIN -
35 - Salmonella paratyphi sitafloxacin norfloxacin -
36 - 31/35 - OR sparfloxacin OFLOXACIN -
37 - 30 and 36 temafloxacin ofloxacin -
38 - - tosufloxacin OXO-
CIPROFLOXACIN
-
39 - - trovafloxacin oxociprofloxacin -
40 - - 1 - 39/OR PEFLOXACIN -
41 - - TYPHOID FEVER pefloxacin -
42 - - typhoid fever PREMAFLOXACIN -
43 - - enteric fever premafloxacin -
44 - - PARATYPHOID
FEVER
PRULIFLOXACIN -
45 - - paratyphoid fever prulifloxacin -
46 - - SALMONELLA TY-
PHI
RUFLOXACIN -
47 - - Salmonella typhi rufloxacin -
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Table 4. Detailed search strategies (Continued)
48 - - SALMONELLA
PARATYPHI
SITAFLOXACIN -
49 - - Salmonella paratyphi sitafloxacin -
50 - - typhus SPARFLOXACIN -
51 - - 41 - 50/OR sparfloxacin -
52 - - 40 and 51 TEMAFLOXACIN -
53 - - limit 52 to human temafloxacin -
54 - - - tosufloxacin -
55 - - - 1 - 54/OR -
56 - - - TYPHOID FEVER -
57 - - - typhoid fever -
58 - - - enteric fever -
59 - - - PARATYPHOID
FEVER
-
60 - - - paratyphoid fever -
61 - - - SALMONELLA TY-
PHI
-
62 - - - Salmonella typhi -
63 - - - SALMONELLA
PARATYPHI
-
64 - - - Salmonella paratyphi -
65 - - - typhus -
66 - - - 56 - 65/OR -
67 - - - 55 and 66 -
68 - - - limit 67 to human -
aCochrane Infectious Diseases Group Specialized Register.
bSearch terms used in combination with the search strategy for retrieving trials developed by The Cochrane Collaboration (Higgins
2006); upper case: MeSH or EMTREE heading; lower case: free text term.
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Conference proceedings
We searched the following conference proceedings for relevant ab-
stracts: 5th International Symposium on Typhoid Fever and other
Salmonelloses, Karachi, Pakistan, 4 to 7 February 2002; 8th West-
ern Pacific Congress of Chemotherapy and Infectious Diseases,
Perth, Australia, 1 to 5December 2002; 43rd Interscience Confer-
ence on Antimicrobial Agents and Chemotherapy (ICAAC), 14
to 17 September 2003, Chicago, USA; Final Programs of the 44th
ICAAC, 30 October to 2 November 2004, in Washington D.C.,
USA; and the 45th ICAAC, 16 to 19 December 2005, Washing-
ton D.C., USA.
Researchers
We contacted Dr Christopher Parry (in 2003) and Dr Jeremy Far-
rar and Dr Christiane Dolecek (in December 2007) for informa-
tion on unpublished and ongoing trials.
Reference lists and review authors’ personal
collections
We also checked the reference lists of all retrieved trials and
searched the review authors’ personal literature collections for rel-
evant trials.
Data collection and analysis
Selection of studies
Durrane Thaver and Asma Azmatullah screened the title, abstract,
or keywords of each record identified with the search strategy, and
retrieved the full text for potentially relevant trials and for records
where the relevance was unclear. Durrane Thaver and Asma Az-
matullah or AliMadni independently applied the inclusion criteria
to each potentially relevant trial to determine their eligibility. We
resolved any disagreements through discussion with Anita Zaidi,
or attempted to contact the trial authors if we still had doubts. We
tabulated the excluded studies along with the reason for excluding
them in the ’Characteristics of excluded studies’. We ensured that
data from each trial was entered only once in our review.
Data extraction and management
Durrane Thaver and Asma Azmatullah or Ali Madni indepen-
dently extracted data. For dichotomous outcomes, such as clinical
failure, we extracted the total number of participants and number
of participants that experienced the event. For continuous out-
comes, such as fever clearance time, we extracted the total num-
ber of participants, arithmetic means, and standard deviations. If
the standard deviation was not reported, we attempted to use the
confidence interval or P value to derive it. We attempted to con-
tact authors for means and standard deviations when they were
not available. We also attempted to contact all trial authors to
obtain additional data or when the data were not in the format
we required. We compared the extracted data to identify errors.
We resolved disagreements by consulting Anita Zaidi (or Zulfiqar
Bhutta). Durrane Thaver and Asma Azmatullah entered data into
Review Manager 4.2.
Assessment of risk of bias in included studies
Durrane Thaver and Asma Azmatullah or Ali Madni assessed the
methodological quality of each included trial by assessing genera-
tion of allocation sequence, allocation concealment, blinding, and
loss to follow up. We assessed generation of allocation sequence
and allocation concealment as adequate, inadequate, or unclear (
Jüni 2001). We described blinding as double (trial uses a placebo
or a double dummy technique such that neither the participant
or care provider/assessor know which treatment is given), single
(participant or care provider/assessor is aware of the treatment
given), or open (all parties are aware of treatment), and considered
it adequate if 90% or more of the randomized culture-positive
participants were in the final analysis and inadequate if less than
90%. If the method was unclear, we attempted to contact the trial
authors for clarification. We resolved disagreements through dis-
cussion and by consulting Anita Zaidi.
Data synthesis
We analysed data using ReviewManager 4.2.We used the odds ra-
tio (OR) for dichotomous data and the mean difference (MD) for
continuous data, and presented each result with a 95% confidence
interval (CI). We combined trials of different fluoroquinolones
when evaluating treatment durations. We have not combined tri-
als comparing: fluoroquinolones with different antibiotics (eg tri-
als of fluoroquinolone versus chloramphenicol are not combined
with trials of fluoroquinolone versus amoxicillin); adult partici-
pants with child participants; or drug-resistant S. Typhi and S.
Paratyphi strains (NaR or MDR) with drug-sensitive S. Typhi and
S. Paratyphi strains. We also analysed norfloxacin trials separate
from the other fluoroquinolones because the WHO does not rec-
ommend this fluoroquinolone for treating enteric fever due to its
low bioavailability (WHO 2003).
Stratification
We stratified the results according to the presence or absence of
drug-resistant strains (MDR and NaR). We defined MDR as re-
sistant to all three first-line antibiotics (chloramphenicol, co-tri-
moxazole, and ampicillin or amoxicillin).
• Fluoroquinolones versus first-line antibiotics
(chloramphenicol, co-trimoxazole, and ampicillin or amoxicillin)
and norfloxacin versus chloramphenicol: Since the presence of
MDR would affect the performance of first-line antibiotics, we
stratified the trials into those that reported the absence of MDR
strains, reported their presence, or did not report them or were
unavailable. We also stratified the trials by the reported absence,
presence, or not reporting of NaR strains, since this would affect
the performance of the fluoroquinolone arm.
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Since the proportion of MDR strains would not differentially af-
fect the performance of the second-line or the fluoroquinolone
antibiotics, we did not stratify the results by MDR strains for the
subsequent comparisons.
• Fluoroquinolones versus second-line antibiotics (azithromycin,
ceftriaxone, cefixime) and norfloxacin versus ceftriaxone: We
stratified these trials by the reported absence, presence, or not
reporting or testing of NaR strains.
• Norfloxacin versus other fluoroquinolones: We did not stratify
these by the NaR strains since both arms involved
fluoroquinolones.
• Different durations of fluoroquinolones: Since the efficacy of
different durations of fluoroquinolones would be affected by
presence of NaR strains, we stratified these by NaR strains as
described above.
However, in all above-mentioned analyses of NaR, in order to dif-
ferentiate trials that had participants withNaR strains but involved
newer fluoroquinolones which are not affected by NaR, we made
a separate category (“NaR present, but newer fluoroquinolone”).
Further analyses with varying proportions strains with reduced
susceptibility to fluoroquinolones may be possible in future up-
dates of the review.
We also conducted separate analyses for those trials that included
mainly (more than 60%) children (defined as less than 16 years
or as in text of trial) and those that included mainly adults; we
classified all participants as adults if they were described as such
by trial authors, regardless of the age of the youngest participant.
Intention-to-treat analyses
We were unable to conduct an intention-to-treat analysis on cul-
ture-positive cases since no further information was available for
culture-positive participants who were lost to follow up. Instead,
we conducted an available-case analysis, and we derived the per
cent loss to follow up and tabulated the results (see Table 5).
Table 5. Assessment of risk of biasa
Comparison Trial Generation of allo-
cation sequence
Allocation
concealment
Blinding Inclusion of all randomized
culture-positive participants
in the final analysis
Fluoroquinolone vs
chloramphenicol
Abejar 1993 Unclear Unclear Open Adequate
Arnold 1993 Unclear Unclear Open Adequate
Cristiano 1995 Adequate Unclear Open Adequate
Bran 1991 Unclear Unclear Double Adequate
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Table 5. Assessment of risk of biasa (Continued)
Gasem 2003 Adequate Adequate Open Adequate
Gottuzzo 1992 Unclear Unclear Double Adequate
Morelli 1992 Adequate Unclear Open Adequate
Phongmany 2005b Adequate Adequate Open Adequate
Quintero 1988 Unclear Unclear Double Adequate
Yousaf 1992 Unclear Unclear Open Inadequate
Fluoroquinolone vs
ampicillin
Flores 1994 Unclear Unclear Open Adequate
Fluoroquinolone vs
co-trimoxazole
Hajji 1988b Adequate Adequate Open Adequate
Limson 1989 Adequate Unclear Open Adequate
Fluoroquinolone vs
azithromycin
Dolecek 2008b Adequate Adequate Open Adequate
Chinh 2000b Adequate Adequate Open Inadequate
Girgis 1999b Adequate Adequate Open Adequate
Parry 2007b Adequate Adequate Open Inadequate
Fluoroquinolone vs
cefixime
Cao 1999b Adequate Adequate Open Inadequate
Pandit 2007b Adequate Adequate Open Inadequate
Yu 1998 Unclear Unclear Open Adequate
Fluoroquinolone vs
ceftriaxone
Tran 1994b Adequate Adequate Open Inadequate
Smith 1994b Adequate Adequate Open Inadequate
Wallace 1993 Unclear Unclear Open Adequate
Norfloxacin vs chlo-
ramphenicol
Nalin 1987 Adequate Unclear Open Adequate
Sarma 1991b Adequate Unclear Open Adequate
Norfloxacin vs cef-
triaxone
Huai 2000 Unclear Unclear Open Adequate
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Table 5. Assessment of risk of biasa (Continued)
Norfloxacin vs other
fluoroquinolones
Bai 1995 Unclear Unclear Open Adequate
Jia 1994 Unclear Unclear Double Adequate
Xiao 1991 Unclear Unclear Open Adequate
Yang 1991 Unclear Unclear Open Adequate
Different durations
of fluoroquinolones
Alam 1995 Unclear Unclear Open Inadequate
Duong 1995b Adequate Adequate Open Inadequate
Kalo 1997 Unclear Unclear Open Adequate
Nguyen 1997b Adequate Adequate Open Inadequate
Tran 1995b Adequate Adequate Open Inadequate
Unal 1996 Unclear Unclear Open Adequate
Vinh 1996b Adequate Adequate Open Inadequate
Vinh 2005b Adequate Adequate Open Adequate
aSee ’Data collection and analysis’ for the assessment methods, and the ’Characteristics of included studies’ for the methods used in
each trial.
bTrial author provided additional information.
Trials with more than two comparison groups
One trial compared a fluoroquinolone with two non-fluoro-
quinolone antibiotics (Yousaf 1992), and another trial compared a
fluoroquinolone with a non-fluoroquinolone antibiotic (azithro-
mycin) as well as a combination of both antibiotics (ofloxacin with
azithromycin) (Parry 2007).We did not include the comparison of
fluoroquinolone with combination of fluoroquinolone and non-
fluoroquinolone. For Yousaf 1992 we separated the data into two
meta-analyses: one comparing a fluoroquinolone with amoxicillin
and the other with chloramphenicol.
When trials compared several different fluoroquinolones with
a single non-fluoroquinolone antibiotic (Arnold 1993; Morelli
1992) or different fluoroquinolones against each other (Xiao
1991), we combined the groups treated with fluoroquinolones
into a single fluoroquinolone group. For two trials, we only se-
lected some groups; we included three groups out of the six for
Morelli 1992 because they were common to other trials included
in this review (Bai 1995; Jia 1994; Yang 1991), and only three of
five groups for Xiao 1991 because each of the comparison groups
had a sample size of less than 10. We intend to include the groups
in future updates if more trials become available.
Heterogeneity
Wechecked for heterogeneity by visually inspecting the forest plots
and by using the chi-squared test for homogeneity (using a 10%
level of statistical significance). When we detected heterogeneity
among studies and still considered it appropriate to pool the data,
we used the random-effects model. We were unable to explore
the following potential sources of heterogeneity using subgroup
analyses because of the limited number of trials in each compari-
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son: drug dose; severe and/or complicated enteric fever (as defined
by trialists) versus uncomplicated enteric fever; and different time
points for outcome measurements.
Sensitivity analyses and publication bias
The small number of trials in each comparison also prevented us
from performing a sensitivity analysis for each of the methodolog-
ical quality factors for all comparisons except for fluoroquinolones
compared to chloramphenicol. We assessed the presence of publi-
cation bias using a funnel plot only for primary outcomes which
had more than five studies.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Trial selection
We assessed 70 trials for eligibility and included 38 (3279 partic-
ipants) (see ’Characteristics of included studies’) and excluded 25
(see ’Characteristics of excluded studies’). Among the remaining
seven trials, which we assessed for eligibility, three were duplicate
publications of the included studies (Hajji 1988; Arnold 1993; Jia
1994), two are ongoing (ISRCTN53258327; ISRCTN66534807;
see ’Characteristics of ongoing studies’), and we were unable to
retrieve two (Flores 1991; Soewandojo 1992; see ’Characteristics
of studies awaiting classification’).
Trial design and location
Eleven trials were conducted in Vietnam, six trials in China, two
trials in each of the Philippines, Mexico, and Italy, and one trial in
each of Albania, Bahrain, Bangladesh, Egypt, Guatemala, India,
Indonesia, Laos, Morocco, Nepal, Pakistan, and Turkey.We could
not determine the location of one trial (Gottuzzo 1992). Two were
multicenter trials conducted in different countries (Nalin 1987;
Arnold 1993).
Most trials were small and therefore lacked statistical power to
detect differences between the treatment regimens. The smallest
trial had 26 participants and the largest had 287 participants.
Participants
Most trials included only adults (minimum age for adults reported
by trialists was ≥ 14 years), and only four trials exclusively in-
cluded children (Vinh 1996; Cao 1999; Huai 2000; Vinh 2005).
Seven trials included children and adults (Xiao 1991; Yang 1991;
Alam 1995; Tran 1995; Pandit 2007; Parry 2007; Dolecek 2008),
although 87%, 79%, and 73% of participants were children in
three of these trials (Tran 1995; Parry 2007; Dolecek 2008) and
were considered as trials on (mostly) children. Two of these, Alam
1995 and Pandit 2007, had 84% and 65% adults respectively,
and were considered as a trial on (mostly) adults. Five trial reports
did not mention the participants’ age; however, four used adult
dosages (Nalin 1987; Quintero 1988; Bran 1991; Jia 1994), and
one used the keyword “adult” (Flores 1994).
All but three trials were conducted on inpatients; Alam 1995 was
conducted on both inpatients and outpatients, and Tran 1995 was
a community-based outpatient trial, while Pandit 2007 recruited
outpatients presenting to the outpatient or emergency department
of the study hospital.
Nineteen trials were conducted exclusively on participants with
uncomplicated enteric fever or participants without major com-
plications of enteric fever, and one included only participants with
severe enteric fever (Cristiano 1995). (The terms “severe”, “com-
plicated”, and “uncomplicated” were as defined by the trial au-
thors.) The remaining trials either did not provide this informa-
tion or included a combination.
Most trials used blood cultures or bone marrow cultures, or both,
to confirm cases of enteric fever. Although three trials included
stool culture-positive cases (Girgis 1999 (three cases); Hajji 1988
(nine cases); Smith 1994 (three cases)) and urine culture-positive
cases (Hajji 1988 (one case)), we included them in the review
since all three trials mainly included blood culture-positive cases.
Five trials did not report the site of culture (Nalin 1987; Quintero
1988; Gottuzzo 1992; Yousaf 1992; Flores 1994), but based on
information available, such as mention of follow up “blood cul-
tures”, we assumed that these trials included participants with pre-
dominantly blood culture-confirmed enteric fever.
Inclusion and exclusion criteria
Trialists tended to report outcomes only for culture-confirmed
cases of enteric fever.Most trialists excluded culture-negative cases
from detailed analysis, even if initially enrolled.
Interventions
Fluoroquinolones versus non-fluoroquinolone antibiotics
Twenty-three trials (1867 participants) compared fluoro-
quinolones with chloramphenicol (10 trials), amoxicillin or ampi-
cillin (two trials), co-trimoxazole (two trials), azithromycin (four
trials), ceftriaxone (three trials), or cefixime (three trials). Of
these, two compared a newer fluoroquinolone (gatifloxacin) with
azithromycin and cefixime respectively (Pandit 2007; Dolecek
2008).
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Norfloxacin trials
Three trials compared the fluoroquinolone norfloxacin with chlo-
ramphenicol (259 participants), one compared it with ceftriaxone
(60 participants), and five trials (171 participants) compared it
with pefloxacin, ofloxacin, and enoxacin.
Different durations of fluoroquinolone
Nine trials (889 participants) compared different fluoroquinolone
treatment durations: 2 days with 3 days (three trials); 3 days with
5 days (two trials), 5 days with 7 days (one trial); 7 days with 10
days (one trial); 7 days with 14 days (one trial); and 10 days with
14 days (one trial).
Length of fluoroquinolone treatment
Most trials comparing fluoroquinolones (excluding norfloxacin)
with a non-fluoroquinolone antibiotic treated the participants
with the fluoroquinolone for seven (8 trials) or 10 days (6 trials)
(range three to 15days). Among trials comparingfluoroquinolones
with first-line antibiotics (chloramphenicol, co-trimoxazole, and
ampicillin or amoxicillin), only three trials used a short-course flu-
oroquinolone regimen of three days (Phongmany 2005) or seven
days (Arnold 1993; Gasem 2003). Among 10 trials that com-
pared a fluoroquinolone with azithromycin (four trials), ceftriax-
one (three trials), or cefixime (three trials), nine used a short-course
fluoroquinolone regimen of five days (three trials) or seven days
(six trials). All other trials used a long-course (greater than seven
days) fluoroquinolone regimen.
Primary outcomes
Wewere able to extract data on all three primary outcomes - clinical
failure, microbiological failure, and relapse - from 24 of the 38
trials, on any two primary outcomes from eight trials, and on any
one primary outcome from six trials.
There were considerable variations regarding the time points at
which outcomes were measured, particularly microbiological fail-
ure (such as day two, the end of treatment, and some days af-
ter treatment) and relapse (such as during therapy and up to two
months of follow up). The precise descriptions also varied consid-
erably; for example, some trialists defined “relapse” as the recur-
rence of similar signs and symptoms with confirmation by blood
and/or bone marrow culture (sterile site, as defined in protocol),
and others as confirmed by positive stool cultures (non-sterile site)
only. Some trialists did not explicitly state how they confirmed
relapse in their trial (see Table 3 ’Definitions of outcomes’).
Secondary outcomes
Twenty-eight trials reported mean fever clearance times, but six
did not report the standard deviation or the information required
to calculate a standard deviation. The 95%confidence intervals for
the mean were reported in three trials (Chinh 2000; Vinh 2005;
Parry 2007) from which we derived the standard deviation. Fever
clearance times are usually skewed: several trials used non-para-
metric tests of statistical significance, and authors provided mean
and standard deviation on request for four trials that reported
a median fever clearance time in the original report (Cao 1999;
Phongmany 2005; Pandit 2007; Dolecek 2008). The Student’s t
test was also used (it is unclear whether data were log transformed
before conducting this test). Caution is required when interpret-
ing the mean difference for fever clearance times, as there may be
some skew, and the denominator in calculating mean fever clear-
ance times was not clear in most trials. Since we could not ascer-
tain whether trial authors had excluded “clinical failures” in their
calculation of mean fever clearance times (or included the fever
clearance time of participants who were switched over to another
drug), the mean fever clearance times included in our meta-anal-
yses could be biased.
We could extract data on the length of hospitalization from 12
trials, complications from 20 trials, serious adverse events from 28
trials, and other adverse events from 23 trials. Five trials reported
laboratory adverse events distinct from clinical adverse events (
Nalin 1987; Hajji 1988; Yang 1991; Abejar 1993; Smith 1994).
We extracted these laboratory data but did not analyse them to-
gether with clinical adverse events to avoid the overlap of partici-
pants. Four trials reported the number of adverse events, and not
the number of participants (Morelli 1992; Duong 1995; Girgis
1999; Chinh 2000). Only one author provided the cost of therapy
as additional data (Girgis 1999).
Twenty-five trials measured convalescent faecal carriage, but we
could not extract data from three trials because one included three
participants who were not blood culture confirmed at enrolment (
Arnold 1993), and two because the participants with positive stool
cultures at follow up also had recurrence of symptoms and were
reported as relapses (Wallace 1993; Unal 1996).
MDR and NaR strains
See Table 1.
Of the 38 included trials, only 13 trials reported the proportion of
participants with NaR strains, among which it was absent in four
trials (Hajji 1988; Smith 1994; Cao 1999; Phongmany 2005).
TheMICs of different fluoroquinolones reported in trials that did
not report NaR strains ranged from < 0.016 to 8 mg/L, suggesting
that some strains may have had reduced susceptibility to fluoro-
quinolones (reference ranges available in (CLSI 2006)), but pre-
cise numbers of such strains in each arm were not available.
One of the two trials comparingnorfloxacinwith chloramphenicol
did not report the proportion of participants with MDR strains.
Among 13 trials comparing other fluoroquinolones (excluding
norfloxacin) with first-line antibiotics, MDR strains were present
in one trial (Phongmany 2005) absent in eight trials, and four
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trials did not report on this (Gottuzzo 1992; Yousaf 1992; Arnold
1993; Flores 1994).
Risk of bias in included studies
See risk of bias summary in Table 5.
Generation of allocation sequence
Twenty-one trials used an adequate randomization method: eight
used random-numbers lists or tables; and the rest were computer
generated. Five of these trials used block randomization. The
method used to generate the allocation sequence in the remaining
17 trials was unclear.
Allocation concealment
Sixteen trials used an adequate method (sealed envelopes) to con-
ceal allocation. The method used in the remaining 22 trials was
unclear.
Blinding
Four trials were described as “double blinded” and 34 trials were
open; two trials did not mention use of placebo, but we assumed
they were open (Flores 1994; Bai 1995).
Inclusion of all randomized culture-positive
participants in the final analysis
We obtained the percentage of participants lost to follow up by
dividing the number of culture-positive participants unaccounted
for at followupby the total number of culture-positive participants
randomized. Thus 26 trials included an adequate (90% or more)
number of participants in final analysis (or assumed to be adequate
when there was no mention of losses to follow up), and 12 trials
included an inadequate number (less than 90%).
Overall methodological quality
Only six open trials used adequate methods to generate the allo-
cation sequence and conceal allocation, and had few or no losses
at the final follow up for which data were reported (Hajji 1988;
Girgis 1999;Gasem2003; Phongmany 2005;Vinh 2005;Dolecek
2008). Ten other open trials used adequate methods of random-
ization and allocation concealment but did not have adequate fol-
low up (Smith 1994; Tran 1994; Duong 1995; Tran 1995; Vinh
1996; Nguyen 1997; Cao 1999; Chinh 2000; Pandit 2007; Parry
2007).
Five open trials reported an adequate method of randomization
and follow up (Nalin 1987; Limson 1989; Sarma 1991; Morelli
1992; Cristiano 1995). Four trials were double-blinded trials with
adequate follow up (Quintero 1988; Bran 1991; Gottuzzo 1992;
Jia 1994). Two open trials did not have any adequate quality mea-
sure (Yousaf 1992; Alam 1995), and the remaining 11 trials had
only adequate follow up.
Effects of interventions
1. Fluoroquinolones versus first-line antibiotics
(chloramphenicol, co-trimoxazole, and ampicillin or
amoxicillin)
1.1. Fluoroquinolones versus chloramphenicol
Ten trials made this comparison (Quintero 1988; Bran 1991;
Gottuzzo 1992; Morelli 1992; Yousaf 1992; Abejar 1993; Arnold
1993; Cristiano 1995; Gasem 2003; Phongmany 2005). Three
did not clarify the proportion of participants with MDR strains
(Gottuzzo 1992; Yousaf 1992; Arnold 1993), and nine did not
report NaR data, while this was absent in one trial (Phongmany
2005). One trial included five different fluoroquinolones −
ofloxacin, pefloxacin, ciprofloxacin, enoxacin, and norfloxacin (
Morelli 1992); we analysed the norfloxacin group separately, as
explained above.
Clinical failure
We did not detect any statistically significant difference in clini-
cal failure (Analysis 1.1, Figure 1) in trials that included partic-
ipants without MDR strains (307 participants, 5 trials), partici-
pants with some MDR strains (50 participants, 1 trial), or an un-
known proportion of participants with MDR strains (237 partic-
ipants, 3 trials), or when we combined all subgroups (594 partic-
ipants, 9 trials). In one included trial (Phongmany 2005), partic-
ipants randomized to chloramphenicol when found infected with
a chloramphenicol-resistant isolate were switched to the fluoro-
quinolone group and consequently did not experience clinical fail-
ure. These were restored to their originally randomized groups by
the authors (with no clinical failures reported in chloramphenicol
arm) (Phongmany 2005).
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Figure 1. Fluoroquinolones vs chloramphenicol: clinical failure
Wedid not detect any statistically significant difference in clin-
ical failure when we included only trials with adequate method-
ological quality (adequatemethods of randomization and adequate
allocation concealment, and no losses to follow up) (105 partici-
pants; Gasem 2003; Phongmany 2005; Analysis not shown).
Microbiological failure
Wedid not detect any statistically significant difference in the odds
of microbiological failure in people without MDR strains (237
participants, 4 trials, Analysis 1.2). (Gasem 2003 performed both
blood and bone marrow cultures for half of the participants at day
three and for the other half of participants at day five of treatment
to assess microbiological failure. We combined the blood culture
results for both days, but we did not use bone marrow culture
results as they were conducted on the same participants whose
blood cultures were also taken.) In trials with an unknown propor-
tion of participants with MDR strains (Analysis 1.2), the odds of
microbiological failure were statistically significantly lower in the
fluoroquinolone group (OR 0.24, 95% CI 0.06 to 0.96; 141 par-
ticipants, 2 trials), but the results that favoured fluoroquinolones
were of borderline statistical significance when we combined the
two subgroups (OR 0.43, 95% CI 0.18 to 1.03; 378 participants,
6 trials).
We did not detect any statistically significant difference in mi-
crobiological failure when we included only trials with adequate
methodological quality (adequate methods of randomization and
adequate allocation concealment, and no losses to follow up) (45
participants, Gasem 2003, Analysis 1.2).
Relapse
In trials with no participants with MDR strains, the odds of re-
lapse were reduced by 88%, which is statistically significant (OR
0.12, 95%CI 0.02 to 0.69; 281 participants, 4 trials, Analysis 1.3,
Figure 2). However, we could not determine the precise definition
or the site of culture to confirm a relapse in most of the trials
(see Table 3), including Morelli 1992, which received the greatest
weight in this meta-analysis. In the two trials with an unknown
proportion of participants with MDR strains, we did not detect
any statistically significant differences, but statistical power was
very limited (186 participants, 2 trials, Analysis 1.3). The odds of
relapse were reduced significantly when we combined both sub-
groups (OR 0.14, 95% CI 0.04 to 0.50; 467 participants, 6 trials,
Analysis 1.3). When we excluded from the analysis those trials
that did not clearly define relapse (Abejar 1993; Cristiano 1995),
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did not confirm relapse using cultures (Gasem 2003), or did not
define relapse at all (Gottuzzo 1992; Morelli 1992), thus retain-
ing only one trial (91 participants) with clearly blood culture-con-
firmed relapses (Arnold 1993) (sterile site-culture confirmed, as
defined in the protocol), we did not find any difference between
fluoroquinolones and chloramphenicol.
Figure 2. Fluoroquinolones vs chloramphenicol: relapse
The only trial with adequate methodological quality in this
comparison did not report any relapses (55 participants, Gasem
2003, Analysis 1.3); however this was only reported during hos-
pitalization, and longer follow up was not done.
Fever clearance time
The meta-analysis of two trials without participants with MDR
strains tended to favour fluoroquinolones for fever clearance time,
but the sample size was small so that the confidence intervals were
very wide (MD -16.07 hours, 95% CI -35.03 to 2.88; 81 partic-
ipants, Analysis 1.4). One trial (Phongmany 2005) with NaR ab-
sent and MDR present reported a statistically significantly lower
mean fever clearance time in the fluoroquinolone group (MD -
38.5 hours, 95% CI -59.90 to -17.10; 48 participants, Analysis
1.4). On combining both subgroups we detected a statistically sig-
nificantly lower mean fever clearance time in the fluoroquinolone
group (MD -25.93 hours, 95% CI -40.12 to -11.74; 129 par-
ticipants, 3 trials, Analysis 1.4). Fever clearance time was slightly
shorter in both Abejar 1993 and Cristiano 1995, but the trialists
did not report standard deviations or precise results of tests of sta-
tistical significance, and we could not include them in the meta-
analysis.
Whenwe included only two above-mentioned trials with adequate
methodological quality (Gasem 2003; Phongmany 2005), we de-
tected a statistically significantly lower mean fever clearance time
in the fluoroquinolone group (MD -27.56 hours, 95% CI -43.38
to -11.75; 103 participants, Analysis not shown).
Length of hospital stay
Three trials reported on the length of hospital stay (Analysis 1.5).
One of them, Cristiano 1995, did not report the standard devi-
ation (fluoroquinolone group: mean 5 days, range 3 to 8 days;
chloramphenicol group: mean 5.53 days, range 2 to 8 days). We
did not detect any statistically significant difference in the length
of hospital stay in the other trial, Gasem 2003 (55 participants),
which had no MDR and did not report NaR. One trial reported
a statistically significantly lower mean length of hospital stay in
the fluoroquinolone group (MD -5.90 days, 95% CI -7.42 to -
4.38; 50 participants, Phongmany 2005). On combining both
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subgroups we detected a statistically significantly lower length of
hospital stay in the fluoroquinolone group (MD -2.57 days, 95%
CI -3.53 to -1.62; 105 participants, 2 trials). We detected statisti-
cally significant heterogeneity in the two trials; this could be due
to differences in durations of fluoroquinolone treatment (15 days
versus 3 days) in the two trials. We did not detect any statistically
significant difference in the length of hospital stay when we used
a random-effects model to combine the trials (105 participants, 2
trials, Analysis not shown). These were the only two trials that re-
ported length of hospital stay, and both were of adequate method-
ological quality.
Convalescent faecal carriage
We found a statistically significant decrease in the odds of conva-
lescent faecal carriage in the fluoroquinolone group in trials that
did not have any participants with MDR strains (OR 0.17, 95%
CI 0.04 to 0.70; 298 participants, 3 trials, Analysis 1.6). No trial
of adequate methodological quality reported this outcome.
Complications and adverse events
We did not detect a statistically significant difference in the num-
ber of complications in two trials, both of adequate methodolog-
ical quality, that reported these data (105 participants, Analysis
1.7). The complications included pneumonia, sepsis, myocarditis,
gastrointestinal bleeding, and perforation (seeTable 2).We did not
detect a statistically significant difference in the number of non-
serious adverse events, such as nausea, epigastric pain, skin rash,
headache, and dizziness (245 participants, 5 trials, Analysis 1.8; see
Table 6). We also did not detect any statistically significant differ-
ences in non-serious adverse events in the two trials with adequate
methodological quality (105 participants, Analysis not shown; see
Table 6). One trial mentioned selected serious adverse events, in-
cluding one participant with severe rash in the ciprofloxacin group
and one with severe leucopenia in the chloramphenicol group (
Gottuzzo 1992; Table 7).
Table 6. Non-serious adverse eventsa
Comparison Trial No. of participants (in brackets except
where specifically stated) with non-seri-
ous adverse eventsb
Laboratory adverse eventsc
Intervention Control Intervention Control
Fluoroquinolone vs
chloramphenicol
Abejar 1993 Fleroxacin:
numbness in upper
extremities (2)
Chloram-
phenicol: numbness
in upper extremities
(1)
Flerox-
acin: increased crea-
tinine (4)
Chloramphenicol:
increased creatinine
(4); increased blood
urea nitrogen (2)
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Table 6. Non-serious adverse eventsa (Continued)
Arnold 1993 Seborrheic dermati-
tis in 14-day fluoro-
quinolone group (1)
Gastrointesti-
nal complaints were
most common, in-
clud-
ing nausea and vom-
iting; insomnia also
reported; no. were
not provided for cul-
ture-positive partic-
ipants but reported
together with cul-
ture-negative partic-
ipants
Gastrointesti-
nal complaints were
most common, in-
clud-
ing nausea and vom-
iting; insomnia also
reported; no. were
not provided for cul-
ture-positive partic-
ipants but reported
together with cul-
ture-negative partic-
ipants
Most frequent laboratory abnormalities in-
cluded low neutrophil or total leukocyte
count, low haemoglobin and haematocrit,
but it does not say which event occurred in
which arm and are reported together with
culture-negative participants
Bran 1991 0 0 0 0
Cristiano 1995 Pe-
floxacin: nausea (3);
epigastric pain (3);
transient rash (1)
Chloramphenicol:
epigastric pain (5)
0 0
Gasem 2003 Ciprofloxacin: 0 Chloramphenicol:
rash (1)
Ciprofloxacin: 0 Chlorampheni-
col: mean decrease
in haemoglobin lev-
els (no. not stated)
Gottuzzo 1992 Ciprofloxacin: not
described
Chlorampheni-
col: leucopenia (10);
others not described
Not described Not described
Morelli 1992 Events in 4 fluo-
roquinolone groups:
epigastric pain (26);
flushing (12);
headache (8); dizzi-
ness (11); skin rash
(4)
Events in chloram-
phenicol group: di-
arrhoea (3); epigas-
tric pain (6); abdom-
inal pain (4)
Not described Not described
Phongmany 2005 0 0 - -
Yousaf 1992 Ofloxacin: (3) Chloramphenicol:
(4)
Not described Not described
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Table 6. Non-serious adverse eventsa (Continued)
Fluoroquinolone vs
ampicillin or amox-
icillin
Yousaf 1992 Ofloxacin: (3) Amoxicillin: (11)
(mostly diarrhoea,
pruritis, rash)
Not described Not described
Fluoroquinolone vs
co-trimoxazole
Hajji 1988 Pefloxacin: photoxi-
city (1)
Co-trimoxazole:
rash (1)
Pefloxacin: increased
transaminase (2)
Co-tri-
moxazole: increased
transaminases (1)
Limson 1989 Ci-
profloxacin: abdom-
inal discomfort (4);
dizziness (1)
Co-trimoxa-
zole: nausea (5); pru-
ritis (1)
0 0
Fluoroquinolone vs
azithromycin
Dolecek 2008 Gatifloxacin: vomit-
ing (1); diarrhoea (1)
Azithromycin: rash
(1)
- -
Chinh 2000 No.
events for ofloxacin:
nausea (1); vomiting
(3); abdominal pain
(4)
No. events for
azithromycin: nau-
sea (5); vomiting (5);
abdominal pain (4);
rash (1)
Ofloxacin: increased
mean lev-
els of alanine and as-
partate aminotrans-
ferase (all 44 partici-
pants)
Azithromycin:
increased mean lev-
els of alanine and as-
partate aminotrans-
ferase (all 44 partici-
pants)
Girgis 1999 Ciprofloxacin: nau-
sea and vomiting
(4); lightheadedness
(2); dry mouth (4);
loose stools (3); con-
stipation (2)
Azithromycin: nau-
sea and vomiting
(6); lightheadedness
(2); dry mouth (3);
loose stools (3); con-
stipation (2)
Ciproflo-
xacin: thrombocyto-
sis (1); mild aspar-
tate transaminase in-
crease (3)
Azithro-
mycin: thrombocy-
tosis (4); mild aspar-
tate transaminase in-
crease (2)
Parry 2007 Ofloxacin: joint dis-
comfort which re-
solved (1); gastroin-
testinal side effects
(no. not stated)
Azithro-
mycin: joint discom-
fort which resolved
(1); gastrointestinal
side effects (no. not
stated)
- -
Fluoroquinolone vs
cefixime
Cao 1999 No.
events for ofloxacin:
abdominal pain (4);
diarrhoea (4); vom-
iting (1)
No. events for ce-
fixime group: ab-
dominal pain (1); di-
arrhoea (4); vomit-
ing (1); rash (1)
Not described Not described
Pandit 2007 Gatifloxacin: nausea
and vomiting (18).
Among these, 2 with
ex-
cessive vomiting re-
Cefixime: nausea
and vomiting (1)
- -
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Table 6. Non-serious adverse eventsa (Continued)
quired intravenous
antiemetics and flu-
ids and observation
in the hospital emer-
gency room for up
to 6 hours; 2 needed
oral antiemetics
Yu 1998 Levofloxacin: 0 Cefixime: nausea
and low appetite (2)
Lev-
ofloxacin: increased
alanine aminotrans-
ferase (2)
Cefixime: increased
alanine aminotrans-
ferase (1)
Fluoroquinolone vs
ceftriaxone
Smith 1994 Ofloxacin: pruritis
(1)
Ceftriaxone: skin
rash (2)
Ofloxacin:
mildly increased cre-
atinine (1)
Ceftriaxone: 0
Norfloxacin vs chlo-
ramphenicol
Nalin 1987 Norfloxacin: clinical
adverse events (6)
Chloram-
phenicol: clinical ad-
verse events (7)
Norfloxacin: labora-
tory adverse events
(10)
Chloram-
phenicol: laboratory
adverse events (20)
Sarma 1991 Norfloxacin: nausea
(3); vomiting (3);
headache (2)
Chloramphenicol: 0 Norfloxacin: 0 Chlorampheni-
col: decreased mean
hematocrit (2), de-
creased white blood
cell
count (3), decreased
platelet count (2)
Norfloxacin vs cef-
triaxone
Huai 2000 Norfloxacin: nausea
and vomiting (3)
Cef-
triaxone: abdominal
discomfort and nau-
sea (1)
Not described Not described
Norfloxacin vs other
fluoroquinolones
Bai 1995 Enoxacin: rash (1) Norfloxacin: ab-
dominal discomfort
(1)
Not described Not described
Jia 1994 Norfloxacin: 0 Pefloxacin: included
nausea,
vomiting, dizziness,
measles like rash and
abdominal discom-
fort (no. not stated)
Not described Not described
Morelli 1992 Norfloxacin: epigas-
tric pain (6); flush-
ing (4); dizziness (4)
No. events
for ofloxacin: epigas-
tric pain (4); flush-
ing (4); headache (2)
Not described Not described
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Table 6. Non-serious adverse eventsa (Continued)
No. events for pe-
floxacin: rash (2);
headache (6); epi-
gastric pain (10)
No. events
for enoxacin: epigas-
tric pain (3); flush
(4); dizziness (7)
Xiao 1991 Norfloxacin: not de-
scribed
Pefloxacin: nau-
sea and anorexia (2);
agitation and abnor-
mal behaviour (1)
Ofloxacin: nausea
(2); measles like rash
(3); salivation (1)
Not described Not described
Yang 1991 Ofloxacin: rash (1) Norfloxacin: rash
(1)
Norfloxacin:
increased alanine
aminotransferase (1)
-
Different durations
of fluoroquinolones
Alam 1995 10-day:
4 participants had
11 events including
malaise (1), dizziness
(1), nausea (1), in-
somnia (1), rash (1),
pruritis (1), lethargy
(1), weakness (1),
and headache (3)
14-day: 9 partici-
pants had 18 events
including joint pain
(1), malaise (3), ab-
dominal pain (3),
headache (1), dizzi-
ness (1), nausea (1),
oral mucosal pain
(2), insomnia (1),
vomiting (1), vertigo
(1), palpitations (1),
and photosensitivity
(1)
10-day: moderate
eosinophilia (5)
14-day: moder-
ate eosinophilia (3);
increased serum cre-
atinine (1)
Duong 1995 3-day: insomnia
(10)
No. events for 5-day:
insomnia (17), nau-
sea and vomiting (1)
Not described Not described
Kalo 1997 7-day: nausea, vom-
iting, or abdominal
discomfort (4), but
it does not say in
which group
10-day: nau-
sea, vomiting, or ab-
dominal discomfort
(4), but it does not
say in which group
Not described Not described
Tran 1995 3-day (11): partici-
pants had insomnia,
dizziness, epigastric
5-day
(4): participants had
insomnia, dizziness,
Not described Not described
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Table 6. Non-serious adverse eventsa (Continued)
pain, nausea, diar-
rhoea, headache and
> 1 symptom; joint
symptoms reported
were not thought to
be fluoroquinolone-
induced
Details were
reported for culture-
positive participants
together with cul-
ture-negative partic-
ipants
vomiting, rash; joint
symptoms reported
were not thought to
be fluoroquinolone-
induced
Details were
reported for culture-
positive participants
together with-
culture negative par-
ticipants
Unal 1996 5-day: nausea and
vomiting (3)
7-day: nausea and
vomiting (3)
5-day: 0 7-day: increase in
transaminases (1)
Vinh 1996 2-day: 0 3-day: urticaria (1) Not described Not described
Vinh 2005 2-day: 0 3-day: 0 - -
aOnly trials reporting on non-serious adverse events are included.
bZero (0) events only when specifically stated by trial author.
cWhenever this was reported separately.
Table 7. Serious adverse eventsa
Comparison Trial* No. participants (in brackets) with serious adverse eventsb
Intervention Control
Fluoroquinolone vs chloram-
phenicol
Arnold 1993 Urinary retention (1), but it does not say in which group or if a culture-negative
or culture-positive participant
Bran 1991 0 0
Cristiano 1995 0 0
Gasem 2003 0 0
Gottuzzo 1992 Ciprofloxacin: severe rash (1); others
not described
Chloramphenicol: severe leucopenia
(1); others not described
Phongmany 2005 0 0
Quintero 1988 0 0
23Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever) (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 7. Serious adverse eventsa (Continued)
Fluoroquinolone vs ampicillin Flores 1994 0 0
Fluoroquinolone vs co-trimox-
azole
Hajji 1988 0 0
Limson 1989 0 0
Fluoroquinolone vs azithromy-
cin
Dolecek 2008 0 0
Chinh 2000 0 0
Girgis 1999 0 0
Parry 2007 0 0
Fluoroquinolone vs cefixime Pandit 2007 0 0
Fluoroquinolone vs ceftriaxone Smith 1994 0 0
Tran 1994 Fleroxacin: 0 Ceftriaxone: anaphylaxis (1)
Norfloxacin vs chlorampheni-
col
Nalin 1987 Nausea and vomiting “considered seri-
ous by the investigator”: number with
event unclear
0
Sarma 1991 0 0
Norfloxacin vs other fluoro-
quinolones
Bai 1995 0 0
Jia 1994 0 0
Xiao 1991 Not described Not described
Yang 1991 0 0
Different durations of fluoro-
quinolones
Alam 1995 0 0
Duong 1995 0 0
Kalo 1997 0 0
Nguyen 1997 0 0
Tran 1995 0 0
Unal 1996 0 0
Vinh 1996 0 0
Vinh 2005 0 0
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aOnly trials reporting on serious adverse events are included.
bZero (0) events only when specifically stated by trial author.
Funnel plot
We generated a funnel plot for clinical failure, microbiological
failure, and relapse for the comparison of fluoroquinolone versus
chloramphenicol, as there were more than five trials in these com-
parisons. No asymmetry was detected for the outcome clinical fail-
ure (Figure 3), while asymmetry was detected for microbiological
failure (Figure 4) and relapse (Figure 5). However, the number of
trials was very limited and well below the recommended number
(10 trials) for meaningful interpretation.
Figure 3. Funnel plot to assess publication bias in outcome clinical failure for comparison of
fluoroquinolones vs chloramphenicol
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Figure 4. Funnel plot to assess publication bias in outcome microbiological failure for comparison of
fluoroquinolones vs chloramphenicol
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Figure 5. Funnel plot to assess publication bias in outcome relapse for comparison of fluoroquinolones vs
chloramphenicol
1.2. Fluoroquinolones versus amoxicillin or ampicillin
Two trials, both with an unknown proportion of participants with
MDR and NaR strains, compared a fluoroquinolone with amoxi-
cillin (Yousaf 1992) or ampicillin (Flores 1994, only abstract avail-
able).
Clinical and microbiological failure, and adverse events
All results for measured outcomes were statistically significant in
favour of the fluoroquinolones − clinical failure (OR 0.08, 95%
CI 0.01 to 0.46; 90 participants, 2 trials, Analysis 2.1), microbio-
logical failure (OR 0.10, 95% CI 0.02 to 0.58; 90 participants, 2
trials, Analysis 2.2), and non-serious adverse events, described as
mostly diarrhoea and rashes (OR 0.17, 95% CI 0.04 to 0.73; 50
participants, 1 trial, Analysis 2.3 and Table 6) − but the numbers
of participants were very small so that confidence intervals were
very wide.
1.3. Fluoroquinolones versus co-trimoxazole
Hajji 1988 and Limson 1989 compared pefloxacin and ciproflo-
xacin respectively with co-trimoxazole. Neither trial included par-
ticipants with MDR strains, and only Hajji 1988 specifically re-
ported the absence of NaR strains in the participants.
Clinical and microbiological failure
There was a trend favouring fluoroquinolones over co-trimoxazole
for clinical failure (82 participants, 2 trials, Analysis 3.1) and mi-
crobiological failure (82 participants, 2 trials, Analysis 3.2), but we
did not find any statistically significant results for these outcomes,
although statistical power was extremely low so that confidence
intervals were very wide.
Fever clearance time
Only Hajji 1988 reported on fever clearance time, which was
104.88 hours (mean) for the fluoroquinolone group compared
with 186.00 hours (mean) for the co-trimoxazole group (Student’s
t test; P value < 0.01; no standard deviation reported).
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Relapse and convalescent faecal carriers
Hajji 1988 reported no relapses or convalescent faecal carriers.
Adverse events
We did not detect any statistically significant differences in non-
serious adverse events, such as rash, nausea, abdominal discomfort,
and dizziness (82 participants, 2 trials, Analysis 3.3; see Table 6).
Hajji 1988 reported no serious adverse events.
2. Fluoroquinolones versus second-line antibiotics
(azithromycin, cefixime, and ceftriaxone)
2.1. Fluoroquinolones versus azithromycin: adults
Girgis 1999 and Chinh 2000 compared ofloxacin and ciproflo-
xacin, respectively, with azithromycin. Chinh 2000 reported that
almost half of the participants were infected with NaR strains,
while Girgis 1999 did not test for NaR. We observed a tendency
for azithromycin to perform better than fluoroquinolones for all
outcomes except fever clearance times, but the sample size was very
small and confidence intervals were very wide. Thus we cannot
exclude chance as an explanation for these findings.
Clinical and microbiological failure
Wedid not detect any statistically significant differences in clinical
failure (152 participants, 2 trials, Analysis 4.1) or microbiological
failure (152 participants, 2 trials, Analysis 4.2). Out of the six
clinical failures in the fluoroquinolone arm in Chinh 2000, four
were infected with NaR strains, which could possibly explain the
trend favouring azithromycin for clinical failure.
Relapse
We did not detect any statistically significant differences in relapse
(102 participants, 2 trials, Analysis 4.3).
Fever clearance time
We also did not find any statistically significant difference in fever
clearance time (152 participants, 2 trials, Analysis 4.4). The higher
proportion of NaR strains in Chinh 2000 could explain the het-
erogeneity observed between the two trials.
Length of hospital stay
We did not detect any statistically significant difference in the
length of hospital stay (152 participants, Analysis 4.5).
Cost of therapy
We did not detect any statistically significant difference in the
cost of therapy (mean US$ 28 (standard deviation (SD) 0) for
fluoroquinolone group andmeanUS$ 35 (SD 0) for azithromycin
group).
Convalescent faecal carriage
We detected a statistically significant increase in the odds of con-
valescent faecal carriage in the fluoroquinolone group (OR 21.33,
95% CI 1.18 to 386.00; 133 participants, 2 trials, Analysis 4.6),
but the outcome was measured very early, at days two to three after
the end of treatment, and the confidence interval is wide.
Complications and adverse events
We did not detect any statistically significant difference in compli-
cations (seeTable 2 for details), as only one participant in each arm
in Chinh 2000 had gastrointestinal bleeding (152 participants, 2
trials, Analysis 4.7). Non-serious adverse events included rashes
and gastrointestinal symptoms, such as vomiting, abdominal pain,
and diarrhoea or constipation, but the trialists did not report the
number of participants with these events (Table 6); there were no
serious adverse events.
2.2. Fluoroquinolones versus azithromycin: children
Two trialsmade this comparison: Parry 2007 had 98%NaR strains
in the fluoroquinolone arm; and Dolecek 2008 had 96% NaR
strains in the fluoroquinolone arm. However, the fluoroquinolone
used in Dolecek 2008 was a new-generation fluoroquinolone, gat-
ifloxacin, which is active against NaR strains; thus the two trial
were not combined. In both trials more than 60% of participants
were children.
Clinical and microbiological failure
Parry 2007: We found a statistically significant increase in odds
of clinical failure with fluoroquinolone (OR 2.67, 95% CI1.16 to
6.11; 125 participants, 1 trial, Analysis 4.8).We did not detect any
statistically significant difference in microbiological failure (125
participants, 1 trial, Analysis 4.9).
Dolecek 2008: We did not detect any statistically significant dif-
ferences in clinical failure (285 participants, Analysis 4.8) or mi-
crobiological failure (285 participants, Analysis 4.9).
Relapse
Parry 2007: There were no relapses among participants seen at
one month’s follow up (114 participants followed from among
130 participants with culture-confirmed enteric fever, or less than
90% follow up at month for two included arms of the trial).
Dolecek 2008: We did not detect a statistically significant differ-
ence in relapse (264 participants, Analysis 4.10).
28Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever) (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Fever clearance time
Parry 2007: There was a statistically significant increase in fever
clearance time (MD 57.60 hours, 95% CI 28.31 to 86.89; 125
participants, Analysis 4.11).
Dolecek 2008: We did not detect a statistically significant differ-
ence in fever clearance time (285 participants, Analysis 4.11).
Length of hospital stay
Parry 2007: There was a borderline statistically significant increase
in the length of hospital stay in the fluoroquinolone group (MD
1.10 days, 95% CI 0.00 to 2.20; 125 participants, Analysis 4.12).
Dolecek 2008: We did not detect a statistically significant differ-
ence in length of hospital stay (285 participants, Analysis 4.12).
Convalescent faecal carriage
Parry 2007: We found a statistically significant increase convales-
cent faecal carriage in the fluoroquinolone group (OR 14.64, 95%
CI 1.84 to 116.48; 124 participants, 1 trial, Analysis 4.13).
Dolecek 2008: We did not detect a statistically significant dif-
ference in convalescent faecal carriage (268 participants, Analysis
4.13).
Complications and adverse events
Parry 2007: We did not detect any statistically significant differ-
ence in complications, which included gastrointestinal bleeding
(125 participants, Analysis 4.14; see Table 2). Non-serious adverse
events such as gastrointestinal and temporary joint symptomswere
reported (numbers for gastrointestinal symptoms not reported, see
Table 6). No serious adverse events were reported.
Dolecek 2008: There was a statistically significant decrease in com-
plications in the fluoroquinolone group (OR 0.05, 95% CI 0.00
to 0.94; 285 participants, Analysis 4.14). We did not detect any
statistically significant differences in non-serious adverse events
(285 participants, Analysis 4.15). There were no serious adverse
events.
2.2. Fluoroquinolones versus cefixime: adults
Two trials of adults, or mostly adults (Yu 1998; Pandit 2007)
compared a fluoroquinolone with cefixime. Although one trial (
Pandit 2007) did have a high proportion of NaR strains, the newer
fluoroquinolone used, gatifloxacin, is reported to be active against
NaR strains; the other trial on adults (Yu 1998) did not provide any
data for NaR strains. These two trials were combined in a meta-
analysis. Pandit 2007 was an outpatient trial, where community
medical auxiliaries conducted twice daily home-based assessments
and provided directly observed treatment with study drugs; all
participants were also seen at the hospital on day 10.
Clinical and microbiological failure
We detected a statistically significant decrease in odds of clinical
failure in the fluoroquinolone group (OR 0.05, 95% CI 0.01 to
0.24; 238 participants, 2 trials, Analysis 5.1, Figure 6), and no
statistically significant difference in microbiological failure (238
participants, Analysis 5.2).
Figure 6. Fluoroquinolones vs cefixime: clinical failure (adults or mostly adults)
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Relapse
There was a statistically significant reduction in relapse with the
fluoroquinolone (OR0.18, 95%CI0.03 to 0.91; 218participants,
2 trials, Analysis 5.3, Figure 7).
Figure 7. Fluoroquinolones vs cefixime: relapse (adults or mostly adults)
Fever clearance time
We detected a statistically significant reduction in fever clearance
time with the fluoroquinolone (MD -41.69 hours, 95%CI -54.96
to -28.42; 238 participants, 2 trials, Analysis 5.4).
Cost of therapy
The estimated cost of treatment provided in one trial was US$
1.2 for seven days of gatifloxacin and US$ 12 for seven days of
cefixime (generic drugs manufactured in India) (Pandit 2007).
Convalescent faecal carriers
We did not find any statistically significant difference in convales-
cent faecal carriers (227 participants, 2 trials, Analysis 5.5).
Complications and adverse events
There was no statistically significant difference for complications,
which included one death in the cefixime group (158 participants,
1 trial, Analysis 5.6; see Table 2), and no serious adverse events
(158 participants, 1 trial).
We found statistically significant heterogeneity in trials compar-
ing non-serious adverse events (Analysis 5.7). We did not find any
statistically significant difference in the one included trial (80 par-
ticipants), but we found a statistically significant increase in the
odds of nausea and vomiting in the other trial (OR 17.74, 95%CI
2.30 to 136.58; 158 participants; see Table 6). The heterogeneity
could be attributed to the different fluoroquinolones used in the
two trials (the relatively newer, gatifloxacin and levofloxacin). We
did not find any statistically significant difference in non-serious
adverse events when we used a random-effects model to combine
the trials (OR 3.30, 95% CI 0.11 to 97.30; 238 participants, 2
trials).
2.2. Fluoroquinolones versus cefixime: children
One trial, Cao 1999, compared a fluoroquinolone with cefixime
in children; no NaR strains were reported. The results for all mea-
sured outcomes favoured fluoroquinolones, but the sample sizes
were small and hence the confidence intervals were very wide.
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Clinical and microbiological failure
We did not detect any statistically significant difference in clinical
failure (82 participants, Analysis 5.8) or microbiological failure
(82 participants, Analysis 5.9).
Relapse
We did not detect any statistically significant difference in relapse
(40 participants, Analysis 5.10).
Fever clearance time
There was a statistically significant reduction in fever clearance
time in the fluoroquinolone group (MD -91.00 hours, 95% CI -
115.89 to -66.11; 78 participants, Analysis 5.11).
Length of hospital stay
We found a statistically significant reduction in the length of hos-
pital stay in the fluoroquinolone group (MD -3.00 days, 95% CI
-4.53 to -1.47; 81 participants, Analysis 5.12).
Convalescent faecal carriers
No convalescent faecal carriers were reported.
Complications and adverse events
There was no statistically significant difference in complications
(82 participants, Analysis 5.13), which included one death and
one child with gastrointestinal bleeding in the fluoroquinolone
arm, and one child requiring blood transfusion in the cefixime arm
(see Table 2). Non-serious adverse events included gastrointestinal
symptoms, such as abdominal pain (see Table 6), but the number
of participants was not reported.
2.3. Fluoroquinolones versus ceftriaxone
Three trials compared a fluoroquinolonewith ceftriaxone protocol
(Wallace 1993; Smith 1994; Tran 1994). There were no NaR
strains in Smith 1994, but this information was unavailable for
Tran 1994 and Wallace 1993. The stratifications by NaR strains
were not meaningful due to the limited number of trials in the
comparison.
Clinical and microbiological failure
The odds of clinical failure were reduced by 92% in the fluoro-
quinolone group (OR 0.08, 95% CI 0.01 to 0.45; 120 partici-
pants, 3 trials, Analysis 6.1, Figure 8). We did not detect a sta-
tistically significant difference in the odds of microbiological fail-
ure (119 participants, 3 trials, Analysis 6.2), but sample sizes were
small and confidence intervals were wide.
Figure 8. Fluoroquinolones vs ceftriaxone: clinical failure
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Relapse
We did not detect a statistically significant difference in the odds
of relapse (81 participants, 3 trials, Analysis 6.3), but sample sizes
were small and confidence intervals were wide.
Fever clearance time
Fever clearance times were statistically significantly lower in the
fluoroquinolone group (MD -101.20 hours, 95% CI -129.21 to -
73.19; 76 participants, 2 trials, Analysis 6.4). Tran 1994 excluded
two clinical failures in the ceftriaxone group when calculating
mean fever clearance time, which may result in an underestimate
of the difference in this outcome.
Length of hospital stay
Smith 1994 reported the on length of hospital stay as a mean of
nine days (range 6 to 13 days) in the ofloxacin group and a mean
of 12 days (range 7 to 23 days) in the ceftriaxone group; standard
deviation was not reported (P < 0.01).
Convalescent faecal carriage
Wedid not detect any significant difference for convalescent faecal
carriage (81 participants, 3 trials, Analysis 6.5).
Complications and adverse events
There was no significant difference in the number of compli-
cations, including anaemia, jaundice (120 participants, 3 trials,
Analysis 6.6; seeTable 2), serious adverse events− one case of ana-
phylaxis in the ceftriaxone group (78 participants, 2 trials, Analysis
6.7; see Table 7), or non-serious adverse events, which included
skin rash and pruritis (47 participants, 1 trial, Analysis 6.8; see
Table 6); however, sample sizes were very small so confidence in-
tervals were very wide.
3. Norfloxacin trials
We analysed norfloxacin trials separately from other fluoro-
quinolone trials because the WHO does not recommend this flu-
oroquinolone for treating enteric fever (WHO 2003).
3.1. Norfloxacin versus chloramphenicol
Only one of three trials reported the proportion of participants
with NaR strains (all strains were resistant to norfloxacin) (Sarma
1991). MDR strains were present in Sarma 1991, not reported
in Nalin 1987, and absent in Morelli 1992. In Sarma 1991 all
eight MDR strains appeared in the norfloxacin group, and only
40 participants were randomized in all.
Clinical and microbiological failure
There was a statistically significant increase in the odds of clinical
failure in the norfloxacin group among all trials (OR 5.80, 95%
CI 1.87 to 17.98; 259 participants, Analysis 7.1); the one trial
that did not report the proportion of MDR or NaR showed no
statistically significant difference (169 participants, Nalin 1987).
We did not detect a statistically significant difference in the odds
of microbiological failure (209 participants, 2 trials, Analysis 7.2).
Relapse
We did not detect a statistically significant difference in the odds
of relapse (90 participants, 2 trials, Analysis 7.3).
Fever clearance time
For fever clearance time (Analysis 7.4), we observed marked het-
erogeneity between Sarma 1991 and Nalin 1987, which could be
explained by the different definitions of fever clearance time used
(see Table 3), thus we did not combine the trials. Sarma 1991,
which also had some participants with MDR strains, showed that
the fever clearance time was statistically significantly lower in the
norfloxacin group (MD -36.00 hours, 95% CI -44.77 to -27.23;
40 participants), while Nalin 1987 showed that it was statistically
significantly higher in the norfloxacin group (MD 38.40 hours,
95% CI 23.08 to 53.72; 169 participants).
Length of hospital stay
The length of hospital staywas uniform (14days) in all participants
included (Analysis 7.5).
Convalescent faecal carriage
We did not detect a statistically significant difference for conva-
lescent faecal carriage (259 participants, 3 trials, Analysis 7.6).
Adverse events
We did not detect a statistically significant difference for non-
serious adverse events, such as gastrointestinal symptoms (Table
6), in the norfloxacin group and decreased blood cell counts in the
chloramphenicol group (209 participants, 2 trials, Analysis 7.7).
3.2. Norfloxacin versus ceftriaxone
One trial involving children, and which did not report the pro-
portion of participants with NaR strains, made this comparison (
Huai 2000).
Clinical failure
There was insufficient statistical power to detect a statistically sig-
nificant difference in clinical failure between the two treatment
groups (60 participants, Analysis 8.1).
Relapse
There was insufficient statistical power to detect a statistically sig-
nificant difference in relapse between the two treatment groups
(60 participants, Analysis 8.2).
Fever clearance time
The fever clearance time was statistically significantly higher in
the norfloxacin group (MD 48 hours, 95% CI 30.82 to 65.18; 60
participants, Analysis 8.3).
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Adverse events
Wedid not find a statistically significant difference for non-serious
adverse events, which were all gastrointestinal (60 participants,
Analysis 8.4; see Table 6).
3.3. Norfloxacin versus other fluoroquinolones
Three trials compared norfloxacin with pefloxacin (three trials),
ofloxacin (three trials, of which two did not state the proportion
of children included in the trials (Xiao 1991; Yang 1991)), or
enoxacin (two trials).
Clinical failure
The odds of clinical failure (Analysis 9.1) increased with nor-
floxacin compared with pefloxacin (OR 30.60, 95% CI 5.75 to
162.86; 200 participants, 3 trials), ofloxacin (OR 28.15, 95% CI
4.80 to 165.14; 123 participants, 3 trials), and enoxacin (OR4.15,
95% CI 1.77 to 9.76; 142 participants, 2 trials).
Relapse
No relapses were reported for norfloxacin and pefloxacin or
enoxacin, and we did not detect a statistically significant differ-
ence between ofloxacin and norfloxacin (106 participants, 2 trials,
Analysis 9.2).
Fever clearance time
The fever clearance time (Analysis 9.3) was statistically signifi-
cantly longer in the norfloxacin groups compared with the pe-
floxacin group (MD 18.83 hours, 95% CI 2.62 to 35.03; 144
participants, 2 trials) and enoxacin group (MD 60.00 hours, 95%
CI 33.81 to 86.19; 102 participants, 1 trial). It was also longer
compared with ofloxacin in Yang 1991 (MD 69.60 hours, 95%
CI 42.03 to 97.17; 56 participants), but not in Xiao 1991 (MD -
12.00 hours, 95% CI -40.58 to 16.58; 17 participants). However,
the mean difference for Xiao 1991, which contributed data to the
pefloxacin and ofloxacin comparisons, could have been underes-
timated because it was unclear whether the trialists had excluded
clinical failures when calculating the mean fever clearance time.
Convalescent faecal carriage
We did not detect any statistically significant difference in con-
valescent faecal carriage (Analysis 9.4) between norfloxacin and
pefloxacin (56 participants, 1 trial), ofloxacin (106 participants, 2
trials), and enoxacin (40 participants, 1 trial).
Adverse events
We did not detect a statistically significant difference in the num-
ber of non-serious adverse events (Analysis 9.5),mainly skin rashes
(see Table 6), between norfloxacin and ofloxacin (56 participants,
1 trial) or enoxacin (102 participants, 1 trial).
4. Different fluoroquinolone durations
4.1. Fluoroquinolones for 2 days versus 3 days
One trial in adults (Nguyen 1997) and two in children (Vinh
1996; Vinh 2005) made this comparison. Although all three trials
reported the percentage of participants with NaR strains − 2.5%
(Vinh 2005), 5% (Nguyen 1997), and 13% (Vinh 1996) − we
were unable to determine its impact on the results because there
were so few trials.
Adults
We did not detect a statistically significant difference in clinical
failure (100 participants, Analysis 10.1), relapse (50 participants,
Analysis 10.3), fever clearance time (100 participants, Analysis
10.4), length of hospital stay (100 participants, Analysis 10.5), or
complications (gastrointestinal bleeding, jaundice, and hypoten-
sion in the 3-day arm) (100 participants, Analysis 10.7; see Table
2). There were no microbiological failures or convalescent faecal
carriers.
Children
We did not detect a statistically significant difference in clinical
failure (296 participants, 2 trials, Analysis 10.1), microbiological
failure (296 participants, 2 trials, Analysis 10.2), relapse (262 par-
ticipants, 2 trials, Analysis 10.3), fever clearance time (296 partic-
ipants, 2 trials, Analysis 10.4), length of hospital stay (296 partic-
ipants, 2 trials, Analysis 10.5), convalescent faecal carriage (262
participants, 2 trials, Analysis 10.6), complications (gastrointesti-
nal bleeding and delirium (296 participants, 2 trials, Analysis 10.7;
see Table 2), or non-serious adverse events (urticaria in 3-day arm)
(296 participants, Analysis 10.8; see Table 6). There were no seri-
ous adverse events.
4.2. Fluoroquinolones for 3 days versus 5 days
Two trials − one with over 70% children (Tran 1995) and one
on adults (Duong 1995) − compared three days with five days of
ofloxacin and fleroxacin, respectively. Duong 1995 did not per-
form NaR testing, while some participants in Tran 1995 had NaR
strains, although the precise number of these participants was not
available.
Adults
We did not detect a statistically significant difference in clinical
failure (63 participants, Analysis 11.1), relapse (40 participants,
Analysis 11.2), fever clearance time (663 participants, Analysis
11.3), or length of hospital stay (63 participants, Analysis 11.4).
There were no microbiological failures, complications, or serious
adverse events in either arm.
Children
We did not detect a statistically significant difference in relapse
(154 participants, Analysis 11.2). Fever clearance time was sta-
tistically significantly lower in the three-day group (MD -12.00
hours, 95% CI -18.07 to -5.93; 195 participants, Analysis 11.3).
There were no statistically significant differences in non-serious
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adverse events, such as insomnia, headache, nausea, vomiting and
diarrhoea (228 participants, Analysis 11.5). There were no clin-
ical failures, microbiological failures, convalescent faecal carriers,
or serious adverse events in either arm.
4.3. Fluoroquinolones for 5 days versus 7 days
One trial, which did not report the proportion of participants with
NaR strains, made this comparison (Unal 1996). There were no
clinical failures in either arm, and we did not detect a statistically
significant difference in microbiological failure (46 participants,
Analysis 12.1), relapse (46 participants, Analysis 12.2), fever clear-
ance time (46 participants, Analysis 12.3), or non-serious adverse
events (46 participants, Analysis 12.4; see Table 6).
Fluoroquinolone for 7 days versus 10 or 14 days
We defined short-course treatment as seven or less days and long-
course treatment as more than seven days. One trial compared
perfloxacin for 7 days with 10 days (Kalo 1997), and amulticenter
trial compared fleroxacin for 7 days with 14 days (Arnold 1993).
Neither trial reported the proportion of participants with NaR
strains. We did not detect a statistically significant difference in
microbiological failure (87 participants, 2 trials, Analysis 13.1) or
relapse (87 participants, 2 trials, Analysis 13.2). There were no
clinical failures or convalescent faecal carriers.
Fluoroquinolones for 10 days versus 14 days
One trial, with seven per cent of the participants with NaR strains,
made this comparison (Alam 1995). We did not detect a statis-
tically significant difference in relapse (69 participants, Analysis
14.1), fever clearance time (69participants, Analysis 14.2), or non-
serious adverse events (gastrointestinal symptoms, headache and
rashes in both arms, and one case of joint pain in the 14-day arm
(69 participants, Analysis 14.3; seeTable 6). There were no clinical
or microbiological failures, or convalescent faecal carriers.
D I S C U S S I O N
Even though in endemic areas enteric fever most commonly af-
fects children, this review demonstrates the paucity of data from
adequately designed randomized controlled trials in children.
Limitations in analysis and interpretation
The sample sizes in each trial, as well as the number of trials
in each comparison, were very small. The pooled sample sizes
were also very small, thus there was very little statistical power,
and we cannot exclude chance as an explanation for results of
many comparisons. The methodological quality and the quality
of reporting of the trials were variable and sometimes poor. The
method of allocation concealment was unclear in 22 trials, and
the method of randomization was unclear in 17 of the 38 trials,
meaning they were potentially open to selection bias. We could
not perform meaningful sensitivity analyses excluding trials with
poor methodological quality due to the small number of trials in
each comparison, except for a limited number of comparisons of
fluoroquinolones with chloramphenicol.
The small number of trials also precluded the meaningful use of
a funnel plot (assessment of publication bias). In the funnel plots
generated for primary outcomes for fluoroquinolones versus chlo-
ramphenicol, no asymmetry was found for clinical failure, but
asymmetry was detected for microbiological failure and relapse.
Although interpretation is extremely limited due to the limited
number of trials, the asymmetry could indicate the failure to pub-
lish smaller trials that did not show any statistically significant dif-
ference between older drugs and fluoroquinolones (Stern 1997).
However, we conducted a thorough search for trials and also iden-
tified an additional two ongoing trials, which we will include in a
future update.
Another factor limiting these analyses and interpretation was the
lack of explicit definitions of outcomes measured in some trials,
especially for relapse, and wide variations in the times at which
the outcomes were measured, particularly for microbiological fail-
ure and relapse. Some trials did not clearly report whether symp-
tomatic relapse was confirmed by a positive blood culture. Resis-
tance data were also not explicitly reported, particularly in older
trials. Four of the 13 trials that compared fluoroquinolones with a
first-line agent (chloramphenicol, co-trimoxazole, and ampicillin
or amoxicillin) did not report the proportion of participants with
MDR strains, and only 13 of 38 trials reported NaR data.
Most of the trials did not explicitly report the number of partic-
ipants included when measuring fever clearance time. The mean
fever clearance times may also be skewed, which means some par-
ticipants take longer times to clear fever due to a variety of rea-
sons, and a meta-analysis of such arithmetic means may not be
entirely accurate. The persistence of fever despite clearance of S.
Typhi and S. Paratyphi from the bloodstream has been attributed
to the continued production of pyrogenic cytokines (Islam 1988;
Lasserre 1991; Bhutta 1994; Acharya 1995) and may also not be
an adequate indicator of antibiotic efficacy.
We did not observe statistically significant heterogeneity in the
included trials with the exception of those involving comparisons
with norfloxacin and for selected secondary outcomes among some
trials, such as in non-serious adverse events with use of a newer
fluoroquinolone (gatifloxacin), and length of hospitalization for
fluoroquinolones versus chloramphenicol. For the norfloxacin tri-
als, we were unable to explain the observed heterogeneity due to
the small number of trials, although the WHO does not recom-
mend norfloxacin for treating enteric fever because of poor oral
bioavailability (WHO2003). Gatifloxacin is a relatively new drug;
an ongoing trial of gatifloxacin in enteric fever was temporarily
stopped due to safety concerns (ISRCTN53258327).
Applicability
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Thesemeta-analyses included only blood or bone marrow culture-
confirmed cases of enteric fever, whereas in most endemic areas,
enteric fever is treated on the basis of clinical suspicion without
confirmation by culture, owing to the absence of culture facilities.
Most trials included adult inpatients. Inpatients represent the se-
vere end of the spectrum of enteric fever. In endemic countries, up
to 90% of cases of enteric fever are managed safely in the outpa-
tient setting (Parry 2002). Also, children differ from adults with
enteric fever in terms of disease presentation, severity, and com-
plications (Butler 1991; Mahle 1993; Walia 2006). Another fac-
tor that may limit applicability in children is the relatively limited
data regarding fluoroquinolone pharmacokinetics and adverse ef-
fects in this age group (Gendrel 2003; Committee 2006). Thus
data obtained from adult inpatients have limited applicability to
situations in many parts of the developing world where the vast
majority of cases of enteric fever are in children and most of which
are treated in the outpatient setting.
The use of fluoroquinolones as first-line antibiotics in such settings
has resulted in gross overuse of these antibiotics and high levels of
resistance to fluoroquinolone have emerged rapidly in S. Typhi and
S. Paratyphi in countries where fluoroquinolones are used as first-
line antibiotics (Biswal 1994; Brown 1994; Rowe 1995; Murdoch
1998; Chandel 2000; Chandel 2001; Threlfall 2001; Butt 2003;
Threlfall 2003; Karunanayake 2004; Slinger 2004; Butt 2005;
Manchanda 2006; Mohanty 2006; Walia 2006; Chau 2007; Joshi
2007).
Impact of resistance strains
The changing pattern of resistance, including rapidly rising resis-
tance to fluoroquinolones, also affects the applicability of these re-
sults - particularly for older fluoroquinolones, such as ofloxacin. In
one recent trial that includedmainly children with a very high pro-
portion of NaR strains, ofloxacin had significantly higher number
of clinical failures (Parry 2007).We conducted sensitivity analyses
to determine the impact of excluding trials with NaR or MDR
strains, and those trials that did not report the proportion of par-
ticipants with NaR or MDR strains. However, the analyses were
mostly uninformative owing to lack of statistical power. Newer
fluoroquinolones (such as gatifloxacin) are not affected by NaR
strains (Pandit 2007; Dolecek 2008), and two trials with NaR
strains but which used gatifloxacin were considered separately,
where possible, from trials of older fluoroquinolones that reported
NaR strains. More meaningful sensitivity analyses involving dif-
ferent proportions of strains with resistance to fluoroquinolones
may be possible in future updates of this review.
Fluoroquinolones versus first-line antibiotics
(chloramphenicol, co-trimoxazole, and ampicillin or
amoxicillin) in children
We are unable to draw conclusions about the use of fluoro-
quinolones compared to first-line drugs in children as we did not
find any trials involving these comparisons.
Fluoroquinolones versus second-line drugs
(azithromycin, ceftriaxone, and cefixime) in children
There were very limited data for these comparisons, and thus no
firm conclusions can bemade.One small, open trial with adequate
methods of randomization and allocation concealment compared
fluoroquinolone with cefixime (Cao 1999). The trial showed that
fluoroquinolones were not significantly different from cefixime for
all the primary outcomes studied (clinical failure, microbiologi-
cal failure, and relapse), although confidence intervals were very
wide. Fluoroquinolones were significantly better than cefixime in
reducing fever clearance times.
An open trial published in 2007, which had adequate methods
of randomization and allocation concealment, involved mostly
children, and had a high proportion of NaR strains, found that
ofloxacin administered for seven days had significantly higher clin-
ical failure and fever clearance times compared with azithromycin
(Parry 2007). Another trial, published in 2008 (Dolecek 2008),
which also had adequate methodological quality, found no statisti-
cally significant differences between a newer fluoroquinolone (gat-
ifloxacin) and azithromycin, although confidence intervals were
very wide.
One trial that could not be included in this review compared
ofloxacin and ceftriaxone in children (Kumar 2007). The only re-
sults presented weremean fever clearance times, which were signif-
icantly different in the ofloxacin group compared to the ceftriax-
one group (4.97 vs 4.26 days, P < 0.05); other details, such as the
number of participants in each group and number of strains with
reduced susceptibility to fluoroquinolones, were not specified.
Fluoroquinolones versus first-line antibiotics
(chloramphenicol, co-trimoxazole, and ampicillin or
amoxicillin) in adults
The sample sizes in these trials were very small and confidence
intervals were very wide. Among 10 trials comparing fluoro-
quinolones with chloramphenicol, only two open trials reported
using adequate methods of randomization and allocation conceal-
ment, and lost no participants during the short-term follow up (
Gasem 2003; Phongmany 2005). We found fluoroquinolones to
be better than chloramphenicol for reducing the odds of relapse.
However, most trials were also of low methodological quality and
did not explicitly report the definition, or the culture site used to
confirm symptomatic relapse, or both. We did not find any signif-
icant difference between fluoroquinolones and chloramphenicol
for relapses clearly confirmed by blood cultures, although this was
based on only one trial with low statistical power and lowmethod-
ological quality. We found fluoroquinolones to be better in reduc-
ing fever clearance time and duration of hospitalization including
in trials of adequate methodological quality. Clinical failure and
microbiological failure were comparable between the two groups
although the confidence intervals were wide.
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We did not detect a statistically significant difference between flu-
oroquinolones and co-trimoxazole for any measured outcome in
adults, but statistical power was very low and only one of the two
open trials had adequate method of randomization, as well as allo-
cation concealment and follow up (Hajji 1988).We found fluoro-
quinolones to be significantly better than amoxicillin or ampicillin
for clinical and microbiological failure. However, neither of the
two included trials reported the proportion of participants with
MDR strains. One trial report was an abstract with limited infor-
mation (Flores 1994), and the other was of low methodological
quality (an open trial that had inadequate randomization and al-
location concealment, and included less than 90% of the partic-
ipants in the analysis) (Yousaf 1992). Thus both may have been
open to selection bias, which may have operated in favour of the
newer fluoroquinolones.
Fluoroquinolones versus second-line drugs
(azithromycin, ceftriaxone, and cefixime) in adults
Fluoroquinolones were not significantly different from azithromy-
cin for any primary outcome in inpatients. However, the confi-
dence intervals were wide because only two small trials contributed
data, although both used adequate methods of randomization and
allocation concealment. The higher number of clinical failures ob-
served in the fluoroquinolone group in one of these trials, Chinh
2000, could be due to a high proportion (> 50%) of participants
infected with NaR strains.
Fluoroquinolones were associated with a significant and large re-
duction in the odds of clinical failure and fever clearance time com-
pared with ceftriaxone, based on three small open trials involving
inpatients (Wallace 1993; Smith 1994; Tran 1994). Two of these
trials used an adequate method of randomization and allocation
concealment (Smith 1994; Tran 1994). We did not find a statis-
tically significant difference between the antibiotics for any other
measured outcomes, although confidence intervals were wide, and
we could not assess the impact of NaR strains on these results
meaningfully.
We found results in favour of fluoroquinolones for clinical failure
and relapse as well as fever clearance time from two trials com-
paring cefixime and a fluoroquinolone (Pandit 2007; Yu 1998),
although one was of low methodological quality and did not re-
port NaR strains. One of these trials used a newer fluoroquinolone
active against NaR strains (Pandit 2007).
Comparison with past reviews
The results of this systematic review differ from those of an earlier
summary of 57 randomized controlled trials of enteric fever, 10 of
which compared a fluoroquinolone with a non-fluoroquinolone
antibiotic (Parry 2002). Parry 2002, which did not use meta-ana-
lytic techniques, reported that clinical failures and fever clearance
times with fluoroquinolone therapy were lower compared with
first-line antibiotics, ceftriaxone, and cefixime. In our meta-analy-
ses of 23 randomized controlled trials comparing fluoroquinolones
with different antibiotics and which separated trials on children
and adults, we found most trials to be of lowmethodological qual-
ity and lacking in statistical power, with wide confidence intervals.
Hence, no conclusive evidence of superiority of fluoroquinolones
over first-line antibiotics (chloramphenicol, co-trimoxazole, and
ampicillin or amoxicillin) could be made for clinical failure. There
is, however, better evidence to suggest that fever clearance times
are lower with fluoroquinolones compared to chloramphenicol
in adults. For comparisons of fluoroquinolones with ceftriaxone
and cefixime, as mentioned above, we found clinical failures to be
lower and fever clearance times also shorter with fluoroquinolones.
However, these results are based on few trials, including some of
low methodological quality, and mainly on data from adults.
Cost of therapy
In this review, we could not compare the cost of fluoroquinolone
therapy in relation to other antibiotics because all but Girgis 1999
and Pandit 2007 did not report these data. In most low-income
countries, fluoroquinolones are available at a much higher cost
than first-line antibiotics; for example, in Pakistan, a 10-day course
of ciprofloxacin costs approximately 1.5 times (local brand) to
up to five times (international brand) that of a conventional 14-
day course of chloramphenicol (retail prices of several brands in
Karachi, Pakistan). The cost of a shorter (three-day) course of
ciprofloxacin, however, ranges from less than half to 1.5 times
greater than a 14-day chloramphenicol regimen; only one trial
made this comparison (Phongmany 2005). Fluoroquinolonesmay
be the least costly option for the treatment of MDR enteric fever
compared with costs of azithromycin, cefixime, and ceftriaxone
(retail prices of several brands in Karachi, Pakistan), but increasing
numbers of clinical failures in trials with NaR strains with older
fluoroquinolones (Chinh 2000; Parry 2007) suggest that this cost
advantage of using older fluoroquinolones has been overwhelmed
by declining efficacy in the face of rising resistance. Rising levels of
resistance could in the near future also affect the efficacy of newer
generation fluoroquinolones (Turner 2006).
Different fluoroquinolones
Among various fluoroquinolones, we found all three classes anal-
ysed (pefloxacin, ofloxacin, and enoxacin) to be significantly supe-
rior compared with norfloxacin for reducing clinical failure. These
trials originated largely fromChina, andnone specified themethod
of randomization, allocation concealment, blinding, or follow up,
and thus we deemed them to be of low methodological quality.
Different durations of fluoroquinolone therapy
A large number of different durations were compared in several
trials. The number of trials for each comparison was small, mostly
with small sample sizes andhence lacking considerably in statistical
power. Only two trials compared a short-course regimen (seven
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days or less) with a long-course regimen (more than seven days).
Clinical failure, microbiological failure, and relapse rates were low
in both arms, but the data were not sufficient to enable us to
exclude chance as an explanation for these findings.
Adverse events
A serious adverse eventwas reported in three instances (anaphylaxis
in ceftriaxone group, severe leucopenia in chloramphenicol group,
and a rash in the ciprofloxacin group). Overall, few participants
reported adverse events. These were mainly abdominal symptoms,
such as nausea or vomiting, abdominal pain, or rashes; however,
a trial involving a newer fluoroquinolone (gatifloxacin) reported a
statistically significantly larger number of participants with nau-
sea and vomiting when compared to the non-fluoroquinolone
arm. Mild joint pain was reported in one case in a 14-day fluo-
roquinolone group. One child in each arm (fluoroquinolone and
azithromycin arm) of a trial reported temporary joint discomfort.
The maximum period of follow up was six months (two trials),
thus most trials could not adequately address long-term adverse
effects, particularly on growing joints.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
A lack of data precludes firm conclusions to be made regarding
superiority of fluoroquinolones over first-line antibiotics (chlo-
ramphenicol, ampicillin, amoxicillin), cefixime, or ceftriaxone in
children. Data from one trial suggest that azithromycin may be
better than ofloxacin (an older fluoroquinolone) in children in-
fectedwith a high proportion of strains with reduced susceptibility
to fluoroquinolones. We did not find any statistically significant
differences in primary outcomes in one trial of azithromycin and
gatifloxacin (a new-generation fluoroquinolone) in children.
In adult inpatients, data suggest that fluoroquinolones may be
better than chloramphenicol for reducing clinical relapse. Limited
data from adults suggest that fluoroquinolones may also be better
than ceftriaxone for reducing clinical failure, and may be better
than cefixime for reducing clinical failure and relapse. We did not
find any statistically significant differences in primary comparisons
of azithromycin and older fluoroquinolones in adults.
No conclusions could be made for superiority of any particular
duration of fluoroquinolone therapy.
No conclusions can be made regarding adverse effects in children,
owing to the short length of follow up in most of these trials, and
few trials involving children.
Implications for research
Appropriate therapy for enteric fever remains a clinical and public
health dilemma. High prevalence of resistance to first-line antibi-
otics (MDR strains) and rapid emergence of resistance to fluoro-
quinolones among S. Typhi and S. Paratyphi have added to the
complexity of this issue in resource-constrained environments.
More evidence is required in the form of larger or multicentred
well-designed and adequately powered trials of fluoroquinolones
in children, particularly in outpatient settingswith adequate follow
up and monitoring of adverse events.
To prevent inappropriate use of fluoroquinolones in children with
prolonged fever, a step-wise approach to determining the cause of
such fever in children and appropriate guidelines for management
must be developed and evaluated in outpatient settings in areas
endemic for enteric fever. Close monitoring of resistance patterns
as well as check on indiscriminate use of alternate agents is needed.
Combination therapy may also reduce the rate of development of
resistance in S. Typhi and S. Paratyphi, and could also be eval-
uated further in trial settings. Newer fluoroquinolones, such as
gatifloxacin, may have efficacy against NaR strains; however more
evidence is needed, including an investigation in tolerance and
safety profile.
Trialists must improve both the methodological quality of ran-
domized controlled trials and explicitly document the methods
they use to minimize selection and observeration bias, including
the use of double blinding.
Trialists should also standardize definitions of primary outcomes
and the time points at which these are measured, including quan-
tification of strains with reduced susceptibility to fluoroquinolones
and other study drugs (including proportion of isolates with high
MICs for fluoroquinolones, and proportion of MDR and NaR
strains for each study arm).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Abejar 1993
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 30 analyseda : 15 in fleroxacin group; 15 in chloramphenicol group
Adult inpatients
Inclusion criteria: clinical with blood culture positive
Exclusion criteria: children and culture negative
Interventions 1. Fleroxacin (400 mg oral once daily for 10 days)
2. Chloramphenicol (50 mg/kg/day in 3 divided doses every 8 hours for 14 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time (no SD)
5. Other adverse events
Notes Location: Philippines
Date: not reported
Severity of illness at entry: not reported
Alam 1995
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 64/72 (88.9%)
Participants 69 analyseda : 35 in 10-day group: 34 in 14-day group
Adults (18 to 65 years) and 11 children (< 18 years)
Both outpatients and inpatients (ciprofloxacin 10-day group had 20 outpatients and 14 inpatients, ciprofloxacin 14-
day group had 21 outpatients and 14 inpatients)
Inclusion criteria: blood or bone marrow culture positive for S. Typhi or S. Paratyphi
Exclusion criteria: hypersensitivity to quinolones; severe renal disease; pregnant or lactating; patients < 18 years were
randomized only if had MDR strain
Interventions 1. Ciprofloxacin (500 mg oral twice daily for 10 days)
2. Ciprofloxacin (500 mg oral twice daily for 14 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
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Alam 1995 (Continued)
4. Fever clearance time
5. Convalescent faecal carriage
6. Serious adverse events
7. Other adverse events
Notes Location: Bangladesh
Date: 1992-3
Severity of illness at entry: not reported
Arnold 1993
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 91 analyseda : 24 in the fluoroquinolone 7-day group; 33 in the fluoroquinolone 14-day group; 34 in the chloram-
phenicol group
Adult inpatients aged 18 to 65 years
Inclusion criteria: clinical
Exclusion criteria: fever > 14 days; signs of typhoid fever > 21 days before enrolment; pregnant or lactating; hyper-
sensitivity to chloramphenicol; nalidixic acid and its derivatives; history of cerebral disorders; severe concomitant
disease; concomitant antimicrobial treatment
Interventions 1. Fleroxacin (400 mg oral once daily for 7 days)
2. Fleroxacin (400 mg oral once daily for 14 days)
3. Chloramphenicol (50 mg/kg/day oral for 14 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time (time to event)
5. Convalescent faecal carriage
Notes Location: multicentre; country names not reported, but authors’ affiliations were Brazil, Mexico, Korea, Indonesia,
and Ivory Coast
Date: not available
Severity of illness at entry: major complications were excluded
Bai 1995
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
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Bai 1995 (Continued)
Participants 102 analyseda : 52 in enoxacin group; 50 in norfloxacin group
Adult inpatients aged 17 to 64 years
Inclusion criteria: clinical with blood or bone marrow culture positive for S. Typhi
Exclusion criteria: not mentioned
Interventions 1. Enoxacin (300 mg oral twice daily for 10 days or 3 to 5 days after afebrile)
2. Norfloxacin (200 mg oral 3 to 4 times a day for 14 days or 3 to 5 days after afebrile)
Outcomes 1. Clinical failure
2. Fever clearance time
3. Complications
4. Serious adverse events
5. Other adverse events
Notes Location: China (Chinese language)
Date: 1989-94
Severity of illness at entry: not reported
Bran 1991
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: double
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 102 analyseda : 51 in ciprofloxacin group; 51 in chloramphenicol group; only the total number of participants (102)
was provided, but we assumed 51 in each group
Age not mentioned (adult dosages used); most probably inpatients
Inclusion criteria: blood and/or bone marrow culture positive for S. Typhi
Exclusion criteria: not reported
Interventions 1. Ciprofloxacin (500 mg oral twice daily for 10 days)
2. Chloramphenicol (750 mg oral every 6 hours for 14 days)
Outcomes 1. Microbiological failure
2. Fever clearance time (no SD)
3. Convalescent faecal carriage
4. Serious adverse events
5. Other adverse events
Notes Location: Guatemala
Date: not reported
Severity of illness at entry: not reported
Conference abstract
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Cao 1999
Methods Generation of allocation sequence: computer-generated
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 40/82 (49%)
Participants 82 analyseda : 38 in ofloxacin group; 44 in cefixime group
Children inpatients aged < 15 years
Inclusion criteria: fever and no obvious source of infection for > 7 days or < 7 days if family history of typhoid fever
Exclusion criteria: severe disease; hypersensitivity to quinolones or third-generation cephalosporins; received either
drug during this illness; or responded to ampicillin, chloramphenicol, or co-trimoxazole
Interventions 1. Ofloxacin (10 mg/kg/day oral in 2 divided doses for 5 days)
2. Cefixime (20 mg/kg/day oral in 2 divided doses for 7 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Complications
6. Length of hospitalization
7. Convalescent faecal carriage
8. Serious adverse events
9. Other adverse events
Notes Location: Vietnam
Date: 1995-6
Severity of illness at entry: all uncomplicated
Author provided further information
Chinh 2000
Methods Generation of allocation sequence: computer-generated
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 38/91(42%)
Participants 88 analyseda : 44 in ofloxacin group; 44 in azithromycin group
Adult inpatients aged ≥ 15 years
Inclusion criteria: clinical with blood culture positive for S. Typhi or S. Paratyphi
Exclusion criteria: severe or complicated disease; significant underlying disease; hypersensitivity to either trial drug;
pregnant; history of treatment with fluoroquinolone or third-generation cephalosporins or macrolides within 1 week
of admission
Interventions 1. Ofloxacin (200 mg oral twice daily for 5 days at 8 mg/kg/day)
2. Azithromycin (1 g oral daily for 5 days at 20 mg/kg/day)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
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4. Fever clearance time (mean and 95% confidence intervals; SD calculated by review author)
5. Complications
6. Length of hospitalization (mean and 95% confidence interval; SD calculated by review author)
7. Convalescent faecal carriage
8. Serious adverse events
9. Other adverse events (number of events stated)
Notes Location: Vietnam
Date: not available
Severity of illness at entry: all uncomplicated
Author provided further information
Cristiano 1995
Methods Generation of allocation sequence: computer-generated
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 60 analyseda : 30 in pefloxacin group; 30 in chloramphenicol group
Adult inpatients aged 17 to 64 years
Inclusion criteria: severe culture-positive typhoid sepsis
Exclusion criteria: received drug active against S. Typhi
Interventions 1. Pefloxacin (1200 mg intravenous in 3 divided doses every 8 hours for 5 days, then oral for 10 days)
2. Chloramphenicol (2 g oral in 4 divided doses every 6 hours for 15 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time (no SD)
5. Convalescent faecal carriage
6. Length of hospitalization (no SD)
7. Serious adverse events
8. Other adverse events
Notes Location: Italy
Date: 1991-3
Severity of illness at entry: all severe
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Dolecek 2008
Methods Generation of allocation sequence: computer-generated, block randomization
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 268/288 (93%)
Participants 285 analyseda : 145 in gatifloxacin group; 140 in azithromycin group
Adult and children inpatients aged 1 to 41 years (210/287 (73%) participants below the age of 15 years)
Inclusion criteria: clinical or culture-positive enteric fever
Exclusion criteria: no consent; pregnancy; age < 6 months; history of hypersensitivity to either of the trial drugs; any
signs of severe typhoid fever or previous reported treatment with a fluoroquinolone antibiotics; a third-generation
cephalosporin or macrolide antibiotic within 1 week before to hospital admission
Interventions 1. Gatifloxacin (10 mg/kg/day oral once daily for 7 days)
2. Azithromycin (20 mg/kg/day oral once daily for 7 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Complications
6. Length of hospitalization
7. Convalescent faecal carriage
8. Serious adverse events
9. Other adverse events
Notes Location: Vietnam (multi-centre, 3 hospitals)
Date: 2004-5
Severity of illness at entry: all uncomplicated
Received as an unpublished trial (with additional data), but reference updated to current citation upon publication
Duong 1995
Methods Generation of allocation sequence: random-number table
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 40/63 (63%)
Participants 63 analyseda : 22 in 3-day group; 41 in 5-day group
Adult inpatients aged 15 to 65 years
Inclusion criteria: clinical
Exclusion criteria: pregnant or lactating; hypersensitivity to nalidixic acid and derivatives; history of cerebral disorders;
severe concomitant disease; complications of enteric fever; received any fluoroquinolone in previous week
Interventions 1. Fleroxacin (400 mg oral once daily for 3 days)
2. Fleroxacin (400 mg oral once daily for 5 days)
Outcomes 1. Clinical failure
2. Microbiological failure
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3. Relapse
4. Fever clearance time
5. Complications
6. Length of hospitalization
7. Serious adverse events
8. Other adverse events (number of events stated)
Notes Location: Vietnam
Date: 1993-4
Severity of illness at entry: all uncomplicated
Author provided further information
Flores 1994
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 40 analyseda : 20 in ofloxacin group; 20 in ampicillin group
Adults (abstract keyword); most probably inpatients
Inclusion criteria: clinical with culture positive
Exclusion criteria: not reported
Interventions 1. Ampicillin (1 g every 6 hours for 10 days)
2. Ofloxacin (400 mg every 12 hours for 10 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Serious adverse events
Notes Location: Mexico
Date: not reported
Severity of illness at entry: not reported
Abstract only
Gasem 2003
Methods Generation of allocation sequence: random-number table
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 55 analyseda : 28 in ciprofloxacin group; 27 in chloramphenicol group
Adult inpatients
Inclusion criteria: clinical and ≥ 14 years
Exclusion criteria: severe complications; treatment with chloramphenicol, ciprofloxacin, other fluoroquinolones
before admission; history of allergy to chloramphenicol/quinolone; malaria or other infection; white blood cell count
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< 2000/mL; pregnant or lactating
Interventions 1. Ciprofloxacin (500 mg twice daily for 7 days)
2. Chloramphenicol (500 mg oral 4 times a day for 14 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Complications
6. Length of hospitalization
7. Serious adverse events
8. Other adverse events
Notes Location: Indonesia
Date: not reported
Severity of illness at entry: none had severe complications on enrolment
Girgis 1999
Methods Generation of allocation sequence: random-number list, block randomization
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 64 analyseda : 28 in ciprofloxacin group; 36 in azithromycin group
Adult inpatients aged > 18 years
Inclusion criteria: clinical
Exclusion criteria: pregnant or lactating; allergy to ciprofloxacin or erythromycin/other macrolides; those with com-
plications of typhoid fever; inability to swallow medications; significant underlying illness; treatment within past 4
days with an antibiotic with potential efficacy against S. Typhi
Interventions 1. Ciprofloxacin (500 mg oral twice daily for 7 days)
2. Azithromycin (1 g oral once daily for the first day followed by oral 500 mg once daily for total duration of 7 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Complications
6. Length of hospitalization
7. Cost of treatment
8. Convalescent faecal carriage
9. Serious adverse events
10. Other adverse events (number of events stated)
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Notes Location: Egypt
Date: 1997-8
Severity of illness at entry: all uncomplicated
Author provided further information
Gottuzzo 1992
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: double
Inclusion of all randomized culture-positive participants in the final analysis: 95/98 (97%)
Participants 98 analyseda : 49 in ciprofloxacin group; 49 in chloramphenicol group
Adult inpatients
Inclusion criteria: clinical with culture positive for S. Typhi or S. Paratyphi
Interventions 1. Ciprofloxacin (500 mg oral every 12 hours for 10 days)
2. Chloramphenicol (750 mg oral every 6 hours for 14 days)
Outcomes 1. Clinical failure
2. Relapse
Notes Location: not available
Date: not available
Severity of illness at entry: not reported
Hajji 1988
Methods Generation of allocation sequence: random-number table
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 42 analyseda : 24 in pefloxacin group; 18 in co-trimoxazole group
Adult inpatients aged > 16 years
Inclusion criteria: clinical
Exclusion criteria: not reported
Interventions 1. Pefloxacin (400 mg oral twice daily for 14 days)
2. Co-trimoxazole (160/800 mg oral twice daily for 14 days)
5 participants were given intravenous pefloxacin for mean 4.8 days; 4 were given intramuscular co-trimoxazole for
mean 6 days
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time (no SD, non-exact P value)
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5. Complications
6. Convalescent faecal carriage
7. Serious adverse events
8. Other adverse events
Notes Location: Morocco
Date: 1984-5
Severity of illness at entry: comatose or neurological disorders in 3 participants in pefloxacin group and 2 participants
in co-trimoxazole group
Author provided further information
Huai 2000
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 60 analyseda : 30 in norfloxacin group; 30 in ceftriaxone group
Children inpatients
Inclusion criteria: clinical with blood or bone marrow positive for S. Typhi
Exclusion criteria: not mentioned
Interventions 1. Norfloxacin (10 to 20 mg/kg/day oral divided in 2 times per day until afebrile, no drug for 5 days, and administer
again for 5 days)
2. Ceftriaxone (100 mg/kg/day intravenous until afebrile, no drug for 5 days, and administer again for 5 days)
Outcomes 1. Clinical failure
2. Relapse
3. Fever clearance time
4. Other adverse events
Notes Location: China (Chinese language)
Date: 1995-8
Severity of illness at entry: norfloxacin group had 7 participants with liver damage and 4 with myocardial damage;
and ceftriaxone group had 8 participants with liver damage and 3 with myocardial damage
Jia 1994
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: double
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 130 analyseda : 63 in pefloxacin group; 67 in norfloxacin group
Age not mentioned (adult dosages used); inpatients
Inclusion criteria: clinical with culture positive blood or bone marrow for S. Typhi
Exclusion criteria: not mentioned
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Interventions 1. Pefloxacin (400 mg plus placebo oral twice daily for 10 to 14 days)
2. Norfloxacin (300 mg plus placebo oral 3 times a day for 10 to 14 days)
Outcomes 1. Clinical failure
2. Fever clearance time
3. Complications
4. Serious adverse events
Notes Location: China (Chinese language)
Date: 1991-2
Severity of illness at entry: not reported
Both groups in Jia 1994 were the same as Weng 1996. Weng 1996 did not report use of placebo as Jia 1994 did.
Weng 1996 also included other groups. Due to the ambiguity surrounding the use of placebo in the norfloxacin
group, we decided to make Jia 1994 the primary reference because the methodology was clearer in this publication
Kalo 1997
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 30 analyseda : 15 in 7-day group; 15 in 10-day group
Adult inpatients aged 16 to 42 years
Inclusion criteria: blood-culture positive; ampicillin-resistant S. Typhi
Exclusion criteria: received quinolones within 2 weeks before hospitalization
Interventions 1. Perfloxacin (400 mg oral twice daily for 7 days)
2. Perfloxacin (400 mg oral twice daily for 10 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Convalescent faecal carriage
5. Serious adverse events
Notes Location: Albania
Date: 1992-4
Severity of illness at entry: not reported
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Limson 1989
Methods Generation of allocation sequence: random-number table
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 40 analyseda : 20 in ciprofloxacin group; 20 in co-trimoxazole group
Adult inpatients aged 18 to 77 years
Inclusion criteria: clinical
Exclusion criteria: complications; drug allergy; renal impairment
Interventions 1. Ciprofloxacin (500 mg oral twice daily for 10 days)
2. Co-trimoxazole (160/800 mg oral twice daily for 14 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Serious adverse events
4. Other adverse events
Notes Location: Philippines
Date: not reported
Severity of illness at entry: all uncomplicated
Morelli 1992
Methods Generation of allocation sequence: computer-generated
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 156 analyseda : 30 each in ofloxacin and chloramphenicol groups; 36 in pefloxacin group; 20 each in ciprofloxacin,
enoxacin, and norfloxacin groups
Adult inpatients aged 16 to 60 years
Inclusion criteria: blood culture positive for S. Typhi; high fever for not more than 5 days; toxic symptomatology
Exclusion criteria: hypersensitivity or allergy to fluoroquinolone or antibiotic treatment
Interventions 1. Ofloxacin (300 mg oral every 8 hours for 15 days)
2. Pefloxacin (400 mg oral every 8 hours for 15 days)
3. Ciprofloxacin (500 mg oral every 8 hours for 15 days)
4. Enoxacin (300 mg oral every 8 hours for 15 days)
5. Norfloxacin (400 mg oral every 8 hours for 15 days)
6. Chloramphenicol (500 mg oral every 6 hours for 15 days)
Outcomes 1. Clinical failure
2. Relapse
3. Fever clearance time (no SD)
4. Convalescent faecal carriage
5. Other adverse events (number of events stated)
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Morelli 1992 (Continued)
Notes Location: Italy
Date: 1985-90
Severity of illness at entry: not reported
We prepared different comparisons with these data: a combination of all 5 fluoroquinolone groups vs the chloram-
phenicol group; and norfloxacin vs ofloxacin, pefloxacin, and enoxacin
Nalin 1987
Methods Generation of allocation sequence: randomized numbers
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 169 analyseda : 90 in norfloxacin group; 79 in chloramphenicol group
Age not mentioned (adult dosages used); most probably inpatients
Inclusion criteria: clinical
Exclusion criteria: pregnant; prior antibiotic
Interventions 1. Chloramphenicol (500 mg every 4 to 6 hours for 14 days)
2. Norfloxacin (400 mg every 8 hours for 14 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Fever clearance time
4. Convalescent faecal carriage
5. Other adverse events
Notes Location: multicentre in Chile, Guatemala, Mexico, and Peru
Date: not reported
Severity of illness at entry: all uncomplicated
Nguyen 1997
Methods Generation of allocation sequence: block randomization
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 49/101 (49%)
Participants 100 analyseda : 47 in 2-day group; 53 in 3-day group
Adult inpatients aged > 15 years
Inclusion criteria: clinical
Exclusion criteria: pregnant; severe disease requiring intensive care; known hypersensitivity to quinolones; received
treatment with quinolones in the week before admission or responded to ampicillin, chloramphenicol, or co-trimox-
azole
Interventions 1. Ofloxacin (15 mg/kg/day oral for 2 days)
2. Ofloxacin (10 mg/kg/day oral for 3 days)
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Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Complications
6. Length of hospitalization
7. Convalescent faecal carriage
8. Serious adverse events
Notes Location: Vietnam
Date: 1993-5
Severity of illness at entry: all uncomplicated
Author provided further information
Pandit 2007
Methods Generation of allocation sequence: computer-generated, block randomization
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 147/169 (87%)
Participants 158 analyseda : 88 in gatifloxacin group; 70 in cefixime group
Adults and children outpatients aged 2.75 to 50 years (60/169 (35.5%) were children aged < 14 years)
Inclusion criteria: clinical
Exclusion criteria: not residing 2.5 km radius from hospital; age not between 2 to 65 years; not willing to give
informed consent; not able to take oral medications; pregnant or lactating; history of seizures; not able to stay in city
for treatment duration; known contraindication to cephalosporins or fluoroquinolones; complicated typhoid fever
or received third-generation cephalosporins, fluoroquinolones, or macrolide in week before presentation to clinic
Interventions 1. Gatifloxacin (10 mg/kg/day in single dose oral for 7 days)
2. Cefixime (20 mg/kg/day in 2 divided doses oral for 7 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Convalescent faecal carriage
6. Complications
7. Serious adverse events
8 Other adverse events
Notes Location: Nepal
Date: 2005
Severity of illness at entry: all uncomplicated
Author provided further information
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Parry 2007
Methods Generation of allocation sequence: computer-generated
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 114/130 (88%)
Participants 125 analyseda : 63 in ofloxacin group; 62 in azithromycin group
Adults and children inpatients 3 to 42 years (87% (163/187) were children < 15 years for all three arms)
Inclusion criteria: clinical
Exclusion criteria: severe or complicated disease; inability to swalloworalmedications; history of significant underlying
disease or hypersensitivity to either of trial drugs; pregnant or lactating; history of treatment with fluoroquinolones
or expanded spectrum cephalosporins; macrolide within 1 week of hospital admission
Interventions 1. Ofloxacin (20 mg/kg/day in 2 divided doses oral for 7 days)
2. Azithromycin (10 mg/kg/day once a day oral for 7 days)
Comparison not included in this review:
3. Ofloxacin-azithromycin (15 mg/kg/day in 2 divided doses oral ofloxacin for 7 days and 10 mg/kg/day once a day
oral azithromycin for first 3 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time (mean and 95% confidence intervals; SD calculated by review author)
5. Complications
6. Length of hospitalization (mean and 95% confidence intervals; SD calculated by review author)
7. Convalescent faecal carriage
8. Serious adverse events
9. Other adverse events (numbers not stated)
Notes Location: Vietnam
Date: 1998-2002
Severity of illness at entry: all uncomplicated
Author provided further information
Phongmany 2005
Methods Generation of allocation sequence: random-number table, block randomization
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 48/50 (96%)
Participants 50 analyseda : 27 in ofloxacin group; 23 in chloramphenicol group
Adult inpatients aged > 15 years
Inclusion criteria: clinical or blood culture positive typhoid fever
Exclusion criteria: age ≤15 years; pregnant; lactating; not able to take oral medication; not willing to give informed
consent; not able to stay in hospital for the duration of treatment; known to have contraindications to chloramphenicol
or ofloxacin; severe typhoid fever; or intractable vomiting
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Interventions 1. Ofloxacin (15 mg/kg/day in 2 divided doses oral for 3 days)
2. Chloramphenicol (50 mg/kg/day oral in 4 divided doses for 14 days)
Outcomes 1. Clinical failure
2. Fever clearance time
3. Complications
4. Length of hospitalization
5. Serious adverse events
6. Other adverse events
Notes Location: Laos
Date: 2001-3
Severity of illness at entry: all uncomplicated
Author provided further information
Quintero 1988
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: double
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 26 analyseda : 13 in ciprofloxacin group; 13 in chloramphenicol group
Age not mentioned (adult dosages used); most probably inpatients
Inclusion criteria: not reported
Exclusion criteria: not reported
Interventions 1. Ciprofloxacin (750 mg oral 3 times a day for unknown duration)
2. Chloramphenicol (750 mg oral 4 times a day for unknown duration)
Outcomes 1. Clinical failure
2. Fever clearance time
3. Serious adverse events
Notes Location: Mexico
Date: not reported
Severity of illness at entry: not reported
Conference abstract
Sarma 1991
Methods Generation of allocation sequence: randomized numbers
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
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Sarma 1991 (Continued)
Participants 40 analyseda : 20 participants in norfloxacin group; 20 participants in chloramphenicol group
Adult inpatients aged 17 to 32 years
Inclusion criteria: clinical with blood-culture positive for S. Typhi or S. Paratyphi
Exclusion criteria: complications of typhoid fever; pregnancy; previous antibiotic; known allergy to norfloxacin or
chloramphenicol
Interventions 1. Norfloxacin (400 mg oral every 12 hours for 7 days)
2. Chloramphenicol (60 mg/kg/day oral in 4 divided doses until afebrile then 40 mg/kg/day in 3 divided doses to
complete 14 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Complications
6. Length of hospitalization
7. Convalescent faecal carriage
8. Serious adverse events
9. Other adverse events
Notes Location: India
Date: 1990
Severity of illness at entry: all uncomplicated
Author provided further information
Smith 1994
Methods Generation of allocation sequence: computer-generated
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 50%
Participants 47 analyseda : 22 in ofloxacin group; 25 in ceftriaxone group
Adult inpatients aged 15 to 63 years
Inclusion criteria: clinical or culture positive for enteric fever
Exclusion criteria: hypersensitivity to beta-lactam antibiotics or quinolones; previous treatment with broad-spectrum
cephalosporins or quinolone within 1 week of hospital admission; those who responded to ampicillin, chlorampheni-
col, or co-trimoxazole
Interventions 1. Ofloxacin (200 mg oral every 12 hours for 5 days)
2. Ceftriaxone (3 g intravenous once a day for 3 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Complications
6. Length of hospitalization (mean and range)
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7. Convalescent faecal carriage
8. Serious adverse events
9. Other adverse events
Notes Location: Vietnam
Date: 1992-3
Severity of illness at entry: all uncomplicated
Author provided further information
Tran 1994
Methods Generation of allocation sequence: computer-generated
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 15/31 (48.4%)
Participants 31 analyseda : 16 in fleroxacin group; 15 in ceftriaxone group
Adult inpatients aged ≥ 16 years
Inclusion criteria: clinical with a negative malaria blood film
Interventions 1. Fleroxacin (400 mg oral for 7 days)
2. Ceftriaxone (2 g intravenous for 5 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Complications
6. Convalescent faecal carriage
7. Serious adverse events
Notes Location: Vietnam
Date: 1992-3
Severity of illness at entry: all uncomplicated
Author provided further information
Tran 1995
Methods Generation of allocation sequence: computer-generated
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 50% (114/228)
Participants 228 analyseda : 118 in 3-day group; 110 in 5-day group
Adults and children outpatients (180 culture positive were aged < 17 years)
Inclusion criteria: clinical
Exclusion criteria: unable to take oral medications due to vomiting; severe disease; shock; impaired consciousness;
bleeding; peritonitis; pregnant; neonates; received a fluoroquinolone
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Interventions 1. Ofloxacin (15 mg/kg/day oral for 3 days)
2. Ofloxacin (10 mg/kg/day oral for 5 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Convalescent faecal carriage
6. Serious adverse events
7. Other adverse events
Notes Location: Vietnam
Date: 1993-3
Severity of illness at entry: all uncomplicated
Author provided further information
Unal 1996
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 46 analyseda : 22 in 5-day group; 24 in 7-day group
Adult inpatients aged > 16 years
Inclusion criteria: febrile disease; 1 or more blood and/or bone marrow culture positive for Salmonella species
Exclusion criteria: age < 16 years; pregnant or lactating; jaundice; hepatic failure; antibiotics in the last 2 weeks
Interventions 1. Pefloxacin (400 mg oral twice daily for 5 days)
2. Pefloxacin (400 mg oral twice daily for 7 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Convalescent faecal carriage
6. Serious adverse events
7. Other adverse events
Notes Location: Turkey
Date: 1992-4
Severity of illness at entry: not reported
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Vinh 1996
Methods Generation of allocation sequence: computer-generated
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 26/100 (26%)
Participants 100 analyseda : 53 in 2-day group; 47 in 3-day group
Children inpatients aged 1 to 15 years
Inclusion criteria: clinical or blood culture positive for S. Typhi
Exclusion criteria: severe disease; complications, such as reduced level of consciousness, jaundice, shock, gastroin-
testinal bleed, clinical signs of intestinal perforation, prostate, and vomiting; unable to take oral medication; allergic
to fluoroquinolones; received antibiotics that had efficacy against this organism
Interventions 1. Ofloxacin (15 mg/kg/day oral in 2 divided doses for 2 days)
2. Ofloxacin (15 mg/kg/day oral in 2 divided doses for 3 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Complications
6. Length of hospitalization
7. Convalescent faecal carriage
8. Serious adverse events
9. Other adverse events
Notes Location: Vietnam
Date: not reported
Severity of illness at entry: all uncomplicated
Author provided further information
Vinh 2005
Methods Generation of allocation sequence: computer-generated
Allocation concealment: sealed envelopes
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 196/202 (97%)
Participants 196 analyseda : 89 in ofloxacin 2-day group; 107 in ofloxacin 3-day group
Children inpatients aged < 15 years
Inclusion criteria: clinical
Exclusion criteria: no informed consent from parent or guardian; previous treatment active against S. Typhi or S.
Paratyphi (but those with no response to chloramphenicol, ampicillin, or co-trimoxazole were included); severe or
complicated disease
Interventions 1. Ofloxacin (10 mg/kg/day oral in 2 divided doses for 2 days)
2. Ofloxacin (10 mg/kg/day oral in 2 divided doses for 3 days)
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Vinh 2005 (Continued)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time (mean and 95% confidence intervals; SD calculated by review author)
5. Complications
6. Length of hospitalization (mean and 95% confidence intervals; SD calculated by review author)
7. Convalescent faecal carriage
8. Serious adverse events
9. Other adverse events
Notes Location: Vietnam
Date: 1994-6
Severity of illness at entry: all uncomplicated
Author provided further information
Wallace 1993
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 41/42 (97.6%)
Participants 42 analyseda : 20 in ciprofloxacin group; 22 in ceftriaxone group
Adult inpatients
Inclusion criteria: blood culture positive for S. Typhi
Exclusion criteria: only positive Widal and/or a positive stool culture; age < 16 years; unable to take oral medications;
possible proven pregnancy; and lack of fever at admission
Interventions 1. Ciprofloxacin (500 mg oral twice daily for 7 days)
2. Ceftriaxone (3 g/day intravenous for 7 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time (SD not reported)
5. Convalescent faecal carriage
6. Complications
Notes Location: Bahrain
Date: not reported
Severity of illness at entry: not reported
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Xiao 1991
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 23 analyseda : 8 in norfloxacin group; 6 in pefloxacin group; and 9 in ofloxacin group
Adult and children inpatients aged 11 to 62 years
Inclusion criteria: clinical with blood or bone marrow culture positive for S. Typhi
Exclusion criteria: not mentioned
Interventions We evaluated 3 of the available 5 groups:
1. Norfloxacin (300 to 400 mg oral thrice a day for 14 days)
2. Pefloxacin (400 mg oral twice daily for 14 days)
3. Ofloxacin (300 mg oral twice daily for 14 days)
Outcomes 1. Clinical failure
2. Fever clearance time
Notes Location: China (Chinese language)
Date: not reported
Severity of illness at entry: some participants had complications
Yang 1991
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 56 analyseda : 28 in ofloxacin group; 28 in norfloxacin group
Inpatients; mean age 27 years (standard deviation 14 years) in ofloxacin group; mean 21 years (standard deviation
10 years) in norfloxacin group
Inclusion criteria: clinical with blood culture positive for S. Typhi
Exclusion criteria: not mentioned
Interventions 1. Ofloxacin (200 mg oral twice daily for 7 to 14 days)
2. Norfloxacin (300 to 400 mg oral 3 to 4 times a day for 10 to 24 days)
Outcomes 1. Clinical failure
2. Microbiological failure (definition incorrect, thus we did not enter data in this review)
3. Relapse
4. Fever clearance time
5. Convalescent faecal carriage
6. Serious adverse events
7. Other adverse events
Notes Location: China (Chinese language)
Date: 1989-91
Severity of illness at entry: not reported
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Yousaf 1992
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 75/85 (88.4%)
Participants 75 analyseda : 25 in ofloxacin group; 25 in chloramphenicol group; 25 in amoxicillin group
Adult inpatients
Inclusion criteria: culture positive
Exclusion criteria: if received previous antibiotic therapy known to be effective against S. Typhi
Interventions 1. Ofloxacin (200 mg oral twice daily for 14 days)
2. Chloramphenicol (50 mg/kg/day, then 30 mg/kg/day when afebrile for 14 days)
3. Amoxicillin (4 to 6 g/day oral for 14 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Other adverse events
Notes Location: Pakistan
Date: 1989-92
Severity of illness at entry: not reported
Yu 1998
Methods Generation of allocation sequence: unclear
Allocation concealment: unclear
Blinding: open
Inclusion of all randomized culture-positive participants in the final analysis: 100%
Participants 80 analyseda : 40 in levofloxacin group; 40 in cefixime group
Adult aged 18 to 65 years; most probably inpatients
Inclusion criteria: clinical with blood or bone marrow culture positive for S. Typhi or S. Paratyphi
Exclusion criteria: not mentioned
Interventions 1. Levofloxacin (200 mg oral twice a day for 10 days)
2. Cefixime (200 mg oral twice a day for 10 days)
Outcomes 1. Clinical failure
2. Microbiological failure
3. Relapse
4. Fever clearance time
5. Complications
6. Convalescent faecal carriage
7. Other adverse events
Notes Location: China (Chinese language)
Date: not reported
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Yu 1998 (Continued)
Severity of illness at entry: included ’mild, common, and severe’ types (1 ’severe type’ illness in levofloxacin group
and 2 in cefixime group)
MDR: multiple-drug resistant; SD: standard deviation; S. Typhi/Paratyphi: Salmonella enterica serotype Typhi/Paratyphi.
aFor details of number of participants enrolled, number randomized, and the number of participants with culture-confirmed enteric
fever, see Table 1: Microbiology.
Characteristics of excluded studies [ordered by study ID]
Agalar 1997 Not a randomized controlled trial because 1 group consisted of participants admitted in 1994 and the other
group of participants admitted in 1995
Akhtar 1989 No mention of randomization
Akhtar 1992 Quasi-randomized controlled trial: participants were allocated alternatively to either ciprofloxacin group or
chloramphenicol group, and resistance strains assigned to a third ciprofloxacin group; author provided this
additional information
Bavdekar 1991 Interventions not randomly assigned
Bethell 1996 Children from the Vinh 1996 trial (which is included in this review) were entered into this pharmacokinetic
study of oral vs intravenous ofloxacin
Chakravorty 1991 All treated with chloramphenicol; some switched over to another drug based on culture results
Chukwani 1998 2 fluoroquinolone drugs were given for different durations (7 days vs 14 days) in this randomized controlled
trial
Daga 1994 Treatment assigned depending on treatment already taken, clinical course, and complications
Hou 1993 Randomized controlled trial comparing Chinese ofloxacin with Japanese ofloxacin
Jinlong 1998 Quasi-randomized controlled trial
Kumar 2007 Described as a randomized controlled parallel study of ofloxacin vs ceftriaxone in 93 children with multi-
drug resistant typhoid fever proven by blood culture. The main outcome reported for both arms is mean fever
clearance time; however the number of children in each arm is not available. We have contacted the author for
additional information (December 2007) and will include this study if further information becomes available
Liberti 2000 No mention of randomization
Lu 1995 A total of 130 participants with any infectious disease were randomized into 2 groups (enoxacin and cefotaxime)
; there were only 2 participants with enteric fever in enoxacin group and 1 participant with enteric fever in
cefotaxime group
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(Continued)
Nelwan 1995 Randomized controlled trial comparing 3 days with 6 days of ciprofloxacin that included 20 participants with
serologically confirmed enteric fever (of a total of 59 participants randomized). We contacted the author (17
December 2003) to obtain additional data for blood culture confirmed cases and will include this in future
updates should it become available
Peyramond 1986 Not a randomized controlled trial
Secmeer 1997 No randomization; allocation based on co-trimoxazole susceptibility
Singh 1993 No mention of randomization
Suhendro 2007 Compares 2 different formulations of ciprofloxacin; described as a prospective, open labelled, clinical trial,
comparing safety and efficacy of extended-release ciprofloxacin 1000 mg once daily (Ciprofloxacin XR) and
ciprofloxacin intermediate release 500 mg 2 times daily (Ciprofloxacin bid) in adults with typhoid fever
Takkar 1994 Not randomized
Tanphaichitra 1986 Randomized controlled trial of gonorrhoea; part of the report, but not part of the trial, were 8 participants
with enteric fever that treated with ofloxacin
Uwaydah 1992 Compares 2 ciprofloxacin doses, not durations
Wain 1997 Study on S. Typhi isolates from blood cultures of participants included in 3 trials included in this review:
Smith 1994; Vinh 1996; and Nguyen 1997
Zavala 1989 No mention of randomization
Zhang 1991 Randomized controlled trial including several infections; randomization not applied to the 63 typhoid partic-
ipants treated with enoxacin
ZhongYang 1997 Randomized controlled trial comparing ofloxacin with norfloxacin for 14 days. It included 158 people with
serologically confirmed enteric fever, out of a total of 429 people randomized. Microbiological failure, the
only reported outcome for blood culture confirmed cases, was measured at different times for both arms (7
to 14 days for the ofloxacin group vs 7 days for the norfloxacin group). We contacted the author (July 2003)
to obtain additional data for blood culture-confirmed cases and will include this in future updates should it
become available
S. Typhi: Salmonella enterica serotype Typhi.
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Characteristics of studies awaiting assessment [ordered by study ID]
Flores 1991
Methods NA
Participants NA
Interventions NA
Outcomes NA
Notes Unable to retrieve this study
Soewandojo 1992
Methods NA
Participants NA
Interventions NA
Outcomes NA
Notes Unable to retrieve this study
NA: not available.
Characteristics of ongoing studies [ordered by study ID]
ISRCTN53258327
Trial name or title “An open randomised study to assess the efficacy of gatifloxacin versus chloramphenicol for the treatment of
uncomplicated typhoid fever in Kathmandu, Nepal”
Methods “open randomised study”
Participants Inclusion criteria: any patient with suspected uncomplicated enteric fever who gives consent
Exclusion criteria: no consent, or pregnant
Interventions 1. Gatifloxacin 10 mg/kg/day once a day for 7 days
2. Chloramphenicol 75 mg/kg/day in 4 divided doses for 14 days
Outcomes 1. Failure of treatment, defined as occurrence of any 1 of: persistent fever at day 10 of treatment; failure to
clear completely the admission symptoms at day 10; blood culture positive at day 10 of treatment; need for
’rescue’ treatment with ceftriaxone; culture-confirmed relapse within 28 days of starting therapy; development
on treatment of any complication (clinically significant bleeding, fall in the Glasgow Coma Score, perforation
of the gastrointestinal tract, admission to hospital within 28 days of starting therapy)
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ISRCTN53258327 (Continued)
Starting date 1 May 2006
Anticipated end date: 30 June 2008
Contact information Dr Buddha Basnyat (rishibas@wlink.com.np), Patan Hospital, Kathmandu, Nepal
Notes Location: Nepal
Registration number: ISRCTN53258327
Source of funding: The Wellcome Trust (UK)
Note: trial was stopped temporarily in September 2006 after the reports of dysglycaemia associated with
gatifloxacin, but it was resumed in December 2006
Percentage of children aged < 14 years in trial: around 45% of 703 enrolled participants
ISRCTN66534807
Trial name or title “A randomised clinical trial of Azithromycin versus Ofloxacin in the treatment of adults with uncomplicated
typhoid fever at Mahosot Hospital, Vientiane, Lao People’s Democratic Republic (PDR)”
Methods “randomised clinical trial”
Participants Inclusion criteria: adult (≥15 years) non-pregnant patients with suspected or blood-culture proven typhoid;
fever > 37.5 °C; informed written consent to the study; able to stay in hospital for 7 days; able to take oral
medication; bodyweight > 40 kg; likely to be able to complete 6 months’ follow up; none of the exclusion
criteria
Exclusion criteria: known hypersensitivity to ofloxacin or azithromycin; administration of chloramphenicol,
co-trimoxazole, ampicillin, azithromycin, or a fluoroquinolone during previous week; pregnancy or breast-
feeding; contraindications to ofloxacin or azithromycin; evidence for severe typhoid
Interventions 1. Ofloxacin 7.5 mg/kg every 12 hours for 3 days
2. Azithromycin 20 mg/kg every 24 hours for 3 days
Outcomes 1. Fever clearance time
2. Cure
3. Relapse
4. Faecal carriage
Starting date 1 May 2004
Anticipated end date: 31 December 2007
Contact information Dr Paul Newton (paul@tropmedres.ac), Microbiology laboratory, Ministry of Health, Mahosot Hospital,
Vientiane, Laos
Notes Location: Laos
Registration number: ISRCTN66534807
Source of funding: The Wellcome Trust (UK)
Percentage of children in trial: none
E-mail update by Dr Newton on 5 December 2007: on hold because of considerable decline in incidence of
typhoid in Vientiane
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D A T A A N D A N A L Y S E S
Comparison 1. Fluoroquinolones vs chloramphenicol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure 9 594 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.25, 1.72]
1.1 NaR not reported and
MDR absent
5 307 Odds Ratio (M-H, Fixed, 95% CI) 0.81 [0.19, 3.34]
1.2 NaR absent and MDR
present
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.27 [0.01, 7.02]
1.3 NaR and MDR not
reported
3 237 Odds Ratio (M-H, Fixed, 95% CI) 0.65 [0.14, 2.91]
2 Microbiological failure 6 378 Odds Ratio (M-H, Fixed, 95% CI) 0.43 [0.18, 1.03]
2.1 NaR not reported and
MDR absent
4 237 Odds Ratio (M-H, Fixed, 95% CI) 0.67 [0.21, 2.12]
2.2 NaR and MDR not
reported
2 141 Odds Ratio (M-H, Fixed, 95% CI) 0.24 [0.06, 0.96]
3 Relapse 6 467 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.04, 0.50]
3.1 NaR not reported and
MDR absent
4 281 Odds Ratio (M-H, Fixed, 95% CI) 0.12 [0.02, 0.69]
3.2 NaR and MDR not
reported
2 186 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.03, 1.07]
4 Fever clearance time 3 129 Mean Difference (IV, Fixed, 95% CI) -25.93 [-40.12, -
11.74]
4.1 NaR not reported and
MDR absent
2 81 Mean Difference (IV, Fixed, 95% CI) -16.07 [-35.03,
2.88]
4.2 NaR absent and MDR
present
1 48 Mean Difference (IV, Fixed, 95% CI) -38.5 [-59.90, -
17.10]
5 Length of hospital stay 2 105 Mean Difference (IV, Fixed, 95% CI) -2.57 [-3.53, -1.62]
5.1 NaR not reported and
MDR absent
1 55 Mean Difference (IV, Fixed, 95% CI) -0.40 [-1.63, 0.83]
5.2 NaR absent and MDR
present
1 50 Mean Difference (IV, Fixed, 95% CI) -5.9 [-7.42, -4.38]
6 Convalescent faecal carriage
(NaR not reported and MDR
absent)
3 298 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.04, 0.70]
7 Complications 2 105 Odds Ratio (M-H, Fixed, 95% CI) 0.71 [0.16, 3.05]
7.1 NaR not reported and
MDR absent
1 55 Odds Ratio (M-H, Fixed, 95% CI) 0.96 [0.18, 5.23]
7.2 NaR absent and MDR
present
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.27 [0.01, 7.02]
8 Adverse events (not serious) 5 245 Odds Ratio (M-H, Fixed, 95% CI) 1.10 [0.46, 2.62]
8.1 NaR not reported and
MDR absent
3 145 Odds Ratio (M-H, Fixed, 95% CI) 1.32 [0.47, 3.73]
8.2 NaR not reported and
MDR not reported
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.72 [0.14, 3.59]
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8.3 NaR absent and MDR
present
1 50 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 2. Fluoroquinolones vs amoxicillin (AMX) or ampicillin (AMP)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure (MDR and NaR
not reported)
2 90 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.46]
2 Microbiological failure (MDR
and NaR not reported)
2 90 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.02, 0.58]
3 Adverse events (not serious)
(MDR and NaR not reported)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
Comparison 3. Fluoroquinolones vs co-trimoxazole
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure (MDR absent) 2 82 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 4.01]
1.1 NaR absent 1 42 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 NaR not reported 1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 4.01]
2 Microbiological failure (MDR
absent)
2 82 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 4.01]
2.1 NaR absent 1 42 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2.2 NaR not reported 1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.01, 4.01]
3 Adverse events (not serious)
(MDR absent)
2 82 Odds Ratio (M-H, Fixed, 95% CI) 0.77 [0.22, 2.69]
3.1 NaR absent 1 42 Odds Ratio (M-H, Fixed, 95% CI) 0.74 [0.04, 12.67]
3.2 NaR not reported 1 40 Odds Ratio (M-H, Fixed, 95% CI) 0.78 [0.19, 3.13]
Comparison 4. Fluoroquinolones vs azithromycin
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure (in adults) 2 152 Odds Ratio (M-H, Fixed, 95% CI) 3.32 [0.63, 17.43]
1.1 NaR present 1 88 Odds Ratio (M-H, Fixed, 95% CI) 3.32 [0.63, 17.43]
1.2 NaR not reported 1 64 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2 Microbiological failure (in
adults)
2 152 Odds Ratio (M-H, Fixed, 95% CI) 2.05 [0.18, 23.44]
2.1 NaR present 1 88 Odds Ratio (M-H, Fixed, 95% CI) 2.05 [0.18, 23.44]
2.2 NaR not reported 1 64 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
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3 Relapse (in adults) 2 102 Odds Ratio (M-H, Fixed, 95% CI) 6.94 [0.31, 154.85]
3.1 NaR present 1 38 Odds Ratio (M-H, Fixed, 95% CI) 6.94 [0.31, 154.85]
3.2 NaR not reported 1 64 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
4 Fever clearance time (in adults) 2 152 Mean Difference (IV, Fixed, 95% CI) -8.95 [-20.09, 2.19]
4.1 NaR present 1 88 Mean Difference (IV, Fixed, 95% CI) 4.0 [-21.50, 29.50]
4.2 NaR not reported 1 64 Mean Difference (IV, Fixed, 95% CI) -12.0 [-24.39, 0.39]
5 Length of hospital stay (days) (in
adults)
2 152 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.32, 2.12]
5.1 NaR present 1 88 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.32, 2.12]
5.2 NaR not reported 1 64 Mean Difference (IV, Fixed, 95% CI) Not estimable
6 Convalescent faecal carriage (in
adults)
2 133 Odds Ratio (M-H, Fixed, 95% CI) 21.33 [1.18, 386.00]
6.1 NaR present 1 69 Odds Ratio (M-H, Fixed, 95% CI) 21.33 [1.18, 386.00]
6.2 NaR not reported 1 64 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
7 Complications (in adults) 2 152 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.51]
7.1 NaR present 1 88 Odds Ratio (M-H, Fixed, 95% CI) 1.0 [0.06, 16.51]
7.2 NaR not reported 1 64 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
8 Clinical failure (mostly children) 2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 NaR present 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
8.2 NaR present (but newer
fluoroquinolone)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
9 Microbiological failure (mostly
children)
2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 NaR present 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
9.2 NaR present (but newer
fluoroquinolone)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
10 Relapse (mostly children) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
10.1 NaR present (but newer
fluoroquinolone)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
11 Fever clearance time (mostly
children)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 NaR present 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
11.2 NaR present (but newer
fluoroquinolone)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
12 Length of hospital stay (mostly
children)
2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 NaR present 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
12.2 NaR present (but newer
fluoroquinolone)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
13 Convalescent faecal carriage
(mostly children)
2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
13.1 NaR present 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
13.2 NaR present (but newer
fluoroquinolone)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
14 Complications (mostly
children)
2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
14.1 NaR present 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
14.2 NaR present (but newer
fluoroquinolone)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
15 Adverse events (not serious)
(mostly children)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
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15.1 NaR present (but newer
fluoroquinolone)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 5. Fluoroquinolones vs cefixime
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure (adults or mostly
adults)
2 238 Odds Ratio (M-H, Fixed, 95% CI) 0.05 [0.01, 0.24]
1.1 NaR not reported 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.13 [0.01, 2.65]
1.2 NaR present (but newer
fluoroquinolone)
1 158 Odds Ratio (M-H, Fixed, 95% CI) 0.03 [0.00, 0.24]
2 Microbiological failure (adults
or mostly adults)
2 238 Odds Ratio (M-H, Fixed, 95% CI) 0.14 [0.02, 1.23]
2.1 NaR not reported 1 80 Odds Ratio (M-H, Fixed, 95% CI) 0.10 [0.01, 1.92]
2.2 NaR present (but newer
fluoroquinolone)
1 158 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.01, 6.53]
3 Relapse (adults or mostly adults) 2 218 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.03, 0.91]
3.1 NaR not reported 1 80 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.2 NaR present (but newer
fluoroquinolone)
1 138 Odds Ratio (M-H, Fixed, 95% CI) 0.18 [0.03, 0.91]
4 Fever clearance time (adults or
mostly adults)
2 238 Mean Difference (IV, Fixed, 95% CI) -41.69 [-54.96, -
28.42]
4.1 NaR not reported 1 80 Mean Difference (IV, Fixed, 95% CI) -36.0 [-51.29, -
20.71]
4.2 NaR present (but newer
fluoroquinolone)
1 158 Mean Difference (IV, Fixed, 95% CI) -57.00 [-85.68, -
32.32]
5 Convalescent faecal carriage
(adults or mostly adults)
2 227 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.01, 6.50]
5.1 NaR not reported 1 80 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 NaR present (but newer
fluoroquinolone)
1 147 Odds Ratio (M-H, Fixed, 95% CI) 0.26 [0.01, 6.50]
6 Complications (adults or mostly
adults)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
6.1 NaR present (but newer
fluoroquinolone)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
7 Adverse events (not serious)
(adults or mostly adults)
2 238 Odds Ratio (M-H, Random, 95% CI) 3.30 [0.11, 97.30]
7.1 NaR not reported 1 80 Odds Ratio (M-H, Random, 95% CI) 0.65 [0.10, 4.11]
7.2 NaR present (but newer
fluoroquinolone)
1 158 Odds Ratio (M-H, Random, 95% CI) 17.74 [2.30, 136.58]
8 Clinical failure (children only) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 NaR absent 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
9 Microbiological failure (children
only)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
9.1 NaR absent 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
10 Relapse (children only) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
10.1 NaR absent 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
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11 Fever clearance time (children
only)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
11.1 NaR absent 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
12 Length of hospital stay
(children only)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12.1 NaR absent 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
13 Complications (children only) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
13.1 NaR absent 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 6. Fluoroquinolones vs ceftriaxone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure 3 120 Odds Ratio (M-H, Fixed, 95% CI) 0.08 [0.01, 0.45]
1.1 NaR absent (adults only) 1 47 Odds Ratio (M-H, Fixed, 95% CI) 0.07 [0.00, 1.26]
1.2 NaR not reported (adults
only)
2 73 Odds Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 0.76]
2 Microbiological failure 3 119 Odds Ratio (M-H, Fixed, 95% CI) 0.32 [0.03, 3.17]
2.1 NaR absent 1 47 Odds Ratio (M-H, Fixed, 95% CI) 0.36 [0.01, 9.37]
2.2 NaR not reported 2 72 Odds Ratio (M-H, Fixed, 95% CI) 0.27 [0.01, 7.25]
3 Relapse 3 81 Odds Ratio (M-H, Fixed, 95% CI) 0.34 [0.03, 3.47]
3.1 NaR absent (adults only) 1 23 Odds Ratio (M-H, Fixed, 95% CI) 0.33 [0.01, 9.07]
3.2 NaR not reported (adults
only)
2 58 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 9.08]
4 Fever clearance time 2 76 Mean Difference (IV, Fixed, 95% CI) -101.20 [-129.21, -
73.19]
4.1 NaR absent (adults only) 1 47 Mean Difference (IV, Fixed, 95% CI) -113.00 [-150.67, -
79.33]
4.2 NaR not reported (adults
only)
1 29 Mean Difference (IV, Fixed, 95% CI) -79.0 [-124.24, -
33.76]
5 Convalescent faecal carriage 3 81 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 9.08]
5.1 NaR absent 1 23 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 NaR not reported 2 58 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 9.08]
6 Complications 3 120 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.59]
6.1 NaR absent 1 47 Odds Ratio (M-H, Fixed, 95% CI) 0.21 [0.01, 4.59]
6.2 NaR not reported 2 73 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
7 Serious adverse events 2 78 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 7.76]
7.1 NaR absent 1 47 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
7.2 NaR not reported 1 31 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 7.76]
8 Adverse events (not serious) 1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
8.1 NaR absent 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
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Comparison 7. Norfloxacin vs chloramphenicol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure 3 259 Odds Ratio (M-H, Fixed, 95% CI) 5.80 [1.87, 17.98]
1.1 MDR and NaR present 1 40 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
1.2 MDR absent and NaR
not reported
1 50 Odds Ratio (M-H, Fixed, 95% CI) 41.48 [2.22, 774.60]
1.3 MDR and NaR not
reported
1 169 Odds Ratio (M-H, Fixed, 95% CI) 2.81 [0.73, 10.79]
2 Microbiological failure 2 209 Odds Ratio (M-H, Fixed, 95% CI) 2.81 [0.73, 10.79]
2.1 MDR and NaR present 1 40 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2.2 MDR and NaR not
reported
1 169 Odds Ratio (M-H, Fixed, 95% CI) 2.81 [0.73, 10.79]
3 Relapse 2 90 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.92]
3.1 MDR and NaR present 1 40 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3.2 MDR absent and NaR
not reported
1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.19 [0.01, 3.92]
4 Fever clearance time 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 MDR and NaR present 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4.2 MDR and NaR not
reported
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5 Length of hospital stay (MDR
and NaR present)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6 Convalescent faecal carriage 3 259 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.29, 3.61]
6.1 MDR and NaR present 1 40 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
6.2 MDR absent and NaR
not reported
1 50 Odds Ratio (M-H, Fixed, 95% CI) 1.15 [0.23, 5.78]
6.3 MDR and NaR not
reported
1 169 Odds Ratio (M-H, Fixed, 95% CI) 0.88 [0.12, 6.36]
7 Adverse events (not serious) 2 209 Odds Ratio (M-H, Fixed, 95% CI) 0.92 [0.40, 2.15]
7.1 MDR and NaR present 1 40 Odds Ratio (M-H, Fixed, 95% CI) 1.24 [0.34, 4.46]
7.2 MDR and NaR not
reported
1 169 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.24, 2.29]
Comparison 8. Norfloxacin vs ceftriaxone
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure (NaR not
reported)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2 Relapse (NaR not reported) 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Fever clearance time (NaR not
reported)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Adverse events (not serious)
(NaR not reported)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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Comparison 9. Norfloxacin vs other fluoroquinolones (FQ)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure 5 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Versus pefloxacin 3 200 Odds Ratio (M-H, Fixed, 95% CI) 30.60 [5.75, 162.86]
1.2 Versus ofloxacin 3 123 Odds Ratio (M-H, Fixed, 95% CI) 28.15 [4.80, 165.14]
1.3 Versus enoxacin 2 142 Odds Ratio (M-H, Fixed, 95% CI) 4.15 [1.77, 9.76]
2 Relapse 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Versus ofloxacin 2 106 Odds Ratio (M-H, Fixed, 95% CI) 2.08 [0.18, 24.31]
3 Fever clearance time 4 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 Versus pefloxacin 2 144 Mean Difference (IV, Fixed, 95% CI) 18.83 [2.62, 35.03]
3.2 Versus ofloxacin 2 73 Mean Difference (IV, Fixed, 95% CI) 30.26 [10.42, 50.10]
3.3 Versus enoxacin 1 102 Mean Difference (IV, Fixed, 95% CI) 60.0 [33.81, 86.19]
4 Convalescent faecal carriage 2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
4.1 Versus pefloxacin 1 56 Odds Ratio (M-H, Fixed, 95% CI) 14.6 [0.71, 298.42]
4.2 Versus ofloxacin 2 106 Odds Ratio (M-H, Fixed, 95% CI) 3.90 [0.63, 24.30]
4.3 Versus enoxacin 1 40 Odds Ratio (M-H, Fixed, 95% CI) 1.59 [0.24, 10.70]
5 Adverse events (not serious) 2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Versus ofloxacin 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
5.2 Versus enoxacin 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 10. Fluoroquinolones for 2 days vs 3 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure (NaR present) 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 Adults only 1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.17 [0.02, 1.47]
1.2 Children only 2 296 Odds Ratio (M-H, Fixed, 95% CI) 2.22 [0.81, 6.12]
2 Microbiological failure (NaR
present)
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 Children only 2 296 Odds Ratio (M-H, Fixed, 95% CI) 1.96 [0.42, 9.05]
3 Relapse (NaR present) 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3.1 Adults only 1 50 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.93]
3.2 Children only 2 262 Odds Ratio (M-H, Fixed, 95% CI) 2.61 [0.38, 18.03]
4 Fever clearance time (NaR
present)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4.1 Adults only 1 100 Mean Difference (IV, Fixed, 95% CI) Not estimable
4.2 Children only 2 296 Mean Difference (IV, Fixed, 95% CI) -8.55 [-20.10, 3.00]
5 Length of hospital stay (NaR
present)
3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
5.1 Adults only 1 100 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.79, 0.39]
5.2 Children only 2 296 Mean Difference (IV, Fixed, 95% CI) -0.44 [-0.98, 0.09]
6 Convalescent faecal carriage
(NaR present)
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
6.1 Children only 2 262 Odds Ratio (M-H, Fixed, 95% CI) 0.30 [0.01, 7.75]
7 Complications (NaR present) 3 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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7.1 Adults only 1 100 Odds Ratio (M-H, Fixed, 95% CI) 0.12 [0.01, 2.21]
7.2 Children only 2 296 Odds Ratio (M-H, Fixed, 95% CI) 1.03 [0.21, 4.96]
8 Adverse events (not serious)
(NaR present)
2 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
8.1 Children only 2 296 Odds Ratio (M-H, Fixed, 95% CI) 0.29 [0.01, 7.28]
Comparison 11. Fluoroquinolones for 3 days vs 5 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Clinical failure (NaR not
reported)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
1.1 Adults only 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2 Relapse 2 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
2.1 Adults only (NaR not
reported)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
2.2 Children mostly (NaR
present)
1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
3 Fever clearance time 2 Mean Difference (IV, Fixed, 95% CI) Totals not selected
3.1 Adults only (NaR not
reported)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
3.2 Children mostly (NaR
present)
1 Mean Difference (IV, Fixed, 95% CI) Not estimable
4 Length of hospital stay (NaR not
reported)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 Adults only 1 Mean Difference (IV, Fixed, 95% CI) Not estimable
5 Adverse events (not serious)
(NaR present)
1 Odds Ratio (M-H, Fixed, 95% CI) Totals not selected
5.1 Children mostly 1 Odds Ratio (M-H, Fixed, 95% CI) Not estimable
Comparison 12. Fluoroquinolones for 5 days vs 7 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological failure (NaR not
reported)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Relapse (NaR not reported) 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Fever clearance time (NaR not
reported)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
4 Adverse events (not serious)
(NaR not reported)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
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Comparison 13. Fluoroquinolones for 7 days vs 10 or 14 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Microbiological failure (NaR not
reported)
2 87 Odds Ratio (M-H, Fixed, 95% CI) 1.39 [0.08, 23.41]
2 Relapse (NaR not reported) 2 87 Odds Ratio (M-H, Fixed, 95% CI) 4.28 [0.17, 109.61]
Comparison 14. Fluoroquinolones for 10 days vs 14 days
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Relapse (NaR present) 1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
2 Fever clearance time (NaR
present)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3 Adverse events (not serious)
(NaR present)
1 Odds Ratio (M-H, Fixed, 95% CI) Subtotals only
Analysis 1.1. Comparison 1 Fluoroquinolones vs chloramphenicol, Outcome 1 Clinical failure.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 1 Fluoroquinolones vs chloramphenicol
Outcome: 1 Clinical failure
Study or subgroup Fluoroquinolone Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR not reported and MDR absent
Abejar 1993 0/15 0/15 0.0 [ 0.0, 0.0 ]
Cristiano 1995 0/30 0/30 0.0 [ 0.0, 0.0 ]
Gasem 2003 1/28 2/27 0.46 [ 0.04, 5.43 ]
Morelli 1992 4/106 0/30 2.68 [ 0.14, 51.15 ]
Quintero 1988 0/13 1/13 0.31 [ 0.01, 8.30 ]
Subtotal (95% CI) 192 115 0.81 [ 0.19, 3.34 ]
Total events: 5 (Fluoroquinolone), 3 (Chloramphenicol)
0.001 0.01 0.1 1 10 100 1000
Favours fluoroquinolone Favours chloramphenicol
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(. . . Continued)
Study or subgroup Fluoroquinolone Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: Chi2 = 1.16, df = 2 (P = 0.56); I2 =0.0%
Test for overall effect: Z = 0.30 (P = 0.77)
2 NaR absent and MDR present
Phongmany 2005 0/27 1/23 0.27 [ 0.01, 7.02 ]
Subtotal (95% CI) 27 23 0.27 [ 0.01, 7.02 ]
Total events: 0 (Fluoroquinolone), 1 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
3 NaR and MDR not reported
Arnold 1993 0/57 1/34 0.19 [ 0.01, 4.90 ]
Gottuzzo 1992 1/48 0/48 3.06 [ 0.12, 77.09 ]
Yousaf 1992 1/25 2/25 0.48 [ 0.04, 5.65 ]
Subtotal (95% CI) 130 107 0.65 [ 0.14, 2.91 ]
Total events: 2 (Fluoroquinolone), 3 (Chloramphenicol)
Heterogeneity: Chi2 = 1.48, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.56 (P = 0.57)
Total (95% CI) 349 245 0.65 [ 0.25, 1.72 ]
Total events: 7 (Fluoroquinolone), 7 (Chloramphenicol)
Heterogeneity: Chi2 = 2.92, df = 6 (P = 0.82); I2 =0.0%
Test for overall effect: Z = 0.86 (P = 0.39)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.2. Comparison 1 Fluoroquinolones vs chloramphenicol, Outcome 2 Microbiological failure.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 1 Fluoroquinolones vs chloramphenicol
Outcome: 2 Microbiological failure
Study or subgroup Fluoroquinolone Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR not reported and MDR absent
Abejar 1993 0/15 1/15 0.31 [ 0.01, 8.28 ]
Bran 1991 0/51 0/51 0.0 [ 0.0, 0.0 ]
Cristiano 1995 0/30 0/30 0.0 [ 0.0, 0.0 ]
Gasem 2003 7/23 8/22 0.77 [ 0.22, 2.65 ]
Subtotal (95% CI) 119 118 0.67 [ 0.21, 2.12 ]
Total events: 7 (Fluoroquinolone), 9 (Chloramphenicol)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
2 NaR and MDR not reported
Arnold 1993 2/57 5/34 0.21 [ 0.04, 1.15 ]
Yousaf 1992 1/25 3/25 0.31 [ 0.03, 3.16 ]
Subtotal (95% CI) 82 59 0.24 [ 0.06, 0.96 ]
Total events: 3 (Fluoroquinolone), 8 (Chloramphenicol)
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 2.02 (P = 0.043)
Total (95% CI) 201 177 0.43 [ 0.18, 1.03 ]
Total events: 10 (Fluoroquinolone), 17 (Chloramphenicol)
Heterogeneity: Chi2 = 1.62, df = 3 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 1.90 (P = 0.058)
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Analysis 1.3. Comparison 1 Fluoroquinolones vs chloramphenicol, Outcome 3 Relapse.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 1 Fluoroquinolones vs chloramphenicol
Outcome: 3 Relapse
Study or subgroup Fluoroquinolone Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR not reported and MDR absent
Abejar 1993 0/15 1/15 0.31 [ 0.01, 8.28 ]
Cristiano 1995 0/30 2/30 0.19 [ 0.01, 4.06 ]
Gasem 2003 0/28 0/27 0.0 [ 0.0, 0.0 ]
Morelli 1992 0/106 3/30 0.04 [ 0.00, 0.74 ]
Subtotal (95% CI) 179 102 0.12 [ 0.02, 0.69 ]
Total events: 0 (Fluoroquinolone), 6 (Chloramphenicol)
Heterogeneity: Chi2 = 1.00, df = 2 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.38 (P = 0.017)
2 NaR and MDR not reported
Arnold 1993 1/57 2/34 0.29 [ 0.02, 3.28 ]
Gottuzzo 1992 0/47 4/48 0.10 [ 0.01, 1.99 ]
Subtotal (95% CI) 104 82 0.17 [ 0.03, 1.07 ]
Total events: 1 (Fluoroquinolone), 6 (Chloramphenicol)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 1.89 (P = 0.059)
Total (95% CI) 283 184 0.14 [ 0.04, 0.50 ]
Total events: 1 (Fluoroquinolone), 12 (Chloramphenicol)
Heterogeneity: Chi2 = 1.39, df = 4 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.04 (P = 0.0023)
0.001 0.01 0.1 1 10 100 1000
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Analysis 1.4. Comparison 1 Fluoroquinolones vs chloramphenicol, Outcome 4 Fever clearance time.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 1 Fluoroquinolones vs chloramphenicol
Outcome: 4 Fever clearance time
Study or subgroup Fluoroquinolone Chloramphenicol Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NaR not reported and MDR absent
Gasem 2003 28 122.4 (33.6) 27 136.8 (52.8) 36.5 % -14.40 [ -37.88, 9.08 ]
Quintero 1988 13 69.6 (26.4) 13 88.8 (52.8) 19.6 % -19.20 [ -51.29, 12.89 ]
Subtotal (95% CI) 41 40 56.1 % -16.07 [ -35.03, 2.88 ]
Heterogeneity: Chi2 = 0.06, df = 1 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 1.66 (P = 0.096)
2 NaR absent and MDR present
Phongmany 2005 27 55 (20.1) 21 93.5 (46.8) 43.9 % -38.50 [ -59.90, -17.10 ]
Subtotal (95% CI) 27 21 43.9 % -38.50 [ -59.90, -17.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.53 (P = 0.00042)
Total (95% CI) 68 61 100.0 % -25.93 [ -40.12, -11.74 ]
Heterogeneity: Chi2 = 2.42, df = 2 (P = 0.30); I2 =17%
Test for overall effect: Z = 3.58 (P = 0.00034)
Test for subgroup differences: Chi2 = 2.36, df = 1 (P = 0.12), I2 =58%
-100 -50 0 50 100
Favours fluoroquinolone Favours chloramphenicol
84Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever) (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.5. Comparison 1 Fluoroquinolones vs chloramphenicol, Outcome 5 Length of hospital stay.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 1 Fluoroquinolones vs chloramphenicol
Outcome: 5 Length of hospital stay
Study or subgroup Fluoroquinolone Chloramphenicol Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NaR not reported and MDR absent
Gasem 2003 28 11.7 (2) 27 12.1 (2.6) 60.5 % -0.40 [ -1.63, 0.83 ]
Subtotal (95% CI) 28 27 60.5 % -0.40 [ -1.63, 0.83 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 NaR absent and MDR present
Phongmany 2005 27 8.9 (2.33) 23 14.8 (3.04) 39.5 % -5.90 [ -7.42, -4.38 ]
Subtotal (95% CI) 27 23 39.5 % -5.90 [ -7.42, -4.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 7.60 (P < 0.00001)
Total (95% CI) 55 50 100.0 % -2.57 [ -3.53, -1.62 ]
Heterogeneity: Chi2 = 30.37, df = 1 (P<0.00001); I2 =97%
Test for overall effect: Z = 5.27 (P < 0.00001)
Test for subgroup differences: Chi2 = 30.37, df = 1 (P = 0.00), I2 =97%
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Analysis 1.6. Comparison 1 Fluoroquinolones vs chloramphenicol, Outcome 6 Convalescent faecal carriage
(NaR not reported and MDR absent).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 1 Fluoroquinolones vs chloramphenicol
Outcome: 6 Convalescent faecal carriage (NaR not reported and MDR absent)
Study or subgroup Fluoroquinolone Chloramphenicol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bran 1991 0/51 1/51 14.8 % 0.33 [ 0.01, 8.21 ]
Cristiano 1995 0/30 2/30 24.4 % 0.19 [ 0.01, 4.06 ]
Morelli 1992 2/106 4/30 60.8 % 0.13 [ 0.02, 0.72 ]
Total (95% CI) 187 111 100.0 % 0.17 [ 0.04, 0.70 ]
Total events: 2 (Fluoroquinolone), 7 (Chloramphenicol)
Heterogeneity: Chi2 = 0.28, df = 2 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.45 (P = 0.014)
0.001 0.01 0.1 1 10 100 1000
Favours fluoroquinolone Favours chloramphenicol
Analysis 1.7. Comparison 1 Fluoroquinolones vs chloramphenicol, Outcome 7 Complications.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 1 Fluoroquinolones vs chloramphenicol
Outcome: 7 Complications
Study or subgroup Fluoroquinolone Chloramphenicol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR not reported and MDR absent
Gasem 2003 3/28 3/27 63.2 % 0.96 [ 0.18, 5.23 ]
Subtotal (95% CI) 28 27 63.2 % 0.96 [ 0.18, 5.23 ]
Total events: 3 (Fluoroquinolone), 3 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.05 (P = 0.96)
2 NaR absent and MDR present
Phongmany 2005 0/27 1/23 36.8 % 0.27 [ 0.01, 7.02 ]
Subtotal (95% CI) 27 23 36.8 % 0.27 [ 0.01, 7.02 ]
Total events: 0 (Fluoroquinolone), 1 (Chloramphenicol)
0.001 0.01 0.1 1 10 100 1000
Favours fluoroquinolone Favours chloramphenicol
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(. . . Continued)
Study or subgroup Fluoroquinolone Chloramphenicol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.78 (P = 0.43)
Total (95% CI) 55 50 100.0 % 0.71 [ 0.16, 3.05 ]
Total events: 3 (Fluoroquinolone), 4 (Chloramphenicol)
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.46 (P = 0.64)
0.001 0.01 0.1 1 10 100 1000
Favours fluoroquinolone Favours chloramphenicol
Analysis 1.8. Comparison 1 Fluoroquinolones vs chloramphenicol, Outcome 8 Adverse events (not serious).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 1 Fluoroquinolones vs chloramphenicol
Outcome: 8 Adverse events (not serious)
Study or subgroup Fluoroquinolone Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR not reported and MDR absent
Abejar 1993 2/15 1/15 2.15 [ 0.17, 26.67 ]
Cristiano 1995 7/30 5/30 1.52 [ 0.42, 5.47 ]
Gasem 2003 0/28 1/27 0.31 [ 0.01, 7.95 ]
Subtotal (95% CI) 73 72 1.32 [ 0.47, 3.73 ]
Total events: 9 (Fluoroquinolone), 7 (Chloramphenicol)
Heterogeneity: Chi2 = 0.96, df = 2 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.52 (P = 0.60)
2 NaR not reported and MDR not reported
Yousaf 1992 3/25 4/25 0.72 [ 0.14, 3.59 ]
Subtotal (95% CI) 25 25 0.72 [ 0.14, 3.59 ]
Total events: 3 (Fluoroquinolone), 4 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.41 (P = 0.68)
3 NaR absent and MDR present
Phongmany 2005 0/27 0/23 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 27 23 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Chloramphenicol)
0.001 0.01 0.1 1 10 100 1000
Favours fluoroquinolone Favours chloramphenicol
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(. . . Continued)
Study or subgroup Fluoroquinolone Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 125 120 1.10 [ 0.46, 2.62 ]
Total events: 12 (Fluoroquinolone), 11 (Chloramphenicol)
Heterogeneity: Chi2 = 1.38, df = 3 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
0.001 0.01 0.1 1 10 100 1000
Favours fluoroquinolone Favours chloramphenicol
Analysis 2.1. Comparison 2 Fluoroquinolones vs amoxicillin (AMX) or ampicillin (AMP), Outcome 1
Clinical failure (MDR and NaR not reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 2 Fluoroquinolones vs amoxicillin (AMX) or ampicillin (AMP)
Outcome: 1 Clinical failure (MDR and NaR not reported)
Study or subgroup Fluoroquinolone AMX or AMP Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Flores 1994 0/20 5/20 41.1 % 0.07 [ 0.00, 1.34 ]
Yousaf 1992 1/25 8/25 58.9 % 0.09 [ 0.01, 0.78 ]
Total (95% CI) 45 45 100.0 % 0.08 [ 0.01, 0.46 ]
Total events: 1 (Fluoroquinolone), 13 (AMX or AMP)
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.82 (P = 0.0048)
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Analysis 2.2. Comparison 2 Fluoroquinolones vs amoxicillin (AMX) or ampicillin (AMP), Outcome 2
Microbiological failure (MDR and NaR not reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 2 Fluoroquinolones vs amoxicillin (AMX) or ampicillin (AMP)
Outcome: 2 Microbiological failure (MDR and NaR not reported)
Study or subgroup Fluoroquinolone AMX or AMP Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Flores 1994 0/20 3/20 30.8 % 0.12 [ 0.01, 2.53 ]
Yousaf 1992 1/25 8/25 69.2 % 0.09 [ 0.01, 0.78 ]
Total (95% CI) 45 45 100.0 % 0.10 [ 0.02, 0.58 ]
Total events: 1 (Fluoroquinolone), 11 (AMX or AMP)
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.87); I2 =0.0%
Test for overall effect: Z = 2.57 (P = 0.010)
0.001 0.01 0.1 1 10 100 1000
Favours fluoroquinolone Favours AMX or AMP
Analysis 2.3. Comparison 2 Fluoroquinolones vs amoxicillin (AMX) or ampicillin (AMP), Outcome 3
Adverse events (not serious) (MDR and NaR not reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 2 Fluoroquinolones vs amoxicillin (AMX) or ampicillin (AMP)
Outcome: 3 Adverse events (not serious) (MDR and NaR not reported)
Study or subgroup Fluoroquinolone AMX or AMP Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Yousaf 1992 3/25 11/25 0.17 [ 0.04, 0.73 ]
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Analysis 3.1. Comparison 3 Fluoroquinolones vs co-trimoxazole, Outcome 1 Clinical failure (MDR absent).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 3 Fluoroquinolones vs co-trimoxazole
Outcome: 1 Clinical failure (MDR absent)
Study or subgroup Fluoroquinolone Co-trimoxazole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Hajji 1988 0/24 0/18 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 24 18 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 NaR not reported
Limson 1989 0/20 2/20 0.18 [ 0.01, 4.01 ]
Subtotal (95% CI) 20 20 0.18 [ 0.01, 4.01 ]
Total events: 0 (Fluoroquinolone), 2 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 44 38 0.18 [ 0.01, 4.01 ]
Total events: 0 (Fluoroquinolone), 2 (Co-trimoxazole)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 3.2. Comparison 3 Fluoroquinolones vs co-trimoxazole, Outcome 2 Microbiological failure (MDR
absent).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 3 Fluoroquinolones vs co-trimoxazole
Outcome: 2 Microbiological failure (MDR absent)
Study or subgroup Fluoroquinolone Co-trimoxazole Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Hajji 1988 0/24 0/18 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 24 18 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 NaR not reported
Limson 1989 0/20 2/20 0.18 [ 0.01, 4.01 ]
Subtotal (95% CI) 20 20 0.18 [ 0.01, 4.01 ]
Total events: 0 (Fluoroquinolone), 2 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
Total (95% CI) 44 38 0.18 [ 0.01, 4.01 ]
Total events: 0 (Fluoroquinolone), 2 (Co-trimoxazole)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.08 (P = 0.28)
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Analysis 3.3. Comparison 3 Fluoroquinolones vs co-trimoxazole, Outcome 3 Adverse events (not serious)
(MDR absent).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 3 Fluoroquinolones vs co-trimoxazole
Outcome: 3 Adverse events (not serious) (MDR absent)
Study or subgroup Fluoroquinolone Co-trimoxazole Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Hajji 1988 1/24 1/18 19.6 % 0.74 [ 0.04, 12.67 ]
Subtotal (95% CI) 24 18 19.6 % 0.74 [ 0.04, 12.67 ]
Total events: 1 (Fluoroquinolone), 1 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
2 NaR not reported
Limson 1989 5/20 6/20 80.4 % 0.78 [ 0.19, 3.13 ]
Subtotal (95% CI) 20 20 80.4 % 0.78 [ 0.19, 3.13 ]
Total events: 5 (Fluoroquinolone), 6 (Co-trimoxazole)
Heterogeneity: not applicable
Test for overall effect: Z = 0.35 (P = 0.72)
Total (95% CI) 44 38 100.0 % 0.77 [ 0.22, 2.69 ]
Total events: 6 (Fluoroquinolone), 7 (Co-trimoxazole)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 0.41 (P = 0.68)
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Analysis 4.1. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 1 Clinical failure (in adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 1 Clinical failure (in adults)
Study or subgroup Fluoroquinolone (FQ) Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present
Chinh 2000 6/44 2/44 3.32 [ 0.63, 17.43 ]
Subtotal (95% CI) 44 44 3.32 [ 0.63, 17.43 ]
Total events: 6 (Fluoroquinolone (FQ)), 2 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.42 (P = 0.16)
2 NaR not reported
Girgis 1999 0/28 0/36 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 28 36 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone (FQ)), 0 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 72 80 3.32 [ 0.63, 17.43 ]
Total events: 6 (Fluoroquinolone (FQ)), 2 (Azithromycin)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.42 (P = 0.16)
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Analysis 4.2. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 2 Microbiological failure (in adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 2 Microbiological failure (in adults)
Study or subgroup Fluoroquinolone Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present
Chinh 2000 2/44 1/44 2.05 [ 0.18, 23.44 ]
Subtotal (95% CI) 44 44 2.05 [ 0.18, 23.44 ]
Total events: 2 (Fluoroquinolone), 1 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.58 (P = 0.56)
2 NaR not reported
Girgis 1999 0/28 0/36 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 28 36 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 72 80 2.05 [ 0.18, 23.44 ]
Total events: 2 (Fluoroquinolone), 1 (Azithromycin)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.58 (P = 0.56)
0.001 0.01 0.1 1 10 100 1000
Favours fluoroquinolone Favours azithromycin
94Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever) (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 4.3. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 3 Relapse (in adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 3 Relapse (in adults)
Study or subgroup Fluoroquinolone Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present
Chinh 2000 2/17 0/21 6.94 [ 0.31, 154.85 ]
Subtotal (95% CI) 17 21 6.94 [ 0.31, 154.85 ]
Total events: 2 (Fluoroquinolone), 0 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 1.22 (P = 0.22)
2 NaR not reported
Girgis 1999 0/28 0/36 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 28 36 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 45 57 6.94 [ 0.31, 154.85 ]
Total events: 2 (Fluoroquinolone), 0 (Azithromycin)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.22 (P = 0.22)
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Analysis 4.4. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 4 Fever clearance time (in adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 4 Fever clearance time (in adults)
Study or subgroup Fluoroquinolone Azithromycin Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NaR present
Chinh 2000 44 134 (76.14) 44 130 (40.61) 19.1 % 4.00 [ -21.50, 29.50 ]
Subtotal (95% CI) 44 44 19.1 % 4.00 [ -21.50, 29.50 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.31 (P = 0.76)
2 NaR not reported
Girgis 1999 28 79.2 (24) 36 91.2 (26.4) 80.9 % -12.00 [ -24.39, 0.39 ]
Subtotal (95% CI) 28 36 80.9 % -12.00 [ -24.39, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.058)
Total (95% CI) 72 80 100.0 % -8.95 [ -20.09, 2.19 ]
Heterogeneity: Chi2 = 1.22, df = 1 (P = 0.27); I2 =18%
Test for overall effect: Z = 1.57 (P = 0.12)
Test for subgroup differences: Chi2 = 1.22, df = 1 (P = 0.27), I2 =18%
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Analysis 4.5. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 5 Length of hospital stay (days) (in
adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 5 Length of hospital stay (days) (in adults)
Study or subgroup Fluoroquinolone Azithromycin Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NaR present
Chinh 2000 44 10.5 (3.38) 44 9.6 (2.37) 0.90 [ -0.32, 2.12 ]
Subtotal (95% CI) 44 44 0.90 [ -0.32, 2.12 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
2 NaR not reported
Girgis 1999 28 14 (0) 36 14 (0) 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 28 36 0.0 [ 0.0, 0.0 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 72 80 0.90 [ -0.32, 2.12 ]
Heterogeneity: Chi2 = 0.00, df = 0 (P<0.00001); I2 =100%
Test for overall effect: Z = 1.45 (P = 0.15)
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Analysis 4.6. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 6 Convalescent faecal carriage (in
adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 6 Convalescent faecal carriage (in adults)
Study or subgroup Fluoroquinolone Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present
Chinh 2000 8/35 0/34 21.33 [ 1.18, 386.00 ]
Subtotal (95% CI) 35 34 21.33 [ 1.18, 386.00 ]
Total events: 8 (Fluoroquinolone), 0 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.038)
2 NaR not reported
Girgis 1999 0/28 0/36 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 28 36 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 63 70 21.33 [ 1.18, 386.00 ]
Total events: 8 (Fluoroquinolone), 0 (Azithromycin)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
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Analysis 4.7. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 7 Complications (in adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 7 Complications (in adults)
Study or subgroup Fluoroquinolone Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present
Chinh 2000 1/44 1/44 1.00 [ 0.06, 16.51 ]
Subtotal (95% CI) 44 44 1.00 [ 0.06, 16.51 ]
Total events: 1 (Fluoroquinolone), 1 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 NaR not reported
Girgis 1999 0/28 0/36 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 28 36 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Azithromycin)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 72 80 1.00 [ 0.06, 16.51 ]
Total events: 1 (Fluoroquinolone), 1 (Azithromycin)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.0 (P = 1.0)
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Analysis 4.8. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 8 Clinical failure (mostly children).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 8 Clinical failure (mostly children)
Study or subgroup Fluoroquinolone Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present
Parry 2007 23/63 11/62 2.67 [ 1.16, 6.11 ]
2 NaR present (but newer fluoroquinolone)
Dolecek 2008 6/145 6/140 0.96 [ 0.30, 3.06 ]
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Analysis 4.9. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 9 Microbiological failure (mostly
children).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 9 Microbiological failure (mostly children)
Study or subgroup Fluoroquinolone Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present
Parry 2007 2/63 2/62 0.98 [ 0.13, 7.21 ]
2 NaR present (but newer fluoroquinolone)
Dolecek 2008 2/145 3/140 0.64 [ 0.11, 3.88 ]
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Analysis 4.10. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 10 Relapse (mostly children).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 10 Relapse (mostly children)
Study or subgroup Fluoroquinolone Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present (but newer fluoroquinolone)
Dolecek 2008 3/137 0/127 6.64 [ 0.34, 129.74 ]
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Analysis 4.11. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 11 Fever clearance time (mostly
children).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 11 Fever clearance time (mostly children)
Study or subgroup Fluoroquinolone Azithromycin Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NaR present
Parry 2007 63 196.8 (97.18) 62 139.2 (67.49) 57.60 [ 28.31, 86.89 ]
2 NaR present (but newer fluoroquinolone)
Dolecek 2008 145 115.97 (57.78) 140 115.24 (60.15) 0.73 [ -12.97, 14.43 ]
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Analysis 4.12. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 12 Length of hospital stay
(mostly children).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 12 Length of hospital stay (mostly children)
Study or subgroup Fluoroquinolone Azithromycin Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NaR present
Parry 2007 63 13.7 (3.85) 62 12.6 (2.21) 1.10 [ 0.00, 2.20 ]
2 NaR present (but newer fluoroquinolone)
Dolecek 2008 145 13.85 (2.79) 140 13.66 (3.04) 0.19 [ -0.49, 0.87 ]
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Analysis 4.13. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 13 Convalescent faecal carriage
(mostly children).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 13 Convalescent faecal carriage (mostly children)
Study or subgroup Fluoroquinolone Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present
Parry 2007 12/62 1/62 14.64 [ 1.84, 116.48 ]
2 NaR present (but newer fluoroquinolone)
Dolecek 2008 1/137 0/131 2.89 [ 0.12, 71.58 ]
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Analysis 4.14. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 14 Complications (mostly
children).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 14 Complications (mostly children)
Study or subgroup Fluoroquinolone Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present
Parry 2007 0/63 2/62 0.19 [ 0.01, 4.05 ]
2 NaR present (but newer fluoroquinolone)
Dolecek 2008 0/145 8/140 0.05 [ 0.00, 0.94 ]
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Analysis 4.15. Comparison 4 Fluoroquinolones vs azithromycin, Outcome 15 Adverse events (not serious)
(mostly children).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 4 Fluoroquinolones vs azithromycin
Outcome: 15 Adverse events (not serious) (mostly children)
Study or subgroup Fluoroquinolone Azithromycin Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present (but newer fluoroquinolone)
Dolecek 2008 2/145 1/140 1.94 [ 0.17, 21.68 ]
0.01 0.1 1 10 100
Favours fluoroquinolone Favours azithromycin
Analysis 5.1. Comparison 5 Fluoroquinolones vs cefixime, Outcome 1 Clinical failure (adults or mostly
adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 1 Clinical failure (adults or mostly adults)
Study or subgroup Fluoroquinolone Cefixime Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR not reported
Yu 1998 0/40 3/40 14.2 % 0.13 [ 0.01, 2.65 ]
Subtotal (95% CI) 40 40 14.2 % 0.13 [ 0.01, 2.65 ]
Total events: 0 (Fluoroquinolone), 3 (Cefixime)
Heterogeneity: not applicable
Test for overall effect: Z = 1.32 (P = 0.19)
2 NaR present (but newer fluoroquinolone)
Pandit 2007 1/88 19/70 85.8 % 0.03 [ 0.00, 0.24 ]
Subtotal (95% CI) 88 70 85.8 % 0.03 [ 0.00, 0.24 ]
Total events: 1 (Fluoroquinolone), 19 (Cefixime)
Heterogeneity: not applicable
Test for overall effect: Z = 3.34 (P = 0.00083)
Total (95% CI) 128 110 100.0 % 0.05 [ 0.01, 0.24 ]
Total events: 1 (Fluoroquinolone), 22 (Cefixime)
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 3.66 (P = 0.00025)
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Analysis 5.2. Comparison 5 Fluoroquinolones vs cefixime, Outcome 2 Microbiological failure (adults or
mostly adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 2 Microbiological failure (adults or mostly adults)
Study or subgroup Fluoroquinolone Cefixime Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR not reported
Yu 1998 0/40 4/40 72.8 % 0.10 [ 0.01, 1.92 ]
Subtotal (95% CI) 40 40 72.8 % 0.10 [ 0.01, 1.92 ]
Total events: 0 (Fluoroquinolone), 4 (Cefixime)
Heterogeneity: not applicable
Test for overall effect: Z = 1.53 (P = 0.13)
2 NaR present (but newer fluoroquinolone)
Pandit 2007 0/88 1/70 27.2 % 0.26 [ 0.01, 6.53 ]
Subtotal (95% CI) 88 70 27.2 % 0.26 [ 0.01, 6.53 ]
Total events: 0 (Fluoroquinolone), 1 (Cefixime)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 128 110 100.0 % 0.14 [ 0.02, 1.23 ]
Total events: 0 (Fluoroquinolone), 5 (Cefixime)
Heterogeneity: Chi2 = 0.19, df = 1 (P = 0.66); I2 =0.0%
Test for overall effect: Z = 1.77 (P = 0.076)
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Analysis 5.3. Comparison 5 Fluoroquinolones vs cefixime, Outcome 3 Relapse (adults or mostly adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 3 Relapse (adults or mostly adults)
Study or subgroup Fluoroquinolone Cefixime Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR not reported
Yu 1998 0/40 0/40 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 40 40 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Cefixime)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 NaR present (but newer fluoroquinolone)
Pandit 2007 2/87 6/51 0.18 [ 0.03, 0.91 ]
Subtotal (95% CI) 87 51 0.18 [ 0.03, 0.91 ]
Total events: 2 (Fluoroquinolone), 6 (Cefixime)
Heterogeneity: not applicable
Test for overall effect: Z = 2.07 (P = 0.038)
Total (95% CI) 127 91 0.18 [ 0.03, 0.91 ]
Total events: 2 (Fluoroquinolone), 6 (Cefixime)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 2.07 (P = 0.038)
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Analysis 5.4. Comparison 5 Fluoroquinolones vs cefixime, Outcome 4 Fever clearance time (adults or
mostly adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 4 Fever clearance time (adults or mostly adults)
Study or subgroup Fluoroquinolone Cefixime Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NaR not reported
Yu 1998 40 82.8 (27.4) 40 118.8 (41.04) 75.3 % -36.00 [ -51.29, -20.71 ]
Subtotal (95% CI) 40 40 75.3 % -36.00 [ -51.29, -20.71 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.61 (P < 0.00001)
2 NaR present (but newer fluoroquinolone)
Pandit 2007 88 103 (52) 70 162 (104) 24.7 % -59.00 [ -85.68, -32.32 ]
Subtotal (95% CI) 88 70 24.7 % -59.00 [ -85.68, -32.32 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.33 (P = 0.000015)
Total (95% CI) 128 110 100.0 % -41.69 [ -54.96, -28.42 ]
Heterogeneity: Chi2 = 2.15, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 6.16 (P < 0.00001)
Test for subgroup differences: Chi2 = 2.15, df = 1 (P = 0.14), I2 =53%
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Analysis 5.5. Comparison 5 Fluoroquinolones vs cefixime, Outcome 5 Convalescent faecal carriage (adults
or mostly adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 5 Convalescent faecal carriage (adults or mostly adults)
Study or subgroup Fluoroquinolone Cefixime Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR not reported
Yu 1998 0/40 0/40 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 40 40 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Cefixime)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 NaR present (but newer fluoroquinolone)
Pandit 2007 0/82 1/65 0.26 [ 0.01, 6.50 ]
Subtotal (95% CI) 82 65 0.26 [ 0.01, 6.50 ]
Total events: 0 (Fluoroquinolone), 1 (Cefixime)
Heterogeneity: not applicable
Test for overall effect: Z = 0.82 (P = 0.41)
Total (95% CI) 122 105 0.26 [ 0.01, 6.50 ]
Total events: 0 (Fluoroquinolone), 1 (Cefixime)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.82 (P = 0.41)
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Analysis 5.6. Comparison 5 Fluoroquinolones vs cefixime, Outcome 6 Complications (adults or mostly
adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 6 Complications (adults or mostly adults)
Study or subgroup Fluoroquinolone Cefixime Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR present (but newer fluoroquinolone)
Pandit 2007 0/88 1/70 0.26 [ 0.01, 6.53 ]
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Favours fluoroquinolone Favours cefixime
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Analysis 5.7. Comparison 5 Fluoroquinolones vs cefixime, Outcome 7 Adverse events (not serious) (adults
or mostly adults).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 7 Adverse events (not serious) (adults or mostly adults)
Study or subgroup Fluoroquinolone Cefixime Odds Ratio Weight Odds Ratio
n/N n/N M-H,Random,95% CI M-H,Random,95% CI
1 NaR not reported
Yu 1998 2/40 3/40 50.8 % 0.65 [ 0.10, 4.11 ]
Subtotal (95% CI) 40 40 50.8 % 0.65 [ 0.10, 4.11 ]
Total events: 2 (Fluoroquinolone), 3 (Cefixime)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.65)
2 NaR present (but newer fluoroquinolone)
Pandit 2007 18/88 1/70 49.2 % 17.74 [ 2.30, 136.58 ]
Subtotal (95% CI) 88 70 49.2 % 17.74 [ 2.30, 136.58 ]
Total events: 18 (Fluoroquinolone), 1 (Cefixime)
Heterogeneity: not applicable
Test for overall effect: Z = 2.76 (P = 0.0057)
Total (95% CI) 128 110 100.0 % 3.30 [ 0.11, 97.30 ]
Total events: 20 (Fluoroquinolone), 4 (Cefixime)
Heterogeneity: Tau2 = 4.98; Chi2 = 6.05, df = 1 (P = 0.01); I2 =83%
Test for overall effect: Z = 0.69 (P = 0.49)
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Analysis 5.8. Comparison 5 Fluoroquinolones vs cefixime, Outcome 8 Clinical failure (children only).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 8 Clinical failure (children only)
Study or subgroup Fluoroquinolone Cefixime Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Cao 1999 1/38 8/44 0.12 [ 0.01, 1.02 ]
0.001 0.01 0.1 1 10 100 1000
Favours fluoroquinolone Favours cefixime
Analysis 5.9. Comparison 5 Fluoroquinolones vs cefixime, Outcome 9 Microbiological failure (children only).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 9 Microbiological failure (children only)
Study or subgroup Fluoroquinolone Cefixime Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Cao 1999 0/38 2/44 0.22 [ 0.01, 4.74 ]
0.001 0.01 0.1 1 10 100 1000
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Analysis 5.10. Comparison 5 Fluoroquinolones vs cefixime, Outcome 10 Relapse (children only).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 10 Relapse (children only)
Study or subgroup Fluoroquinolone Cefixime Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Cao 1999 0/20 1/20 0.32 [ 0.01, 8.26 ]
0.01 0.1 1 10 100
Favours fluoroquinolone Favours cefixime
Analysis 5.11. Comparison 5 Fluoroquinolones vs cefixime, Outcome 11 Fever clearance time (children
only).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 11 Fever clearance time (children only)
Study or subgroup Fluoroquinolone Cefixime Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NaR absent
Cao 1999 37 119 (50) 41 210 (62) -91.00 [ -115.89, -66.11 ]
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Analysis 5.12. Comparison 5 Fluoroquinolones vs cefixime, Outcome 12 Length of hospital stay (children
only).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 12 Length of hospital stay (children only)
Study or subgroup Fluoroquinolone Cefixime Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NaR absent
Cao 1999 37 11 (3) 44 14 (4) -3.00 [ -4.53, -1.47 ]
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Analysis 5.13. Comparison 5 Fluoroquinolones vs cefixime, Outcome 13 Complications (children only).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 5 Fluoroquinolones vs cefixime
Outcome: 13 Complications (children only)
Study or subgroup Fluoroquinolone Cefixime Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Cao 1999 2/38 1/44 2.39 [ 0.21, 27.43 ]
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Analysis 6.1. Comparison 6 Fluoroquinolones vs ceftriaxone, Outcome 1 Clinical failure.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 6 Fluoroquinolones vs ceftriaxone
Outcome: 1 Clinical failure
Study or subgroup Fluoroquinolone Ceftriaxone Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent (adults only)
Smith 1994 0/22 6/25 41.1 % 0.07 [ 0.00, 1.26 ]
Subtotal (95% CI) 22 25 41.1 % 0.07 [ 0.00, 1.26 ]
Total events: 0 (Fluoroquinolone), 6 (Ceftriaxone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.81 (P = 0.071)
2 NaR not reported (adults only)
Tran 1994 0/16 2/15 17.2 % 0.16 [ 0.01, 3.71 ]
Wallace 1993 0/20 6/22 41.7 % 0.06 [ 0.00, 1.18 ]
Subtotal (95% CI) 36 37 58.9 % 0.09 [ 0.01, 0.76 ]
Total events: 0 (Fluoroquinolone), 8 (Ceftriaxone)
Heterogeneity: Chi2 = 0.20, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.21 (P = 0.027)
Total (95% CI) 58 62 100.0 % 0.08 [ 0.01, 0.45 ]
Total events: 0 (Fluoroquinolone), 14 (Ceftriaxone)
Heterogeneity: Chi2 = 0.24, df = 2 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 2.87 (P = 0.0042)
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Analysis 6.2. Comparison 6 Fluoroquinolones vs ceftriaxone, Outcome 2 Microbiological failure.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 6 Fluoroquinolones vs ceftriaxone
Outcome: 2 Microbiological failure
Study or subgroup Fluoroquinolone Ceftriaxone Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Smith 1994 0/22 1/25 0.36 [ 0.01, 9.37 ]
Subtotal (95% CI) 22 25 0.36 [ 0.01, 9.37 ]
Total events: 0 (Fluoroquinolone), 1 (Ceftriaxone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
2 NaR not reported
Tran 1994 0/16 1/14 0.27 [ 0.01, 7.25 ]
Wallace 1993 0/20 0/22 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 36 36 0.27 [ 0.01, 7.25 ]
Total events: 0 (Fluoroquinolone), 1 (Ceftriaxone)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.78 (P = 0.44)
Total (95% CI) 58 61 0.32 [ 0.03, 3.17 ]
Total events: 0 (Fluoroquinolone), 2 (Ceftriaxone)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 0.98 (P = 0.33)
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Analysis 6.3. Comparison 6 Fluoroquinolones vs ceftriaxone, Outcome 3 Relapse.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 6 Fluoroquinolones vs ceftriaxone
Outcome: 3 Relapse
Study or subgroup Fluoroquinolone Ceftriaxone Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent (adults only)
Smith 1994 0/11 1/12 0.33 [ 0.01, 9.07 ]
Subtotal (95% CI) 11 12 0.33 [ 0.01, 9.07 ]
Total events: 0 (Fluoroquinolone), 1 (Ceftriaxone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
2 NaR not reported (adults only)
Tran 1994 0/8 0/8 0.0 [ 0.0, 0.0 ]
Wallace 1993 0/20 1/22 0.35 [ 0.01, 9.08 ]
Subtotal (95% CI) 28 30 0.35 [ 0.01, 9.08 ]
Total events: 0 (Fluoroquinolone), 1 (Ceftriaxone)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 39 42 0.34 [ 0.03, 3.47 ]
Total events: 0 (Fluoroquinolone), 2 (Ceftriaxone)
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.98); I2 =0.0%
Test for overall effect: Z = 0.91 (P = 0.36)
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Analysis 6.4. Comparison 6 Fluoroquinolones vs ceftriaxone, Outcome 4 Fever clearance time.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 6 Fluoroquinolones vs ceftriaxone
Outcome: 4 Fever clearance time
Study or subgroup Fluoroquinolone Ceftriaxone Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 NaR absent (adults only)
Smith 1994 22 81 (25) 25 196 (87) 61.7 % -115.00 [ -150.67, -79.33 ]
Subtotal (95% CI) 22 25 61.7 % -115.00 [ -150.67, -79.33 ]
Heterogeneity: not applicable
Test for overall effect: Z = 6.32 (P < 0.00001)
2 NaR not reported (adults only)
Tran 1994 16 81 (40) 13 160 (75) 38.3 % -79.00 [ -124.24, -33.76 ]
Subtotal (95% CI) 16 13 38.3 % -79.00 [ -124.24, -33.76 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.42 (P = 0.00062)
Total (95% CI) 38 38 100.0 % -101.20 [ -129.21, -73.19 ]
Heterogeneity: Chi2 = 1.50, df = 1 (P = 0.22); I2 =33%
Test for overall effect: Z = 7.08 (P < 0.00001)
Test for subgroup differences: Chi2 = 1.50, df = 1 (P = 0.22), I2 =33%
-1000 -500 0 500 1000
Favours fluoroquinolone Favours ceftriaxone
115Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever) (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 6.5. Comparison 6 Fluoroquinolones vs ceftriaxone, Outcome 5 Convalescent faecal carriage.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 6 Fluoroquinolones vs ceftriaxone
Outcome: 5 Convalescent faecal carriage
Study or subgroup Fluoroquinolone Ceftriaxone Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Smith 1994 0/11 0/12 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 11 12 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Ceftriaxone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 NaR not reported
Tran 1994 0/8 0/8 0.0 [ 0.0, 0.0 ]
Wallace 1993 0/20 1/22 0.35 [ 0.01, 9.08 ]
Subtotal (95% CI) 28 30 0.35 [ 0.01, 9.08 ]
Total events: 0 (Fluoroquinolone), 1 (Ceftriaxone)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
Total (95% CI) 39 42 0.35 [ 0.01, 9.08 ]
Total events: 0 (Fluoroquinolone), 1 (Ceftriaxone)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.63 (P = 0.53)
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Analysis 6.6. Comparison 6 Fluoroquinolones vs ceftriaxone, Outcome 6 Complications.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 6 Fluoroquinolones vs ceftriaxone
Outcome: 6 Complications
Study or subgroup Fluoroquinolone Ceftriaxone Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Smith 1994 0/22 2/25 0.21 [ 0.01, 4.59 ]
Subtotal (95% CI) 22 25 0.21 [ 0.01, 4.59 ]
Total events: 0 (Fluoroquinolone), 2 (Ceftriaxone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
2 NaR not reported
Tran 1994 0/16 0/15 0.0 [ 0.0, 0.0 ]
Wallace 1993 0/20 0/22 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 36 37 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Ceftriaxone)
Heterogeneity: Chi2 = 0.0, df = 0 (P<0.00001); I2 =0.0%
Test for overall effect: Z = 0.0 (P < 0.00001)
Total (95% CI) 58 62 0.21 [ 0.01, 4.59 ]
Total events: 0 (Fluoroquinolone), 2 (Ceftriaxone)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.99 (P = 0.32)
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Analysis 6.7. Comparison 6 Fluoroquinolones vs ceftriaxone, Outcome 7 Serious adverse events.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 6 Fluoroquinolones vs ceftriaxone
Outcome: 7 Serious adverse events
Study or subgroup Fluoroquinolone Ceftriaxone Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Smith 1994 0/22 0/25 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 22 25 0.0 [ 0.0, 0.0 ]
Total events: 0 (Fluoroquinolone), 0 (Ceftriaxone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 NaR not reported
Tran 1994 0/16 1/15 0.29 [ 0.01, 7.76 ]
Subtotal (95% CI) 16 15 0.29 [ 0.01, 7.76 ]
Total events: 0 (Fluoroquinolone), 1 (Ceftriaxone)
Heterogeneity: not applicable
Test for overall effect: Z = 0.73 (P = 0.46)
Total (95% CI) 38 40 0.29 [ 0.01, 7.76 ]
Total events: 0 (Fluoroquinolone), 1 (Ceftriaxone)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.73 (P = 0.46)
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Analysis 6.8. Comparison 6 Fluoroquinolones vs ceftriaxone, Outcome 8 Adverse events (not serious).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 6 Fluoroquinolones vs ceftriaxone
Outcome: 8 Adverse events (not serious)
Study or subgroup Fluoroquinolone Ceftriaxone Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 NaR absent
Smith 1994 1/22 2/25 0.55 [ 0.05, 6.49 ]
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Analysis 7.1. Comparison 7 Norfloxacin vs chloramphenicol, Outcome 1 Clinical failure.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 7 Norfloxacin vs chloramphenicol
Outcome: 1 Clinical failure
Study or subgroup Norfloxacin Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 MDR and NaR present
Sarma 1991 0/20 0/20 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 20 20 0.0 [ 0.0, 0.0 ]
Total events: 0 (Norfloxacin), 0 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 MDR absent and NaR not reported
Morelli 1992 8/20 0/30 41.48 [ 2.22, 774.60 ]
Subtotal (95% CI) 20 30 41.48 [ 2.22, 774.60 ]
Total events: 8 (Norfloxacin), 0 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 2.49 (P = 0.013)
3 MDR and NaR not reported
Nalin 1987 9/90 3/79 2.81 [ 0.73, 10.79 ]
Subtotal (95% CI) 90 79 2.81 [ 0.73, 10.79 ]
Total events: 9 (Norfloxacin), 3 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 130 129 5.80 [ 1.87, 17.98 ]
Total events: 17 (Norfloxacin), 3 (Chloramphenicol)
Heterogeneity: Chi2 = 2.85, df = 1 (P = 0.09); I2 =65%
Test for overall effect: Z = 3.04 (P = 0.0023)
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Analysis 7.2. Comparison 7 Norfloxacin vs chloramphenicol, Outcome 2 Microbiological failure.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 7 Norfloxacin vs chloramphenicol
Outcome: 2 Microbiological failure
Study or subgroup Norfloxacin Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 MDR and NaR present
Sarma 1991 0/20 0/20 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 20 20 0.0 [ 0.0, 0.0 ]
Total events: 0 (Norfloxacin), 0 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 MDR and NaR not reported
Nalin 1987 9/90 3/79 2.81 [ 0.73, 10.79 ]
Subtotal (95% CI) 90 79 2.81 [ 0.73, 10.79 ]
Total events: 9 (Norfloxacin), 3 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.51 (P = 0.13)
Total (95% CI) 110 99 2.81 [ 0.73, 10.79 ]
Total events: 9 (Norfloxacin), 3 (Chloramphenicol)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.51 (P = 0.13)
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Analysis 7.3. Comparison 7 Norfloxacin vs chloramphenicol, Outcome 3 Relapse.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 7 Norfloxacin vs chloramphenicol
Outcome: 3 Relapse
Study or subgroup Norfloxacin Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 MDR and NaR present
Sarma 1991 0/20 0/20 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 20 20 0.0 [ 0.0, 0.0 ]
Total events: 0 (Norfloxacin), 0 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 MDR absent and NaR not reported
Morelli 1992 0/20 3/30 0.19 [ 0.01, 3.92 ]
Subtotal (95% CI) 20 30 0.19 [ 0.01, 3.92 ]
Total events: 0 (Norfloxacin), 3 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.07 (P = 0.28)
Total (95% CI) 40 50 0.19 [ 0.01, 3.92 ]
Total events: 0 (Norfloxacin), 3 (Chloramphenicol)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 1.07 (P = 0.28)
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Analysis 7.4. Comparison 7 Norfloxacin vs chloramphenicol, Outcome 4 Fever clearance time.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 7 Norfloxacin vs chloramphenicol
Outcome: 4 Fever clearance time
Study or subgroup Norfloxacin Chloramphenicol Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 MDR and NaR present
Sarma 1991 20 88 (12) 20 124 (16) -36.00 [ -44.77, -27.23 ]
2 MDR and NaR not reported
Nalin 1987 90 160.8 (60) 79 122.4 (40.8) 38.40 [ 23.08, 53.72 ]
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Analysis 7.5. Comparison 7 Norfloxacin vs chloramphenicol, Outcome 5 Length of hospital stay (MDR and
NaR present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 7 Norfloxacin vs chloramphenicol
Outcome: 5 Length of hospital stay (MDR and NaR present)
Study or subgroup Norfloxacin Chloramphenicol Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Sarma 1991 20 14 (0) 20 14 (0) 0.0 [ 0.0, 0.0 ]
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Analysis 7.6. Comparison 7 Norfloxacin vs chloramphenicol, Outcome 6 Convalescent faecal carriage.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 7 Norfloxacin vs chloramphenicol
Outcome: 6 Convalescent faecal carriage
Study or subgroup Norfloxacin Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 MDR and NaR present
Sarma 1991 0/20 0/20 0.0 [ 0.0, 0.0 ]
Subtotal (95% CI) 20 20 0.0 [ 0.0, 0.0 ]
Total events: 0 (Norfloxacin), 0 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P < 0.00001)
2 MDR absent and NaR not reported
Morelli 1992 3/20 4/30 1.15 [ 0.23, 5.78 ]
Subtotal (95% CI) 20 30 1.15 [ 0.23, 5.78 ]
Total events: 3 (Norfloxacin), 4 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.17 (P = 0.87)
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(. . . Continued)
Study or subgroup Norfloxacin Chloramphenicol Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
3 MDR and NaR not reported
Nalin 1987 2/90 2/79 0.88 [ 0.12, 6.36 ]
Subtotal (95% CI) 90 79 0.88 [ 0.12, 6.36 ]
Total events: 2 (Norfloxacin), 2 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.13 (P = 0.90)
Total (95% CI) 130 129 1.03 [ 0.29, 3.61 ]
Total events: 5 (Norfloxacin), 6 (Chloramphenicol)
Heterogeneity: Chi2 = 0.04, df = 1 (P = 0.84); I2 =0.0%
Test for overall effect: Z = 0.04 (P = 0.96)
0.1 0.2 0.5 1 2 5 10
Favours norfloxacin Favours chloramphenicol
Analysis 7.7. Comparison 7 Norfloxacin vs chloramphenicol, Outcome 7 Adverse events (not serious).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 7 Norfloxacin vs chloramphenicol
Outcome: 7 Adverse events (not serious)
Study or subgroup Norfloxacin Chloramphenicol Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 MDR and NaR present
Sarma 1991 8/20 7/20 37.6 % 1.24 [ 0.34, 4.46 ]
Subtotal (95% CI) 20 20 37.6 % 1.24 [ 0.34, 4.46 ]
Total events: 8 (Norfloxacin), 7 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.33 (P = 0.74)
2 MDR and NaR not reported
Nalin 1987 6/90 7/79 62.4 % 0.73 [ 0.24, 2.29 ]
Subtotal (95% CI) 90 79 62.4 % 0.73 [ 0.24, 2.29 ]
Total events: 6 (Norfloxacin), 7 (Chloramphenicol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.53 (P = 0.59)
Total (95% CI) 110 99 100.0 % 0.92 [ 0.40, 2.15 ]
Total events: 14 (Norfloxacin), 14 (Chloramphenicol)
Heterogeneity: Chi2 = 0.36, df = 1 (P = 0.55); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.86)
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Analysis 8.1. Comparison 8 Norfloxacin vs ceftriaxone, Outcome 1 Clinical failure (NaR not reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 8 Norfloxacin vs ceftriaxone
Outcome: 1 Clinical failure (NaR not reported)
Study or subgroup Norfloxacin Ceftriaxone Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Huai 2000 6/30 2/30 3.50 [ 0.65, 18.98 ]
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Analysis 8.2. Comparison 8 Norfloxacin vs ceftriaxone, Outcome 2 Relapse (NaR not reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 8 Norfloxacin vs ceftriaxone
Outcome: 2 Relapse (NaR not reported)
Study or subgroup Norfloxacin Ceftriaxone Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Huai 2000 2/30 0/30 5.35 [ 0.25, 116.31 ]
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Analysis 8.3. Comparison 8 Norfloxacin vs ceftriaxone, Outcome 3 Fever clearance time (NaR not
reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 8 Norfloxacin vs ceftriaxone
Outcome: 3 Fever clearance time (NaR not reported)
Study or subgroup Norfloxacin Ceftriaxone Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Huai 2000 30 134.4 (38.4) 30 86.4 (28.8) 48.00 [ 30.82, 65.18 ]
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Analysis 8.4. Comparison 8 Norfloxacin vs ceftriaxone, Outcome 4 Adverse events (not serious) (NaR not
reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 8 Norfloxacin vs ceftriaxone
Outcome: 4 Adverse events (not serious) (NaR not reported)
Study or subgroup Norfloxacin Ceftriaxone Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Huai 2000 3/30 1/30 3.22 [ 0.32, 32.89 ]
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Analysis 9.1. Comparison 9 Norfloxacin vs other fluoroquinolones (FQ), Outcome 1 Clinical failure.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 9 Norfloxacin vs other fluoroquinolones (FQ)
Outcome: 1 Clinical failure
Study or subgroup Norfloxacin Other FQ Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Versus pefloxacin
Jia 1994 13/67 0/63 45.2 % 31.46 [ 1.83, 541.56 ]
Morelli 1992 8/20 0/36 23.6 % 49.64 [ 2.67, 923.71 ]
Xiao 1991 6/8 1/6 31.3 % 15.00 [ 1.03, 218.30 ]
Subtotal (95% CI) 95 105 100.0 % 30.60 [ 5.75, 162.86 ]
Total events: 27 (Norfloxacin), 1 (Other FQ)
Heterogeneity: Chi2 = 0.38, df = 2 (P = 0.83); I2 =0.0%
Test for overall effect: Z = 4.01 (P = 0.000061)
2 Versus ofloxacin
Morelli 1992 8/20 0/30 30.9 % 41.48 [ 2.22, 774.60 ]
Xiao 1991 6/8 0/9 16.9 % 49.40 [ 2.02, 1207.15 ]
Yang 1991 5/28 0/28 52.1 % 13.34 [ 0.70, 253.89 ]
Subtotal (95% CI) 56 67 100.0 % 28.15 [ 4.80, 165.14 ]
Total events: 19 (Norfloxacin), 0 (Other FQ)
Heterogeneity: Chi2 = 0.43, df = 2 (P = 0.81); I2 =0.0%
Test for overall effect: Z = 3.70 (P = 0.00022)
3 Versus enoxacin
Bai 1995 18/50 5/52 56.7 % 5.29 [ 1.78, 15.69 ]
Morelli 1992 8/20 4/20 43.3 % 2.67 [ 0.65, 10.97 ]
Subtotal (95% CI) 70 72 100.0 % 4.15 [ 1.77, 9.76 ]
Total events: 26 (Norfloxacin), 9 (Other FQ)
Heterogeneity: Chi2 = 0.57, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 3.26 (P = 0.0011)
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Analysis 9.2. Comparison 9 Norfloxacin vs other fluoroquinolones (FQ), Outcome 2 Relapse.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 9 Norfloxacin vs other fluoroquinolones (FQ)
Outcome: 2 Relapse
Study or subgroup Norfloxacin Other FQ Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Versus ofloxacin
Morelli 1992 0/20 0/30 0.0 [ 0.0, 0.0 ]
Yang 1991 2/28 1/28 2.08 [ 0.18, 24.31 ]
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Analysis 9.3. Comparison 9 Norfloxacin vs other fluoroquinolones (FQ), Outcome 3 Fever clearance time.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 9 Norfloxacin vs other fluoroquinolones (FQ)
Outcome: 3 Fever clearance time
Study or subgroup Norfloxacin Other FQ Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Versus pefloxacin
Jia 1994 67 124.56 (78.48) 63 99.84 (26.4) 66.4 % 24.72 [ 4.83, 44.61 ]
Xiao 1991 8 163.2 (26.4) 6 156 (26.4) 33.6 % 7.20 [ -20.74, 35.14 ]
Subtotal (95% CI) 75 69 100.0 % 18.83 [ 2.62, 35.03 ]
Heterogeneity: Chi2 = 1.00, df = 1 (P = 0.32); I2 =0%
Test for overall effect: Z = 2.28 (P = 0.023)
2 Versus ofloxacin
Xiao 1991 8 163.2 (26.4) 9 175.2 (33.6) 48.2 % -12.00 [ -40.58, 16.58 ]
Yang 1991 28 175.2 (69.6) 28 105.6 (26.4) 51.8 % 69.60 [ 42.03, 97.17 ]
Subtotal (95% CI) 36 37 100.0 % 30.26 [ 10.42, 50.10 ]
Heterogeneity: Chi2 = 16.22, df = 1 (P = 0.00006); I2 =94%
Test for overall effect: Z = 2.99 (P = 0.0028)
3 Versus enoxacin
Bai 1995 50 240 (72) 52 180 (62.4) 100.0 % 60.00 [ 33.81, 86.19 ]
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(. . . Continued)
Study or subgroup Norfloxacin Other FQ Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 50 52 100.0 % 60.00 [ 33.81, 86.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 4.49 (P < 0.00001)
Test for subgroup differences: Chi2 = 6.87, df = 2 (P = 0.03), I2 =71%
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Analysis 9.4. Comparison 9 Norfloxacin vs other fluoroquinolones (FQ), Outcome 4 Convalescent faecal
carriage.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 9 Norfloxacin vs other fluoroquinolones (FQ)
Outcome: 4 Convalescent faecal carriage
Study or subgroup Norfloxacin Other FQ Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Versus pefloxacin
Morelli 1992 3/20 0/36 100.0 % 14.60 [ 0.71, 298.42 ]
Subtotal (95% CI) 20 36 100.0 % 14.60 [ 0.71, 298.42 ]
Total events: 3 (Norfloxacin), 0 (Other FQ)
Heterogeneity: not applicable
Test for overall effect: Z = 1.74 (P = 0.082)
2 Versus ofloxacin
Morelli 1992 3/20 0/30 25.9 % 12.20 [ 0.59, 250.22 ]
Yang 1991 1/28 1/28 74.1 % 1.00 [ 0.06, 16.82 ]
Subtotal (95% CI) 48 58 100.0 % 3.90 [ 0.63, 24.30 ]
Total events: 4 (Norfloxacin), 1 (Other FQ)
Heterogeneity: Chi2 = 1.44, df = 1 (P = 0.23); I2 =31%
Test for overall effect: Z = 1.46 (P = 0.15)
3 Versus enoxacin
Morelli 1992 3/20 2/20 100.0 % 1.59 [ 0.24, 10.70 ]
Subtotal (95% CI) 20 20 100.0 % 1.59 [ 0.24, 10.70 ]
Total events: 3 (Norfloxacin), 2 (Other FQ)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
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Analysis 9.5. Comparison 9 Norfloxacin vs other fluoroquinolones (FQ), Outcome 5 Adverse events (not
serious).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 9 Norfloxacin vs other fluoroquinolones (FQ)
Outcome: 5 Adverse events (not serious)
Study or subgroup Norfloxacin Other FQ Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Versus ofloxacin
Yang 1991 1/28 1/28 1.00 [ 0.06, 16.82 ]
2 Versus enoxacin
Bai 1995 1/50 1/52 1.04 [ 0.06, 17.11 ]
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Analysis 10.1. Comparison 10 Fluoroquinolones for 2 days vs 3 days, Outcome 1 Clinical failure (NaR
present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 10 Fluoroquinolones for 2 days vs 3 days
Outcome: 1 Clinical failure (NaR present)
Study or subgroup 2 days 3 days Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults only
Nguyen 1997 1/47 6/53 100.0 % 0.17 [ 0.02, 1.47 ]
Subtotal (95% CI) 47 53 100.0 % 0.17 [ 0.02, 1.47 ]
Total events: 1 (2 days), 6 (3 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.61 (P = 0.11)
2 Children only
Vinh 1996 6/53 2/47 35.7 % 2.87 [ 0.55, 14.98 ]
Vinh 2005 6/89 4/107 64.3 % 1.86 [ 0.51, 6.81 ]
Subtotal (95% CI) 142 154 100.0 % 2.22 [ 0.81, 6.12 ]
Total events: 12 (2 days), 6 (3 days)
Heterogeneity: Chi2 = 0.16, df = 1 (P = 0.69); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
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Analysis 10.2. Comparison 10 Fluoroquinolones for 2 days vs 3 days, Outcome 2 Microbiological failure
(NaR present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 10 Fluoroquinolones for 2 days vs 3 days
Outcome: 2 Microbiological failure (NaR present)
Study or subgroup 2 days 3 days Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children only
Vinh 1996 0/53 1/47 64.5 % 0.29 [ 0.01, 7.28 ]
Vinh 2005 4/89 1/107 35.5 % 4.99 [ 0.55, 45.46 ]
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Analysis 10.3. Comparison 10 Fluoroquinolones for 2 days vs 3 days, Outcome 3 Relapse (NaR present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 10 Fluoroquinolones for 2 days vs 3 days
Outcome: 3 Relapse (NaR present)
Study or subgroup 2 days 3 days Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults only
Nguyen 1997 0/24 1/26 100.0 % 0.35 [ 0.01, 8.93 ]
Subtotal (95% CI) 24 26 100.0 % 0.35 [ 0.01, 8.93 ]
Total events: 0 (2 days), 1 (3 days)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
2 Children only
Vinh 1996 1/34 0/32 35.7 % 2.91 [ 0.11, 74.08 ]
Vinh 2005 2/89 1/107 64.3 % 2.44 [ 0.22, 27.33 ]
Subtotal (95% CI) 123 139 100.0 % 2.61 [ 0.38, 18.03 ]
Total events: 3 (2 days), 1 (3 days)
Heterogeneity: Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 0.97 (P = 0.33)
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Analysis 10.4. Comparison 10 Fluoroquinolones for 2 days vs 3 days, Outcome 4 Fever clearance time (NaR
present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 10 Fluoroquinolones for 2 days vs 3 days
Outcome: 4 Fever clearance time (NaR present)
Study or subgroup 2 days 3 days Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults only
Nguyen 1997 47 97 (33) 53 97 (44) 100.0 % 0.0 [ -15.14, 15.14 ]
Subtotal (95% CI) 47 53 100.0 % 0.0 [ -15.14, 15.14 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
2 Children only
Vinh 1996 53 100 (64) 47 107 (60) 22.6 % -7.00 [ -31.31, 17.31 ]
Vinh 2005 89 92 (48.13) 107 101 (44.86) 77.4 % -9.00 [ -22.12, 4.12 ]
Subtotal (95% CI) 142 154 100.0 % -8.55 [ -20.10, 3.00 ]
Heterogeneity: Chi2 = 0.02, df = 1 (P = 0.89); I2 =0.0%
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Chi2 = 0.77, df = 1 (P = 0.38), I2 =0.0%
-100 -50 0 50 100
Favours 2 days Favours 3 days
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Analysis 10.5. Comparison 10 Fluoroquinolones for 2 days vs 3 days, Outcome 5 Length of hospital stay
(NaR present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 10 Fluoroquinolones for 2 days vs 3 days
Outcome: 5 Length of hospital stay (NaR present)
Study or subgroup 2 days 3 days Mean Difference Weight Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults only
Nguyen 1997 47 7.6 (1.4) 53 7.8 (1.6) 100.0 % -0.20 [ -0.79, 0.39 ]
Subtotal (95% CI) 47 53 100.0 % -0.20 [ -0.79, 0.39 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
2 Children only
Vinh 1996 53 12.1 (2.3) 47 12.7 (3.5) 20.8 % -0.60 [ -1.78, 0.58 ]
Vinh 2005 89 7.6 (2.17) 107 8 (2.11) 79.2 % -0.40 [ -1.00, 0.20 ]
Subtotal (95% CI) 142 154 100.0 % -0.44 [ -0.98, 0.09 ]
Heterogeneity: Chi2 = 0.09, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 1.61 (P = 0.11)
Test for subgroup differences: Chi2 = 0.35, df = 1 (P = 0.55), I2 =0.0%
-4 -2 0 2 4
Favours 2 days Favours 3 days
Analysis 10.6. Comparison 10 Fluoroquinolones for 2 days vs 3 days, Outcome 6 Convalescent faecal
carriage (NaR present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 10 Fluoroquinolones for 2 days vs 3 days
Outcome: 6 Convalescent faecal carriage (NaR present)
Study or subgroup 2 days 3 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children only
Vinh 1996 0/34 1/32 0.30 [ 0.01, 7.75 ]
Vinh 2005 0/89 0/107 0.0 [ 0.0, 0.0 ]
0.01 0.1 1 10 100
Favours 2 days Favours 3 days
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Analysis 10.7. Comparison 10 Fluoroquinolones for 2 days vs 3 days, Outcome 7 Complications (NaR
present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 10 Fluoroquinolones for 2 days vs 3 days
Outcome: 7 Complications (NaR present)
Study or subgroup 2 days 3 days Odds Ratio Weight Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults only
Nguyen 1997 0/47 4/53 100.0 % 0.12 [ 0.01, 2.21 ]
Subtotal (95% CI) 47 53 100.0 % 0.12 [ 0.01, 2.21 ]
Total events: 0 (2 days), 4 (3 days)
Heterogeneity: not applicable
Test for overall effect: Z = 1.43 (P = 0.15)
2 Children only
Vinh 1996 0/53 2/47 85.6 % 0.17 [ 0.01, 3.63 ]
Vinh 2005 2/89 0/107 14.4 % 6.14 [ 0.29, 129.64 ]
Subtotal (95% CI) 142 154 100.0 % 1.03 [ 0.21, 4.96 ]
Total events: 2 (2 days), 2 (3 days)
Heterogeneity: Chi2 = 2.65, df = 1 (P = 0.10); I2 =62%
Test for overall effect: Z = 0.04 (P = 0.97)
0.001 0.01 0.1 1 10 100 1000
Favours 2 days Favours 3 days
Analysis 10.8. Comparison 10 Fluoroquinolones for 2 days vs 3 days, Outcome 8 Adverse events (not
serious) (NaR present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 10 Fluoroquinolones for 2 days vs 3 days
Outcome: 8 Adverse events (not serious) (NaR present)
Study or subgroup 2 days 3 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children only
Vinh 1996 0/53 1/47 0.29 [ 0.01, 7.28 ]
Vinh 2005 0/89 0/107 0.0 [ 0.0, 0.0 ]
0.01 0.1 1 10 100
Favours 2 days Favours 3 days
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Analysis 11.1. Comparison 11 Fluoroquinolones for 3 days vs 5 days, Outcome 1 Clinical failure (NaR not
reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 11 Fluoroquinolones for 3 days vs 5 days
Outcome: 1 Clinical failure (NaR not reported)
Study or subgroup 3 days 5 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults only
Duong 1995 0/22 1/41 0.60 [ 0.02, 15.35 ]
0.01 0.1 1 10 100
Favours 3 days Favours 5 days
Analysis 11.2. Comparison 11 Fluoroquinolones for 3 days vs 5 days, Outcome 2 Relapse.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 11 Fluoroquinolones for 3 days vs 5 days
Outcome: 2 Relapse
Study or subgroup 3 days 5 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Adults only (NaR not reported)
Duong 1995 0/14 1/26 0.59 [ 0.02, 15.35 ]
2 Children mostly (NaR present)
Tran 1995 0/79 1/75 0.31 [ 0.01, 7.79 ]
0.01 0.1 1 10 100
Favours 3 days Favours 5 days
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Analysis 11.3. Comparison 11 Fluoroquinolones for 3 days vs 5 days, Outcome 3 Fever clearance time.
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 11 Fluoroquinolones for 3 days vs 5 days
Outcome: 3 Fever clearance time
Study or subgroup 3 days 5 days Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults only (NaR not reported)
Duong 1995 22 89 (31) 41 82 (36) 7.00 [ -10.01, 24.01 ]
2 Children mostly (NaR present)
Tran 1995 103 60 (21.6) 92 72 (21.6) -12.00 [ -18.07, -5.93 ]
-100 -50 0 50 100
Favours 3 days Favours 5 days
Analysis 11.4. Comparison 11 Fluoroquinolones for 3 days vs 5 days, Outcome 4 Length of hospital stay
(NaR not reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 11 Fluoroquinolones for 3 days vs 5 days
Outcome: 4 Length of hospital stay (NaR not reported)
Study or subgroup 3 days 5 days Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Adults only
Duong 1995 22 7.5 (0.15) 41 7.47 (0.14) 0.03 [ -0.05, 0.11 ]
-0.5 -0.25 0 0.25 0.5
Favours 3 days Favours 5 days
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Analysis 11.5. Comparison 11 Fluoroquinolones for 3 days vs 5 days, Outcome 5 Adverse events (not
serious) (NaR present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 11 Fluoroquinolones for 3 days vs 5 days
Outcome: 5 Adverse events (not serious) (NaR present)
Study or subgroup 3 days 5 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Children mostly
Tran 1995 11/118 4/110 2.72 [ 0.84, 8.83 ]
0.1 0.2 0.5 1 2 5 10
Favours 3 days Favours 5 days
Analysis 12.1. Comparison 12 Fluoroquinolones for 5 days vs 7 days, Outcome 1 Microbiological failure
(NaR not reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 12 Fluoroquinolones for 5 days vs 7 days
Outcome: 1 Microbiological failure (NaR not reported)
Study or subgroup 5 days 7 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Unal 1996 1/22 0/24 3.42 [ 0.13, 88.40 ]
0.01 0.1 1 10 100
Favours 5 days Favours 7 days
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Analysis 12.2. Comparison 12 Fluoroquinolones for 5 days vs 7 days, Outcome 2 Relapse (NaR not
reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 12 Fluoroquinolones for 5 days vs 7 days
Outcome: 2 Relapse (NaR not reported)
Study or subgroup 5 days 7 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Unal 1996 1/22 0/24 3.42 [ 0.13, 88.40 ]
0.01 0.1 1 10 100
Favours 5 days Favours 7 days
Analysis 12.3. Comparison 12 Fluoroquinolones for 5 days vs 7 days, Outcome 3 Fever clearance time (NaR
not reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 12 Fluoroquinolones for 5 days vs 7 days
Outcome: 3 Fever clearance time (NaR not reported)
Study or subgroup 5 days 7 days Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Unal 1996 22 74.4 (24) 24 81.6 (24) -7.20 [ -21.08, 6.68 ]
-100 -50 0 50 100
Favours 5 days Favours 7 days
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Analysis 12.4. Comparison 12 Fluoroquinolones for 5 days vs 7 days, Outcome 4 Adverse events (not
serious) (NaR not reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 12 Fluoroquinolones for 5 days vs 7 days
Outcome: 4 Adverse events (not serious) (NaR not reported)
Study or subgroup 5 days 7 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Unal 1996 3/22 4/24 0.79 [ 0.16, 4.00 ]
0.1 0.2 0.5 1 2 5 10
Favours 5 days Favours 7 days
Analysis 13.1. Comparison 13 Fluoroquinolones for 7 days vs 10 or 14 days, Outcome 1 Microbiological
failure (NaR not reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 13 Fluoroquinolones for 7 days vs 10 or 14 days
Outcome: 1 Microbiological failure (NaR not reported)
Study or subgroup 7 days 10 or 14 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arnold 1993 1/24 1/33 1.39 [ 0.08, 23.41 ]
Kalo 1997 0/15 0/15 0.0 [ 0.0, 0.0 ]
Total (95% CI) 39 48 1.39 [ 0.08, 23.41 ]
Total events: 1 (7 days), 1 (10 or 14 days)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.23 (P = 0.82)
0.01 0.1 1 10 100
Favours 7 days Favours 10 or 14 days
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Analysis 13.2. Comparison 13 Fluoroquinolones for 7 days vs 10 or 14 days, Outcome 2 Relapse (NaR not
reported).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 13 Fluoroquinolones for 7 days vs 10 or 14 days
Outcome: 2 Relapse (NaR not reported)
Study or subgroup 7 days 10 or 14 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Arnold 1993 1/24 0/33 4.28 [ 0.17, 109.61 ]
Kalo 1997 0/15 0/15 0.0 [ 0.0, 0.0 ]
Total (95% CI) 39 48 4.28 [ 0.17, 109.61 ]
Total events: 1 (7 days), 0 (10 or 14 days)
Heterogeneity: Chi2 = 0.0, df = 0 (P = 1.00); I2 =0.0%
Test for overall effect: Z = 0.88 (P = 0.38)
0.001 0.01 0.1 1 10 100 1000
Favours 7 days Favours 10 or 14 days
Analysis 14.1. Comparison 14 Fluoroquinolones for 10 days vs 14 days, Outcome 1 Relapse (NaR present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 14 Fluoroquinolones for 10 days vs 14 days
Outcome: 1 Relapse (NaR present)
Study or subgroup 10 days 14 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alam 1995 0/35 2/34 0.18 [ 0.01, 3.96 ]
0.001 0.01 0.1 1 10 100 1000
Favours 10 days Favours 14 days
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Analysis 14.2. Comparison 14 Fluoroquinolones for 10 days vs 14 days, Outcome 2 Fever clearance time
(NaR present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 14 Fluoroquinolones for 10 days vs 14 days
Outcome: 2 Fever clearance time (NaR present)
Study or subgroup 10 days 14 days Mean Difference Mean Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Alam 1995 35 100.8 (45.6) 34 117.6 (62.4) -16.80 [ -42.65, 9.05 ]
-100 -50 0 50 100
Favours 10 days Favours 14 days
Analysis 14.3. Comparison 14 Fluoroquinolones for 10 days vs 14 days, Outcome 3 Adverse events (not
serious) (NaR present).
Review: Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever)
Comparison: 14 Fluoroquinolones for 10 days vs 14 days
Outcome: 3 Adverse events (not serious) (NaR present)
Study or subgroup 10 days 14 days Odds Ratio Odds Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Alam 1995 4/35 9/34 0.36 [ 0.10, 1.30 ]
0.01 0.1 1 10 100
Favours 10 days Favours 14 days
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Last assessed as up-to-date: 1 April 2008.
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2 April 2008 New search has been performed New trials: Five new trials added for the following com-
parisons: fluoroquinolone vs chloramphenicol (adults, 1
trial); fluoroquinolone vs cefixime (mostly adults, 1 trial);
fluoroquinolone vs azithromycin (mostly children, 2 tri-
als); and fluoroquinolone 2 days vs 3 days (children, 1
trial). Two ongoing trials identified and referenced. Two
trials were screened for eligibility and excluded (Kumar
2007; Suhendro 2007).
Tables and figures: Updated Table 1 (Microbiology) to
include “Multidrug resistance (MDR) defined as”, and
addedminimum inhibitory concentrations (MICs) of flu-
oroquinolones where nalidixic acid resistance was not
stated. (See ’Background’ for explanation). Added funnel
plots for the fluoroquinolones vs chloramphenicol com-
parison: Analysis 1.1 (clinical failure), Analysis 1.2 (mi-
crobiological failure), and Analysis 1.3 (relapse).
Methods:Durrane Thaver and AsmaAzmatullah selected
the studies from the updated search results, and extracted
data and assessed the methodological quality for the new
included trials.
Minor corrections: Analysis 6.6 (Complications: NaR
not reported) and Table 2 (Complications): for Wallace
1993 for ceftriaxone group, changed from 1 to 0 (this was
described as a ’persistent’ complication, and appears to
not have developed during treatment).
Analysis 7.4 (Mean fever clearance time: MDR and NaR
not reported): for Nalin 1987 (norfloxacin vs chloram-
phenicol) changed 167.5 hours to corrected value of 160.8
hours for norfloxacin group.
Analysis 11.2 (Relapse), Analysis 11.3 (Fever clearance
time), and Analysis 11.5 (Adverse events: not serious): for
Tran 1995 changed from children only to childrenmostly,
as stated in text of review.
Table 3 (Definitions of outcomes): For Abejar 1993,
moved statement (“blood culture positive at Day 23?”)
fromunder “relapse” to “microbiological failure” (resolved
disagreement after consensus).
Table 1 (Microbiology): Revision of MDR status for Xiao
1991 and Huai 2000, and included additional informa-
tion for resistance data for Yu 1998.
Table 2 (Complications): for Gottuzzo 1992, moved “gas-
trointestinal bleed, others not stated” to correct column.
2 April 2008 New citation required but conclusions have not changed New author: Asma Azmatullah joined the author team.
Main changes to the results because of the new trials:
For adults, fluoroquinolones had statistically significantly
lower fever clearance times compared with chlorampheni-
col, and also had statistically significantly lower clinical
failure and relapse rates compared with cefixime.
Conclusions: Our conclusions are unchanged, that is,
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(Continued)
“data are limited, particularly for children”.
Table 1. Microbiology
Compari-
son
Trial Partici-
pants
Culture
positive
(site)
S. Typhi/
Paratyphi
Number
(%)a with
MDR
MDR
defined asb
Number
(%*)a NaRc
Notes on re-
sistance
Fluoro-
quinolone vs
chloram-
phenicol
Abejar 1993 Not stated 30 (blood) 30/0
Fluoro-
quinolone:
15
Chloram-
phenicol: 15
0 Not stated
No
resistance to
chloram-
pheni-
col in chlo-
rampheni-
col group
Not stated -
Arnold
1993
184
enrolled and
randomized
91 (blood) 85/6
Fluoro-
quinolone
7-day: 23/1
Fluoro-
quinolone
14-day:
30/3
Chloram-
phenicol:
32/2
Not stated Not stated Not stated -
Bran 1991 102
randomized
102 (blood
and/or bone
marrow)
102/0 0 Not stated
No
resistance to
chloram-
phenicol in
either group
Not stated -
Cristiano
1995
60
enrolled and
randomized
60 (blood) 60/0
Fluoro-
quinolone:
30
Chloram-
phenicol: 30
0 Not stated
No
resistance to
chloram-
phenicol,
ampi-
cillin, or co-
trimoxazole
Not stated
MIC range
of pefloxacin
was < 0.016
to 0.5
-
Gasem 2003 100
enrolled and
randomized
55 (blood
and/or bone
marrow)
50/5 0 Not stated
No
resistance to
Not stated
MIC range
of ciproflo-
-
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Table 1. Microbiology (Continued)
chloram-
phenicol
12.8% resis-
tant
to ampicillin
or co-
trimoxazole
xacinwas <1
Gottuzzo
1992
Not stated 98 (not
stated)
Not stated Not stated Not stated Not stated -
Morelli
1992
156
enrolled and
randomized
156 (blood) 156/0 0 Not stated
MIC range
for chloram-
phenicol
was 0.5 to 4
mg/L
Not stated
MIC
ranges were:
ofloxacin
0.03 to 0.25;
pefloxacin
0.06 to 0.5;
ciprofloxa-
cin 0.016 to
0.063;
enoxacin
0.25;
norfloxacin
0.063 to
0.25
-
Phongmany
2005
107
enrolled and
randomized
50 (blood) 50/0
Fluoro-
quinolone:
27
Chloram-
phenicol: 23
3/50 (6%)
Fluoro-
quinolone:
1/27
Chloram-
phenicol:
2/23
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
0 Chloram-
phenicol re-
sistance:
4/50
Fluoro-
quinolone:
1/27
Chloram-
phenicol:
3/23d
Ampicillin:
5/50
Fluoro-
quinolone:
2/27
Chloram-
phenicol:
3/23
Co-trimoxa-
zole: 4/50
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Table 1. Microbiology (Continued)
Fluoro-
quinolone:
1/27
Chloram-
phenicol:
3/23
Quintero
1988
Not stated 26 (not
stated)
26/0
Fluoro-
quinolone:
13
Chloram-
phenicol: 13
0 Not stated
No
resistance to
chloram-
phenicol
Not stated -
Yousaf 1992 85
enrolled and
randomized
85 (not
stated)
Not stated Not stated Not stated Not stated -
Fluoro-
quinolone vs
ampicillin
Flores 1994 Not stated 40 (not
stated)
40/0
Fluoro-
quinolone:
20
Ampicillin:
20
Not stated Not stated Not stated -
Fluoro-
quinolone vs
co-
trimoxazole
Hajji 1988 77
enrolled and
randomized
42 (blood
and/or
stool)
28/4
(from blood
culture)
0 Not stated
1 isolate re-
sistant to co-
trimox-
azole was in
pefloxacin
group
0 -
Limson
1989
53
enrolled and
randomized
40 (blood) 28/12
Fluoro-
quinolone:
15/5
Co-trimoxa-
zole: 13/7
0 Not stated
No resis-
tance to co-
trimoxazole
16 were re-
sistant
to chloram-
phenicol
Not stated -
Fluoro-
quinolone vs
azithromy-
cin
Dolecek
2008
358
enrolled and
randomized
288 (blood
or bone
marrow)
282/5
Fluoro-
quinolone:
144/1
Azithromy-
cin: 138/4
153 (58%)
of 263 S. Ty-
phi
Fluoro-
quinolone:
87/137
Azithromy-
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
253 (96%)
of 263 S. Ty-
phi
Fluoro-
quinolone:
132/137
Azithromy-
All 5
S. Paratyphi
were suscep-
tible
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Table 1. Microbiology (Continued)
cin: 66/126 cin:
121/126
Chinh 2000 97
enrolled and
randomized
91 (blood) 86/2 68 (78%) of
87
Fluoro-
quinolone:
35
Azithromy-
cin: 33
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
46 (52.3%;
of 87 strains
evaluated)
Fluoro-
quinolone:
21
Azithromy-
cin: 25
-
Girgis 1999 123
enrolled and
randomized
64 (62 by
blood, 2 by
stool)
60/4
Fluoro-
quinolone:
34/2
Azithromy-
cin: 26/2
21/64
(33%)
Fluoro-
quinolone:
15
Azithromy-
cin: 6
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
Not stated -
Parry 2007 160
enrolled and
random-
ized (exclud-
ing fluoro-
quinolone
with
azithromy-
cin combi-
nation arm)
130 (blood
and/or bone
marrow)
125/0
Fluoro-
quinolone:
63/0
Azithromy-
cin: 62/0
110/125
(88%)
Fluoro-
quinolone:
57/63
Azithromy-
cin: 53/62
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
117/125
(94%)
Fluoro-
quinolone:
62/63
Azithromy-
cin: 55/62
-
Fluoro-
quinolone vs
cefixime
Cao 1999 138
enrolled and
randomized
82 (blood) 82/0
Fluoro-
quinolone:
38
Cefixime:
44
70 (85%)
S. Typhi: 32
S. Paratyphi:
38
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
and tetracy-
cline
0 -
Pandit 2007 390
enrolled and
randomized
169 (blood) 119/50
Fluoro-
quinolone:
65/27
Cefixime:
54/23
0 Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
136/163
(83%)
Fluoro-
quinolone:
71/89
Cefixime:
65/74
-
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Table 1. Microbiology (Continued)
Yu 1998 80 random-
ized
80 (blood or
bone
marrow)
40/40
Fluoro-
quinolone:
21/19
Cefixime:
19/21
Not stated
Individual
drug resis-
tance was re-
ported, but
reported to-
gether with
isolates in-
volved in an-
other trial
Not stated Not stated
MIC for lev-
ofloxacin
was ≤0.03
to 1 mg/L,
but reported
together
with isolates
involved in
another trial
3/98 strains
resistant
to cefixime,
but unclear
which arm
these were in
and
alsowere not
separated
from isolates
involved in
another trial
Fluoro-
quinolone vs
ceftriaxone
Smith 1994 60
enrolled and
randomized
47
(44 by blood
and/or bone
marrow, 3
by stool)
41/6
Fluoro-
quinolone:
21/1
Ceftriaxone:
20/5
26 (55%)
Fluoro-
quinolone:
14
Ceftriaxone:
12
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
and tetracy-
cline
0 -
Tran 1994 46
enrolled and
randomized
31 (blood) 27/4
Fluoro-
quinolone:
14/2
Ceftriaxone:
13/2
12 (38%) Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
Not stated
MIC for
fleroxacin
was mostly
0.06 (addi-
tional infor-
mation from
trial author)
-
Wallace
1993
43 enrolled
and 42 ran-
domized
42 (blood) 42/0
Fluoro-
quinolone:
20
Ceftriaxone:
22
22 (52%)
Fluoro-
quinolone:
11
Ceftriaxone:
11
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
Not stated -
Norfloxacin
vs chloram-
phenicol
Nalin 1987 184
enrolled and
randomized
169 (not
stated)
169/0
Fluoro-
quinolone:
90
Chloram-
phenicol: 79
Not stated Not stated
1 isolate
with ’inter-
mediate sus-
ceptibil-
ity’ in nor-
floxacin
group
Not stated -
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Table 1. Microbiology (Continued)
Sarma 1991 40
enrolled and
randomized
40 (blood
and/or bone
marrow)
38/2 8 (20%) Not stated 4 (10%) (all
reported as
resistant to
norfloxacin)
-
Norfloxacin
vs
ceftriaxone
Huai 2000 196
enrolled, but
only 60 cases
resistant to
ampi-
cillin, co-tri-
moxazole, or
chloram-
pheni-
col were ran-
domized
60 (56 by
blood, 4 by
bone
marrow)
60/0
Fluoro-
quinolone:
30
Ceftriaxone:
30
Not stated Not stated
All
described as
resistant to
ampi-
cillin, chlo-
rampheni-
col, or co-
trimoxazole
Not stated -
Fluoro-
quinolone vs
an-
other fluoro-
quinolone
Bai 1995 102
randomized
102 (blood
or bone
marrow)
102/0
Nor-
floxacin: 50
Enoxacin:
52
Not stated Not stated Not stated -
Jia 1994 130
randomized
130 (blood
or bone
marrow)
130/0
Nor-
floxacin: 67
Pefloxacin:
63
Not stated Not stated Not stated -
Xiao 1991 40 random-
ized (5
groups)
37 (blood or
bone
marrow) (6
groups)
37/0 Not stated Not stated.
All resistant
to chloram-
phenicol; 1
resistant to
norfloxacin;
4 resistant to
pefloxacin
Not stated
For 30 iso-
lates tested,
MIC range
for ciproflo-
xacin was
0.03 to 1;
norfloxacin
< 0.03 to
2; ofloxacin
0.03 to
8; pefloxacin
0.03 to 2
-
Yang 1991 56 random-
ized
56 (blood) 56/0
Nor-
floxacin: 28
Ofloxacin:
28
Not stated Not stated
Resistance
to chloram-
pheni-
col in 18/27,
ampicillin in
Not stated
Resis-
tance to nor-
floxacin: 3
(in ofloxacin
group)
-
148Fluoroquinolones for treating typhoid and paratyphoid fever (enteric fever) (Review)
Copyright © 2008 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Microbiology (Continued)
24/28, and
co-
trimoxazole
in 25/26 iso-
lates
tested from
ofloxacin
group
Dif-
ferent dura-
tions of fluo-
roquinolone
Alam 1995 76
enrolled and
randomized
72 (blood or
bone
marrow)
61/8
Fluoro-
quinolone
10-day:
30/5
Fluoro-
quinolone
14-day:
31/3
36/69
(52%)
Fluoro-
quinolone
10-day: 18
Fluoro-
quinolone
14-day: 18
Resistance
to all drugs
used
convention-
ally against
S. Typhi and
S. Paratyphi
5/69 (7%)
Fluoro-
quinolone
10-day: 2
Fluoro-
quinolone
14-day: 3
(derived
from data
presented
for MIC for
ciprofloxa-
cin)
-
Duong
1995
95
enrolled and
randomized
63 (blood or
bone
marrow)
62/1
Fluoro-
quinolone
5-day: 40/1
Fluoro-
quinolone
3-day: 22/0
Around
80%
[trialist’s es-
timate]
Not
available
Not stated -
Kalo 1997 30 (
ampicillin-
resistant)
enrolled and
randomized
30 (blood) 30/0 12/30
(40%)
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
Not stated -
Nguyen
1997
107
enrolled and
randomized
101 (blood) 95/5
Fluoro-
quinolone
2-day: 43/4
Fluoro-
quinolone
3-day: 52/1
75/95
(79%)
Fluoro-
quinolone
2-day: 35
Fluoro-
quinolone
3-day: 40
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
and tetracy-
cline
5/95 (5%)
Fluoro-
quinolone
2-day: 1
Fluoro-
quinolone
3-day: 4
-
Tran 1995 438 en-
rolled, 425
228 (blood) 207/19
(2 other
189
Fluoro-
Resistant to
standard an-
Few
NaR strains
-
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Table 1. Microbiology (Continued)
randomized Salmonella) quinolone
3-day: 98
Fluoro-
quinolone
5-day: 91
tibiotics present,
number not
stated
Unal 1996 46 random-
ized
46 (blood
and/or bone
marrow)
19/27
Fluoro-
quinolone
5-day: 8/14
Fluoro-
quinolone
7-day:
11/13
6/46 (13%)
Fluoro-
quinolone
5-day: 3
Fluoro-
quinolone
7-day: 3
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
Not stated
MIC for pe-
floxacin was
0.06 to 1
-
Vinh 1996 108
enrolled and
randomized
100 (blood) 100/0
Fluoro-
quinolone
2-day: 53
Fluoro-
quinolone
3-day: 47
84
Fluoro-
quinolone
2-day: 46
Fluoro-
quinolone
3-day: 38
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
and tetracy-
cline
13 (13%)
Fluoro-
quinolone
2-day: 6
Fluoro-
quinolone
3-day: 7
-
Vinh 2005 235
enrolled and
randomized
202 (blood) 196/0
Fluoro-
quinolone
2-day: 89
Fluoro-
quinolone
3-day: 107
176/196
(90%)
Fluoro-
quinolone
2-day:
82/89
Fluoro-
quinolone
3-day:
94/107
Resistant to
all 3 (chlo-
rampheni-
col, ampi-
cillin, co-tri-
moxazole)
4/161
(2.5%)
Fluoro-
quinolone
2-day: 1/72
Fluoro-
quinolone
3-day: 3/89
-
MDR: multiple-drug-resistant strain; MIC: minimum inhibitory concentration; NaR: nalidixic acid-resistant strain.
aCalculation: number with MDR or NaR divided by number culture positive.
bAs stated or implied in text of report.
cOr MIC of fluoroquinolone if available (all ranges in mg/L).
dThese participants were switched to fluoroquinolone when organisms were found resistant to assigned drug.
Table 2. Complicationsa
Comparison Trial No. of participants (in brackets) with complicationsb
Intervention Control
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Table 2. Complicationsa (Continued)
Fluoroquinolone vs chloram-
phenicol
Arnold 1993 Gastrointestinal haemorrhage, gastrointestinal perforation, and pneumonia
occurred, but report does not say in which group, and trial combined both
culture-negative and culture-positive participants
Gasem 2003 Ciprofloxacin: pneumonia (3) Chloramphenicol: sepsis, myocardi-
tis, pneumonia (1); gastrointestinal
bleed (1); pneumonia (1)
Gottuzzo 1992 Ciprofloxacin: gastrointestinal bleed
(1); others not described
Not described
Phongmany 2005 Ofloxacin: 0 Chloramphenicol: gastrointestinal
bleed and perforation (1)
Fluoroquinolone vs co-trimox-
azole
Hajji 1988 0 0
Fluoroquinolone vs azithromy-
cin
Dolecek 2008 Gatifloxacin: 0 Azithromycin: liver dysfunction (2);
pneumonia (2); gastrointestinal bleed
(4)
Chinh 2000 Ofloxacin: gastrointestinal bleed (1) Azithromycin: gastrointestinal bleed
(1)
Girgis 1999 0 0
Parry 2007 Ofloxacin: 0 Azithromycin: gastrointestinal bleed
(2)
Fluoroquinolone vs cefixime Cao 1999 Ofloxacin: death (1); small gastroin-
testinal bleed (1)
Cefixime: required blood transfusion
(1)
Pandit 2007 Gatifloxacin: 0 Cefixime: death with gastrointesti-
nal bleed; thrombocytopenia; dissem-
inated intravascular coagulation (1)
Yu 1998 0 0
Fluoroquinolone vs ceftriaxone Smith 1994 Ofloxacin: 0 Ceftriaxone: anaemia (1); jaundice
and anaemia (1)
Tran 1994 0 0
Wallace 1993 0 0
Norfloxacin vs chlorampheni-
col
Nalin 1987 Norfloxacin: gastrointestinal bleed
(number unclear)
Chloramphenicol: 0
Sarma 1991 0 0
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Table 2. Complicationsa (Continued)
Norfloxacin vs other fluoro-
quinolones
Bai 1995 0 0
Jia 1994 0 0
Xiao 1991 Gastrointestinal bleeds (2) and en-
cephalopathy (1): unclear which
group they occurred in
Gastrointestinal bleeds (2) and en-
cephalopathy (1): unclear which
group they occurred in
Yang 1991 Not described Not described
Different durations of fluoro-
quinolones
Duong 1995 0 0
Nguyen 1997 2-day: 0 3-day: gastrointestinal bleed (2); jaun-
dice (1); hypotension (1)
Vinh 1996 2-day: 0 3-day: delirium (1); gastrointestinal
bleed (1)
Vinh 2005 2-day: gastrointestinal bleed (2) 3-day: 0
aOnly trials reporting on complications are included.
bZero (0) events only when specifically stated by trial author.
Table 3. Definitions of outcomesa
Comparison Trial Clinical failure Microbiologi-
cal failure
Relapse Fever clearance
time
Stool culture
taken
Flu-
oroquinolones vs
chlorampheni-
col
Abejar 1993 Not defined Not
defined (positive
day 23blood cul-
ture?)
Not defined Outcome not re-
ported
Outcome not re-
ported
Arnold 1993 Cure
or improvement
in 7 days
Non-eradi-
cation of original
pathogen
from blood sam-
ples be-
tween days 2 and
9 of treatment
Reappearance of
signs and symp-
toms within 3
weeks after the
end of treatment
accompanied by
reappear-
ance of pathogen
in blood
Outcome not re-
ported
32 to 60 days; re-
sults unclear
Bran 1991 Not defined Not defined Outcome not re-
ported
Not defined 2 months after
treatment
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Table 3. Definitions of outcomesa (Continued)
Cristiano 1995 Not defined Blood culture
positive at end of
treatment (at 15
days)
Within 30 days
after end of treat-
ment (the 2 re-
lapseswere blood
culture negative
and were stool
culture positive
before relapse)
Not defined 30 days
Gasem 2003 Not afebrile
within 7 days of
treatment
Blood culture
positive at days 3
and 5
Reappearance of
fever after de-
fervescence dur-
ing hospitaliza-
tion (under 14
days)
Defined as first
day that temper-
ature fell < 37.5
°C and remained
under for ≥ 48
hours
Outcome not re-
ported
Gottuzzo 1992 “One participant
who developed a
gastrointesti-
nal bleed in first
36 hours of treat-
ment was con-
sidered a failure”
Outcome not re-
ported
Not defined Outcome not re-
ported
Outcome not re-
ported
Morelli 1992 Persistence of
fever
Outcome not re-
ported
Not defined Not defined 3 weeks
Phongmany
2005
Continuation of
symp-
toms and tym-
panic tempera-
ture > 38 °C for
> 10 days af-
ter start of treat-
ment or contin-
uation of symp-
toms and high
tympanic
temperature > 39
°C at 7 days af-
ter start of treat-
ment or develop-
ment of signs of
severe disease
Outcome not re-
ported
Outcome not re-
ported
Time from onset
of treatment to
first recording of
a tympanic tem-
perature < 38 °C
(~ 37.5 °C ax-
illary) which re-
mained < 38 °C
for
48 hours (’Fever
Clearance Time
38’)
Outcome not re-
ported
Quintero 1988 “persistent fever” Outcome not re-
ported
Outcome not re-
ported
Not defined Outcome not re-
ported
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Table 3. Definitions of outcomesa (Continued)
Yousaf 1992 Persistence or
reappear-
ance of all pre-
senting signs and
symptoms or in-
crease in severity
of at least 1 sign
or symptom or
both
Persis-
tence of baseline
pathogen at day
14
Outcome not re-
ported
Outcome not re-
ported
Outcome not re-
ported
Flu-
oroquinolone vs
ampicillin
Flores 1994 At end of treat-
ment
At end of treat-
ment
Outcome not re-
ported
Outcome not re-
ported
Outcome not re-
ported
Fluoro-
quinolone vs co-
trimoxazole
Hajji 1988 Fever and pres-
ence
of clinical symp-
toms and posi-
tive cultures
Positive cultures
at days 4, 15, and
30
Reappearance of
fever, clinical
symptoms,
and/or bacter-
aemia at days 4,
15, and 30
Time for rec-
tal temperature
to be sustained≤
37.5 °C for ≥ 2
days
30 days
Limson 1989 Persis-
tent fever or no
improvement in
symptoms after 5
days of therapy
Positive cultures
during and after
therapy
Outcome not re-
ported
Outcome not re-
ported
Outcome not re-
ported
Flu-
oroquinolone vs
azithromycin
Dolecek 2008 Persistence of
fever and symp-
toms 2 days after
the end of treat-
ment, ie on day
10
Positive
blood culture on
day 7 to 9 after
the start of treat-
ment
Symptoms and
signs suggestive
of
typhoid fever
within 1 month
after completion
of treat-
ment (only cul-
ture positive data
extracted)
Time from start
of antibi-
otic treatment to
when the axil-
lary temperature
first fell ≤ 37. 5
°C and remained
there for at least
48 hours
Follow ups at 1,
3, and 6 months;
participants who
attended at least
2 consecutive
follow-up visits
were evaluated
Chinh 2000 Persistence of
fever and symp-
toms for > 5
days after the end
of treatment or
development of
severe complica-
tions (severe gas-
trointestinal
bleed, intestinal
perforation, visi-
Isolation of S.
Typhi/S. Paraty-
phi from blood
or other sterile
site after comple-
tion of treatment
Recurrence of
signs and symp-
toms suggestive
of enteric fever
after discharge at
4 to 6 weeks of
follow up
Time from start
of treatment un-
til body temper-
ature fell < 37.5
°C and remained
at ≤ 37.5 °C for
48 hours
Days 2 to 3 after
end of treatment
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Table 3. Definitions of outcomesa (Continued)
ble jaundice,my-
ocardi-
tis, renal failure,
shock, coma)
during treatment
requiring change
in treatment
Girgis 1999 Lack of resolu-
tion of symp-
toms by day 7 or
development of
major complica-
tions of typhoid
fever after 5 days
of therapy
Blood
culture positive
for S. Typhi/S.
Paratyphi on day
10
Re-
currence of fever
with signs/symp-
toms of typhoid
fever in 4 weeks
of therapy com-
pletion and cul-
ture positive
First day
on which max-
imum tempera-
ture≤ 38 °C and
at this level for≥
48 hours
1 month
Parry 2007 Presence of fever
and at least
1 other typhoid
related symptom
for > 7 days af-
ter start of treat-
ment or devel-
opment of severe
complications
(severe gastroin-
testinal bleeding,
perforation, visi-
ble jaundice,my-
ocarditis, pneu-
monia, renal fail-
ure, shock, or al-
tered conscious-
ness level, during
treatment
requiring change
in therapy
Isolation
of S. Typhi or S.
Paratyphi from
blood or sterile
site after comple-
tion of treatment
Recurrence
of symptoms or
signs sug-
gestive of enteric
fever within 4-
week period af-
ter patient had
been discharged
well from hospi-
tal accompanied
by positive blood
culture for S. Ty-
phi or S. Paraty-
phi
Time from start
of treatment un-
til body temper-
ature reached ≤
37.5 °C and re-
mained at this
for 48 hours
After end of ini-
tial 7-day treat-
ment and be-
fore hospital dis-
charge (with iso-
late having
the same suscep-
tibility pattern as
original isolate)
Fluoro-
quinolone vs ce-
fixime
Cao 1999 Deterio-
ration in clinical
condition or fail-
ure of resolution
of symptoms
requiring further
treatment
Blood culture
positive for S.
Typhi after com-
pletion of treat-
ment
Symptoms
suggestive of ty-
phoid fever with
a positive blood
or bone marrow
culture up to 4
weeks after dis-
chargeb
Time from onset
of treatment un-
til fever was 37.5
°C or below for
at least 24 hours
1 month mostly,
few seen after a
longer period
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Table 3. Definitions of outcomesa (Continued)
Pandit 2007 Any severe com-
plication, persis-
tence of fever (>
38 °C), persis-
tence of symp-
toms for > 7 days
af-
ter start of treat-
ment, requiring
additional or res-
cue treatment
Blood cul-
ture positive on
day 10
Fever with blood
culture positive
within a month
of completing
treatment (pa-
tients given res-
cue treatment or
prolonged treat-
ment were ex-
cluded)
Time to 1st drop
in oral tempera-
ture ≤
37.5 °C remain-
ing≤ 37.5 °C for
48 hours
1 month
Yu 1998 “ineffi-
cient” (categories
included in as-
sessment of clin-
ical effectiveness
were “cure, effec-
tive, improved
and inefficient”)
Eradicated (bac-
teria elimination
rate)
Carrying bacte-
ria at 3 months
follow up
Not defined Not defined
Fluoro-
quinolone vs cef-
triaxone
Smith 1994 Acute treatment
failure as contin-
uing symptoms
and fever for at
least 7 days after
starting the treat-
ment regimen
Blood culture
positive at day 8
Re-
currence of fever
and symptoms in
the period up to
6 weeks after dis-
charge with
a positive blood
or bone marrow
cultureb
Time
to defervescence
to < 37.5 °C for
at least 48 hours
4 to 6 weeks
Tran 1994 No reduction of
maximum daily
temperature
to < 37.5 °C nor
complete disap-
pearance of all
other signs and
symptoms
within 14 days
and with clini-
cal evidence of
infection during
further follow up
Blood, bone
marrow, or stool
culture within
14 days, and all
culture negative
for at least 21
days
Re-
turn of fever and
symptoms up to
4 weeks after dis-
charge with a
blood or bone
marrow culture
positiveb
Time until fever
reached < 37.5
°C
1 month
Wallace 1993 Fever > 38 °C af-
ter 7 days of ther-
apy or who de-
teriorated clini-
Blood culture
positive at day 3
Readmission for
typhoid within 2
months of dis-
charge with stool
Not defined Days 1, 7, and
28; results un-
clear
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Table 3. Definitions of outcomesa (Continued)
cally after 5 full
days
or blood culture
pos-
itive for S. Typhi
of the same an-
tibiogram (1 re-
lapse had both
stool and blood
culture positive)
Nor-
floxacin vs chlo-
ramphenicol
Nalin 1987 Not defined Not defined Outcome not re-
ported
First day
at which temper-
ature < 37.5 °C
Not defined
Sarma 1991 Persistence of all
signs and symp-
toms of infection
Positive blood
culture at 7 days
Recurrence of ill-
ness within 14
days of comple-
tion of treatment
Disap-
pearance of fever
after therapy and
maintenance of
normal tempera-
ture with clinical
cure and blood
sterilization
56 days
Norfloxacin vs
ceftriaxone
Huai 2000 Fever after 7 days
of
treatment, posi-
tive bacteria, ex-
istence of symp-
toms and com-
plications
Outcome not re-
ported
Relapse after 1
month of follow
up
Not defined Outcome not re-
ported
Norfloxacin
vs another fluo-
roquinolone
Bai 1995 No
effect or deterio-
rated after 3 days
of treatment
Outcome not re-
ported
Outcome not re-
ported
Restoration of
normal tempera-
ture
Outcome not re-
ported
Jia 1994 No effect or de-
teriorated
Outcome not re-
ported
Outcome not re-
ported
Restoration of
normal tempera-
ture
Outcome not re-
ported
Xiao 1991 Temperature not
de-
creased or even
increased, clini-
cal symp-
toms were im-
proved or dete-
riorated after 1
week of treat-
ment
Outcome not re-
ported
Outcome not re-
ported
Not defined Outcome not re-
ported
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Table 3. Definitions of outcomesa (Continued)
Yang 1991 Temperature not
decreased after 8
or
more days treat-
ment or changed
to other treat-
ment
Tem-
perature back to
normal but bac-
teria culture pos-
itive from faeces
Tempera-
ture back to nor-
mal after treat-
ment but after 2
to 4 weeks fever
started again and
blood
cultures positive
and S. Typhi iso-
lated
Not defined At
“convalescence”
Different dura-
tions of fluoro-
quinolones
Alam 1995 Lack of improve-
ment or deterio-
ration in clinical
conditionduring
treatment
Growth of S. Ty-
phi or S. Paraty-
phi in blood in
first follow up
(day 3)
Recurrence
of febrile illness
with growth of S.
Typhi
or S. Paratyphi in
blood culture af-
ter initial cure
Time to return of
oral temperature
to ≤ 37.5 °C af-
ter initiation of
therapy and re-
mained so for at
least 48 hours
Second follow
up (at 2 months)
Duong 1995 No
improvement or
reappearance of
signs and symp-
toms at least 48
hours after end
of treatment
Blood or bone
marrow culture
positive 48 hours
after last dose of
fleroxacin
Blood culture
positive within 1
month follow up
Not defined Outcome not re-
ported
Kalo 1997 Fever at day 5 Blood culture
positive at day 4
Re-
lapse during hos-
pitalization and
2 month follow
up
Outcome not re-
ported
Days 7 to 12
Nguyen 1997 Continuing
fever and symp-
toms for 7 days
after
the start of treat-
ment or deterio-
ration in clinical
condition before
7 days that war-
ranted further
treatment
Blood or bone
marrow culture
positive after end
of treatment be-
fore discharge
Recurrent
fever and symp-
toms with bone
marrow or blood
culture positive
mostly up to 6
weeks after dis-
chargeb
Time at which
fever fell below
37.5 °C for at
least 24 hours
Usually 6 weeks
(occasionally up
to 12 weeks)
Tran 1995 Per-
sistent fever and
symptoms for >
7 days after start
Blood or bone
marrow culture
positive after end
of treatment
Symptoms since
study with pos-
itive blood cul-
ture
Not defined 1 month
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Table 3. Definitions of outcomesa (Continued)
of treatment
Unal 1996 Continued or
worsening symp-
toms after 7 days
of therapy
Failure to eradi-
cate organism
Similar signs and
symp-
toms after appar-
ently being cured
for a month (the
participant had
a positive stool
culture)
Time for tem-
perature to be
below 37.5 °C
for at least 48
hours
1 month; results
unclear
Vinh 1996 Continued
fever and symp-
toms for > 7 days
after treatment
Positive blood
culture or bone
marrow cul-
ture for S. Typhi
taken > 48 hours
after the last dose
of treatment
Recurrence of
fever and symp-
toms with posi-
tive
blood or bone
marrow culture
up to6weeks (26
participants fol-
lowed up to 12
weeks) after dis-
chargeb
Time from start
of treatment un-
til axillary tem-
perature fell be-
low 37.5 °C and
remained below
this level for > 48
hours
4 to 6 weeks (for
66 participants);
and at 3 months
(for 26 partici-
pants)
Vinh 2005 Fever and symp-
toms persisting
for ≥ 7 days af-
ter start of ther-
apy, or develop-
ment of severe or
complicated dis-
ease
Blood culture
positive for same
organism
between 7 to 28
days after com-
pletion of ther-
apy
Recur-
rence of typhoid
fever symptoms
usually with pos-
itive blood cul-
ture after hospi-
tal discharge un-
til 28 days post
discharge (only
data for blood
culture-con-
firmed relapse
extracted)
Period from start
of treatment un-
til tempera-
ture remained at
or below 37.5 °C
for at least 48
hours
Immediately af-
ter treatment
S. Typhi/S. Paratyphi: Salmonella enterica serovar Typhi/Paratyphi.
aAll definitions as stated or implied by trial authors.
bWith an organism with the same sensitivity pattern, ribotype, and plasmid profile as the original isolate.
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